AU784993B2

AU784993B2 - CRSP protein (cysteine-rich secreted proteins), nucleic acid molecules encoding them and uses therefor

Info

Publication number: AU784993B2
Application number: AU38155/02A
Authority: AU
Inventors: Sean A. Mccarthy
Original assignee: Millennium Pharmaceuticals Inc
Current assignee: Millennium Pharmaceuticals Inc
Priority date: 1997-04-16
Filing date: 2002-05-02
Publication date: 2006-08-17
Anticipated expiration: 2018-04-16
Also published as: AU2005248943A1; AU3815502A; AU2006235978B2; AU2006235978A1; AU2005248943B2

Description

AUSTRALIA

PATENTS ACT 1990 DIVISIONAL APPLICATION NAME OF APPLICANT: Millennium Pharmaceuticals, Inc.

ADDRESS FOR SERVICE: DAVIES COLLISON CAVE Patent Attorneys 1 Little Collins Street Melbourne, 3000.

INVENTION TITLE: "CRSP protein (Cysteine-Rich Secreted Proteins), nucleic acid molecules encoding them and uses therefor" The following statement is a full description of this invention, including the best method of performing it known to us: CRSP PROTEIN (CYSTEINE-RICH SECRETED PROTEINS), NUCLEIC ACID MOLECULES ENCODING THEM AND USES THEREFOR Background of the Invention Secreted proteins play an integral role in the formation, differentiation, and maintenance of cells in multicellular organisms. For instance, secretory proteins are known in the art to be involved in signalling between cells which are not in direct contact. Such secreted signaling molecules are particularly important in the development of vertebrate tissue during embryogenesis as well as in the maintenance of the differentiated state of adult tissues. For example, inductive interactions that occur between neighboring cell layers and tissues in the developing embryo are largely dependent on the existence and regulation of secreted signaling molecules. In inductive interactions, biochemical signals secreted by one cell population influence the developmental fate of a second cell population, typically by altering the fate of the second cell population. For example, the Wnt proteins are now recognized as one of the major families of developmentally important signaling molecules in organisms ranging from Drosophila to mice. For review see Cadigan, K.M. and R. Nusse (1997) Genes Development, 11:3286-3305.

It is also now well recognized that major families of signaling molecules have a dual role to play in both the development of an organism as well as in promoting or maintaining the differentiated state of tissues in the adult animal. Furthermore, major families of signaling molecules have been implicated in controlling proliferation of cells in mature adult tissue, for example, during normal cell turnover in the adult organism as well as in tissue regeneration activated as a result of damage to the adult tissue.

Summary of the Invention The present invention is based, at least in part, on the discovery of nucleic acid molecules which encode a novel family of secreted proteins, referred to herein as the Cysteine-Rich Secreted Proteins ("CRSPs" or "CRSP proteins"). The CRSP molecules of the present invention are useful as modulating agents in regulating a variety of cellular processes. Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding CRSP proteins or biologically active portions thereof, as well as nucleic acid fragments suitable as primers or hybridization probes for the detection of CRSP-encoding nucleic acids.

In one embodiment, a CRSP nucleic acid molecule is 60% homologous to the nucleotide sequence shown in SEQ ID NO: 1, SEQ ID NO:3, or complement thereof. In yet another embodiment, a CRSP nucleic acid molecule is 80% homologous to the -2nucleotide sequence shown in SEQ ID NO:4, SEQ ID NO:6, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98634, or a complement thereof. In yet another embodiment, a CRSP nucleic acid molecule is homologous to the nucleotide sequence shown in SEQ ID NO:7, SEQ ID NO:9, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98452, or a complement thereof. In yet another embodiment, a CRSP nucleic acid molecule is 85% homologous to the nucleotide sequence shown in SEQ ID NO:7, SEQ ID NO:9, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98452, or a complement thereof. In yet another embodiment, a CRSP nucleic acid molecule is 70% homologous to the nucleotide sequence shown in SEQ ID NO:10, SEQ ID NO:12, or a complement thereof. In a preferred embodiment, an isolated CRSP nucleic acid molecule has the nucleotide sequence shown SEQ ID NO:3, or a complement thereof. In another embodiment, a CRSP nucleic acid molecule further comprises nucleotides 1-37 of SEQ ID NO: 1. In yet another preferred embodiment, a CRSP nucleic acid molecule further comprises nucleotides 1088-2479 of SEQ ID NO: 1. In another preferred embodiment, an isolated CRSP nucleic acid molecule has the nucleotide sequence shown in SEQ ID NO: 1.

In another preferred embodiment, an isolated CRSP nucleic acid molecule has the nucleotide sequence shown SEQ ID NO:6, or a complement thereof. In another embodiment, a CRSP nucleic acid molecule further comprises nucleotides 1-125 of SEQ ID NO:4. In yet another preferred embodiment, a CRSP nucleic acid molecule further comprises nucleotides 797-848 of SEQ ID NO:4. In another preferred embodiment, an isolated CRSP nucleic acid molecule has the nucleotide sequence shown in SEQ ID NO:4.

In another preferred embodiment, an isolated CRSP nucleic acid molecule has the nucleotide sequence shown SEQ ID NO:9, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98452, or a complement thereof. In another embodiment, a CRSP nucleic acid molecule further comprises nucleotides 1-92 of SEQ ID NO:7. In yet another preferred embodiment, a CRSP nucleic acid molecule further comprises nucleotides 891-1529 of SEQ ID NO:7. In another preferred embodiment, an isolated CRSP nucleic acid molecule has the nucleotide sequence shown in SEQ ID NO:7.

-3- In another preferred embodiment, an isolated CRSP nucleic acid molecule has the nucleotide sequence shown SEQ ID NO: 12, or a complement thereof. In another embodiment, a CRSP nucleic acid molecule further comprises nucleotides 538-702 of SEQ ID NO:10. In yet another preferred embodiment, an isolated CRSP nucleic acid molecule has the nucleotide sequence shown in SEQ ID NO: In another embodiment, a CRSP nucleic acid molecule includes a nucleotide sequence encoding a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of SEQ ID NO:2, SEQ ID 5, SEQ ID NO:8, or SEQ ID NO:11.

In another preferred embodiment, a CRSP nucleic acid molecule includes a nucleotide sequence encoding a protein having an amino acid sequence at least 60% homologous to the amino acid sequence of SEQ ID NO:2. In yet another preferred embodiment, a CRSP nucleic acid molecule includes a nucleotide sequence encoding a protein having an amino acid sequence at least 60% homologous to the amino acid sequence of SEQ ID In yet another preferred embodiment, a CRSP nucleic acid molecule includes a nucleotide sequence encoding a protein having an amino acid sequence at least homologous to the amino acid sequence of SEQ ID NO:8. In yet another preferred embodiment, a CRSP nucleic acid molecule includes a nucleotide sequence encoding a protein having an amino acid sequence at least 75% homologous to the amino acid sequence of SEQ ID NO:8. In yet another preferred embodiment, a CRSP nucleic acid molecule includes a nucleotide sequence encoding a protein having an amino acid sequence at least 65% homologous to the amino acid sequence of SEQ ID NO: 11.

In another embodiment, an isolated nucleic acid molecule of the present invention encodes a CRSP protein which includes a signal sequence and at least one cysteine-rich domain, and is secreted. In another embodiment, an isolated nucleic acid molecule of the present invention encodes a CRSP protein which includes a signal sequence and at least one cysteine-rich domain, preferably a cysteine-rich region, and is secreted. In yet another embodiment, a CRSP nucleic acid molecule encodes a CRSP protein and is a naturally occurring nucleotide sequence.

Another embodiment of the invention features CRSP nucleic acid molecules which specifically detect CRSP nucleic acid molecules relative to nucleic acid molecules encoding non-CRSP proteins. For example, in one embodiment, a CRSP nucleic acid molecul hybridizes under stringent conditions to a nucleic acid molecule comprising the nucleotides 470-2479 of nucleotide sequence shown in SEQ ID NO:1, to nucleotides 1-475 of nucleotide sequence shown in SEQ ID NO:4, or to nucleotides 1-600 of nucleotide sequence shown in SEQ ID NO:7, or hybridizes under stringent conditions to the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98634, to the nucleotide sequence of the DNA insert of the plasmid -4deposited with ATCC as Accession Number 98633, or to the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98452. In another embodiment, the CRSP nucleic acid molecule is at least 500 nucleotides in length and hybridizes under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7, or SEQ ID NO: 10 or a complement thereof.

Another embodiment of the invention provides an isolated nucleic acid molecule which is antisense to the coding strand of a CRSP nucleic acid.

Another aspect of the invention provides a vector comprising a CRSP nucleic acid molecule. In certain embodiments, the vector is a recombinant expression vector.

In another embodiment, the invention provides a host cell containing a vector of the invention. The invention also provides a method for producing a CRSP protein by culturing in a suitable medium, a host cell of the invention containing a recombinant expression vector suchthat a CRSP protein is produced.

Another aspect of this invention features isolated or recombinant CRSP proteins and polypeptides. In one embodiment, an isolated CRSP protein has a signal sequence and at least one cysteine-rich domain, preferably a cysteine-rich region, and is secreted.

In another embodiment, an isolated CRSP protein has an amino acid sequence sufficiently homologous to the amino acid sequence of SEQ ID NO:2, SEQ ID SEQ ID NO:8, or SEQ ID NO: 11. In a preferred embodiment, a CRSP protein has an amino acid sequence at least about 60% homologous to the amino acid sequence of SEQ ID NO:2. In another preferred embodiment, a CRSP protein has an amino acid sequence at least about 60% homologous to the amino acid sequence of SEQ ID NO:5. In another preferred embodiment, a CRSP protein has an amino acid sequence at least about homologous to the amino acid sequence of SEQ ID NO:8. In another preferred embodiment, a CRSP protein has an amino acid sequence at least about homologous to the amino acid sequence of SEQ ID NO:8. In another preferred embodiment, a CRSP protein has an amino acid sequence at least about homologous to the amino acid sequence of SEQ ID NO: 11. In another embodiment, a CRSP protein has the amino acid sequence of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO:11.

Another embodiment of the invention features an isolated CRSP protein which is encoded by a nucleic acid molecule having a nucleotide sequence at least about homologous to a nucleotide sequence of SEQ ID NO:1, or a complement thereof.

Another embodiment of the invention features an isolated CRSP protein which is encoded by a nucleic acid molecule having a nucleotide sequence at least about homologous to a nucleotide sequence of SEQ ID NO:4, or a complement thereof.

Another embodiment of the invention features an isolated CRSP protein which is encoded by a nucleic acid molecule having a nucleotide sequence at least about homologous to a nucleotide sequence of SEQ ID NO:7, or a complement thereof.

Another embodiment of the invention features an isolated CRSP protein which is encoded by a nucleic acid molecule having a nucleotide sequence at least about homologous to a nucleotide sequence of SEQ ID NO:10, or a complement thereof. This invention further features an isolated CRSP protein which is encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO:10, or a complement thereof.

The CRSP proteins of the present invention, or biologically active portions thereof, can be operatively linked to a non-CRSP polypeptide to form CRSP fusion proteins. The invention further features antibodies that specifically bind CRSP proteins, such as monoclonal or polyclonal antibodies. In addition, the CRSP proteins or biologically active portions thereof can be incorporated into pharmaceutical compositions, which optionally include pharmaceutically acceptable carriers.

In another aspect, the present invention provides a method for detecting CRSP expression in a biological sample by contacting the biological sample with an agent capable of detecting a CRSP nucleic acid molecule, protein or polypeptide such that the presence of a CRSP nucleic acid molecule, protein or polypeptide is detected in the biological sample.

In another aspect, the present invention provides a method for detecting the presence of CRSP activity in a biological sample by contacting the biological sample with an agent capable of detecting an indicator of CRSP activity such that the presence of CRSP activity is detected in the biological sample.

In another aspect, the invention provides a method for modulating CRSP activity comprising contacting the cell with an agent that modulates CRSP activity such that CRSP activity in the cell is modulated. In one embodiment, the agent inhibits CRSP activity. In another embodiment, the agent stimulates CRSP activity. In one embodiment, the agent is an antibody that specifically binds to a CRSP protein. In another embodiment, the agent modulates expression of CRSP by modulating transcription of a CRSP gene or translation of a CRSP mRNA. In yet another embodiment, the agent is a nucleic acid molecule having a nucleotide sequence that is antisense to the coding strand of a CRSP mRNA or a CRSP gene.

-6- In one embodiment, the methods of the present invention are used to treat a subject having a disorder characterized by aberrant CRSP protein or nucleic acid expression or activity by administering an agent which is a CRSP modulator to the subject. In one embodiment, the CRSP modulator is a CRSP protein. In another embodiment the CRSP modulator is a CRSP nucleic acid molecule. In yet another embodiment, the CRSP modulator is a peptide, peptidomimetic, or other small molecule.

In a preferred embodiment, the disorder characterized by aberrant CRSP protein or nucleic acid expression is a developmental, differentiative, or proliferative disorder.

The present invention also provides a diagnostic assay for identifying the presence or absence of a genetic alteration characterized by at least one of aberrant modification or mutation of a gene encoding a CRSP protein; (ii) mis-regulation of said gene; and (iii) aberrant post-translational modification of a CRSP protein, wherein a wild-type form of said gene encodes an protein with a CRSP activity.

In another aspect the invention provides a method for identifying a compound that binds to or modulates the activity of a CRSP protein, by providing a indicator composition comprising a CRSP protein having CRSP activity, contacting the indicator composition with a test compound, and determining the effect of the test compound on CRSP activity in the indicator composition to identify a compound that modulates the activity of a CRSP protein.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

Brief Description of the Drawings Figure 1 depicts the cDNA sequence and predicted amino acid sequence of human CRSP-1. The nucleotide sequence corresponds to nucleic acids 1 to 2479 of SEQ ID NO:1. The amino acid sequence corresponds to amino acids 1 to 350 of SEQ ID NO:2.

Figure 2 depicts the cDNA sequence and predicted amino acid sequence of human CRSP-2. The nucleotide sequence corresponds to nucleic acids 1 to 848 of SEQ ID NO:4. The amino acid sequence corresponds to amino acids 1 to 224 of SEQ ID Figure 3 depicts the cDNA sequence and predicted amino acid sequence of human CRSP-3. The nucleotide sequence corresponds to nucleic acids 1 to 1529 of SEQ ID NO:7. The amino acid sequence corresponds to amino acids 1 to 266 of SEQ ID NO:8.

Figure 4 depicts the cDNA sequence and predicted amino acid sequence of human CRSP-4. The nucleotide sequence corresponds to nucleic acids 1 to 702 of SEQ ID NO:10. The amino acid sequence corresponds to amino acids 1 to 179 of SEQ ID NO:11.

Figure 5 depicts the cDNA sequence and predicted amino acid sequence of human CRSP-like-N. The nucleotide sequence corresponds to nucleic acids 1 to 928 of SEQ ID NO: 13. The amino acid sequence corresponds to amino acids 1 to 242 of SEQ ID NO: 14.

Figure 6 is depicts the amino acid sequences of human CRSP-1, human CRSP-2, human CRSP-3, and human CRSP-4, as well as the consensus sequence generated form the alignment of these sequences. The figure details the relationship between the CRSP proteins of the instant invention.

Figure 7 is a schematic diagram depicting the the relationship between the CRSP proteins of the instant invention. The figure depicts the biological and functional domains of human CRSP. Signal peptides are indicated by filled boxes. The cysteinerich domains of a CRSP cysteine-rich region are depicted as CRD-1 and CRD-2.

Figure 8 depicts the cDNA sequence and predicted amino acid sequence of murine CRSP-1. The nucleotide sequence corresponds to nucleic acids 1 to 928 of SEQ ID NO:16. The amino acid sequence corresponds to amino acids 1 to 349 of SEQ ID NO:17.

Figure 9 is a schematic diagram depicting the relationship between the CRSP-1 nucleotide sequence and those of RIG and RIG-like 7-1 (Accession Nos. U32331 and AF034208, respectively).

Detailed Description of the Invention The present invention is based on the discovery of novel molecules, referred to herein as CRSP protein and nucleic acid molecules, which comprise a family of molecules having certain conserved structural and functional features. The term "family" when referring to the protein and nucleic acid molecules of the invention is intended to mean two or more proteins or nucleic acid molecules having a common structural domain and having sufficient amino acid or nucleotide sequence homology as defined herein. Such family members can be naturally occurring and can be from either the same or different species. For example, a family can contain a first protein of human origin, as well as other, distinct proteins of human origin or alternatively, can contain homologues of non-human origin. Members of a family may also have common functional characteristics.

In one embodiment, a CRSP family member is identified based on the presence of at least one "cysteine-rich domain" in the protein or corresponding nucleic acid -8molecule. As defined herein, a "cysteine-rich domain" refers to a portion of a CRSP protein CRSP-1) which is rich in cysteine residues, at least about 6, 7, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids are cysteine residues. Preferably, a "cysteine-rich domain" is a protein domain having an amino acid sequence of about 100 amino acids, preferably about 35-95 amino acids, more preferably about 40-90 amino acids, more preferably about 45-85 amino acids, even more preferably about amino acids, and even more preferably about 55-75, 60-70, or 65 amino acids, of which at least about 3-20, preferably about 5-15, or more preferably about 6, 7, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids are cysteine residues.

A preferred cysteine-rich domain has at least about 10, at least about 15, 16, 17, 18, 19, or preferably 20 cysteine residues located at the same relative amino acid position as the cysteine residues in human CRSP-I having SEQ ID NO:2. For example, as shown in Figure 6, CRSP-2 has at least about 10 cysteine residues located at the same relative amino acid position as the cysteine residues in human CRSP-1 having SEQ ID NO:2 cysl51 in CRSP-2, SEQ ID NO:5, is located at the same relative amino acid position as cys214 in CRSP-1, SEQ ID NO:2; cys156 in CRSP-2, SEQ ID NO:5, is located at the same relative amino acid position as cys219 in CRSP-1, SEQ ID NO:2; and cys157 in CRSP-2, SEQ ID NO:5, is located at the same relative amino acid position as cys220 in CRSP-1, SEQ ID NO:2). Similarly, as shown in Figure 6, CRSP-3 has at least about 10 cysteine residues located at the same relative amino acid position as the cysteine residues in human CRSP-1 having SEQ ID NO:2. As also shown in Figure 6, CRSP-4 has at least about 10 cysteine residues located at the same relative amino acid position as the cysteine residues in human CRSP-l having SEQ ID NO:2.

A preferred CRSP protein of the present invention is a human protein encoded by a nucleotide sequence correpsonding to a naturally-occurring human gene.) For example, in one embodiment, a CRSP-I protein (human CRSP-1) contains a first cysteine-rich domain containing about amino acids 147-195 of SEQ ID NO:2, having cysteine residues, and a second cysteine-rich domain containing about amino acids 201- 284 of SEQ ID NO:2, having 10 cysteine residues (the positions of the cysteine residues are depicted in Figure In another embodiment, a CRSP-2 (human CRSP-2) protein contains a first cysteine-rich domain containing about amino acids 41-90 of SEQ ID having 10 cysteine residues, and a second cysteine-rich domain containing about amino acids 41-218 of SEQ ID NO:5, having 10 cysteine residues (the positions of the cysteine residues are depicted in Figure In another embodiment, a CRSP-3 protein (human CRSP-3) contains a first cysteine-rich domain containing about amino acids 138 of SEQ ID NO:8, having 10 cysteine residues, and a second cysteine-rich domain containing about amino acids 182-263 of SEQ ID NO:8, having 10 cysteine residues (the positions of the cysteine residues are depicted in Figure In another embodiment, a CRSP-4 protein (human CRSP-4) contains a first cysteine-rich domain containing about amino acids 1-47 of SEQ ID NO: 11, having 8 cysteine residues, and a second cysteine-rich domain containing about amino acids 96-176 of SEQ ID NO: 11, having cysteine residues (the positions of the cysteine residues are depicted in Figure 6).

Preferred CRSP proteins have more than one cysteine-rich domains, more preferably have at least two cysteine-rich domains and, thus, have a cysteine-rich region.

As used herein, the term "cysteine-rich region" refers to a protein domain which includes at least two cysteine-rich domains and has an amino acid sequence of about 120-200, preferably about 130-190, more preferably about 140-180 amino acid residues, and even more preferably at least about 135-175 amino acids of which at least about 10-30, preferably about 15-20, and more preferably about 16, 17, 18, or 19 of the amino acids are cysteine residues. In a preferred embodiment, a cysteine-rich region is located in the C-terminal region of a CRSP protein. For example, in one embodiment, a CRSP-1 protein contains a cysteine rich region containing about amino acids 147-284 of SEQ ID NO:2, having 20 cysteine residues at the positions indicated in Figure 6. In another embodiment, a CRSP-2 protein contains a cysteine rich region containing about amino acids 41-218 of SEQ ID NO:5, having 20 cysteine residues at the positions indicated in Figure 6. In another embodiment, a CRSP-3 protein contains a cysteine rich region containing about amino acids 85-263 of SEQ ID NO:8, having 20 cysteine residues at the positions indicated in Figure 6. In another embodiment, a CRSP-4 protein contains a cysteine rich region containing about amino acids 1-176 of SEQ ID NO:2, having 18 cysteine residues at the positions indicated in Figure 6.

In another embodiment, in addition to cysteine-rich domains, the cysteine-rich region contains a spacer region which separates the first and second cysteine-rich domains. As used herein, the "spacer region" refers to amino acid residues which are located between the first and second cysteine-rich domains of a cysteine-rich region and includes amino acid residues located C-terminal to the first cysteine-rich domain and Nterminal to the second cysteine-rich domain. As defined herein, a "spacer region" refers to a protein domain of about 5-70 amino acids, preferably about 10-65 amino acids, more preferably about 15-60 amino acids, even more preferably about 20-55 amino acids, and even more preferably about 25-50, 30-45 or 35-40 amino acids. For example, CRSP- protein contains a spacer region of about amino acids 196-200 of SEQ ID NO:2; CRSP-2 protein contains a spacer region of about amino acids 91-137 of SEQ ID NO:5; CRSP-3 protein contains a spacer region of about amino acids 139-181 of SEQ ID NO:8; and CRSP-4 protein contains a spacer region of about amino acids 48-95 of SEQ ID NO:11.

In another embodiment of the invention, the CRSP protein has at least one cysteine-rich domain, preferably a cysteine-rich region, and a signal sequence. As used herein, a "signal sequence" refers to a peptide containing about 20 amino acids which occurs at the N-terminus of secretory and integral membrane proteins and which contains a large number of hydrophobic amino acid residues. For example, a signal sequence contains at least about 14-28 amino acid residues, preferably about 16-26 amino acid residues, more preferably about 18-24 amino acid residues, and more preferably about 20-22 amino acid residues, and has at least about 40-70%, preferably about 50-65%, and more preferably about 55-60% hydrophobic amino acid residues Alanine, Valine, Leucine, Isoleucine, Phenylalanine, Tyrosine, Tryptophan, or Proline). Such a "signal sequence", also referred to in the art as a "signal peptide", serves to direct a protein containing such a sequence to a lipid bilayer. For example, in one embodiment, a CRSP-1 protein contains a signal sequence of about amino acids 1 23 of SEQ ID NO:2: In another embodiment, a CRSP-2 protein contains a signal sequence of about amino acids 1-19 of SEQ ID NO:5. In another embodiment, a CRSP- 3 protein contains a signal sequence of about amino acids 1-20 of SEQ ID NO:8.

CRSP proteins of the present invention can be used to identify additional CRSP family members. For example, a protein having homology to CRSP-1 was identified using the nucleotide sequence encoding the N-terminal unique region of CRSP-I to search a protein sequence database. Such a protein, referred to herein as "CRSP-like-N" is depicted in Figure 5. The nucleotide sequence of CRSP-like-N (SEQ ID NO:13) encodes a protein having 242 amino acids (SEQ ID NO:14). The nucleotide sequence of CRSP-like-N includes a 5' untranslated region containing nucleotides 1-74 of SEQ ID NO:13, a coding region containing nucleotides 75-800 of SEQ ID NO: 13 (corresponding to nucleotides 1-726 of SEQ ID NO: 15), and a 3' untranslated region containing nucleotides 801-928 of SEQ ID NO:13.

Accordingly, one embodiment of the invention features a CRSP protein having at least one cysteine-rich domain, preferably at least one cysteine-rich region. Another embodiment features a CRSP protein having at least one cysteine-rich region, wherein the cysteine-rich region includes at least one cysteine-rich domains. Another embodiment features a CRSP protein having at least one cysteine-rich region, wherein the cysteine-rich region includes at least two cysteine-rich domains. Another embodiment features a protein having 20, 30, 40, 50, 60, 70, 80, 90, 95, or 99% homology to a cysteine-rich domain of a CRSP protein of the invention CRSP-1, CRSP-2, CRSP-3, or CRSP-4).

Yet another embodiment of the invention features a CRSP protein having at least one cysteine-rich domain, preferably at least one cysteine-rich region and a signal -11peptide. Another embodiment features a CRSP protein having at least one cysteine-rich domain, preferably at least one cysteine-rich region and a signal peptide, wherein the cysteine-rich region includes at least two cysteine-rich domains. Another embodiment features a CRSP protein having at least one cysteine-rich domain, preferably at least one cysteine-rich region and a signal peptide, wherein the cysteine-rich region includes at least two cysteine-rich domains and a spacer.

Preferred CRSP molecules of the present invention have an amino acid sequence sufficiently homologous to the amino acid sequence ofSEQ ID NO:2, SEQ ID SEQ ID NO:8, or SEQ ID NO:I 1. As used herein, the term "sufficiently homologous" refers to a first amino acid or nucleotide sequence which contains a sufficient or minimum number of identical or equivalent an amino acid residue which has a similar side chain) amino acid residues or nucleotides to a second amino acid or nucleotide sequence such that the first and second amino acid or nucleotide sequences share common structural domains and/or a common functional activity. For example, amino acid or nucleotide sequences which share common structural domains have at least about 40% homology, preferably 50% homology, more preferably 60%-70% homology across the amino acid sequences of the domains and contain at least one, preferably two, more preferably three, and even more preferably four, five or six structural domains, are defined herein as sufficiently homologous. Furthermore, amino acid or nucleotide sequences which share at least 40%, preferably 50%, more preferably 70, or 80% homology and share a common functional activity are defined herein as sufficiently homologous.

As used interchangeably herein, a "CRSP activity", "biological activity of CRSP" or "functional activity of CRSP", refers to an activity exerted by a CRSP protein, polypeptide or nucleic acid molecule on a CRSP responsive cell as determined in vivo, or in vitro, according to standard techniques. In one embodiment, a CRSP activity is a direct activity, such as an association with a CRSP-target molecule. As used herein, a "target molecule" is a molecule with which a CRSP protein binds or interacts in nature, such that CRSP-mediated function is acheived. A CRSP target molecule can be a non- CRSP molecule or a CRSP protein or polypeptide of the present invention. In an exemplary embodiment, a CRSP target molecule is a membrane-bound protein a cell-surface receptor or "CRSP receptor") or a modified form of such a protein which has been altered such that the protein is soluble recombinantly produced such that the protein does not express a membrane-binding domain). In another embodiment, a CRSP target is a second soluble protein molecule a "CRSP binding partner" or "CRSP substrate"). In such an exemplary embodiment, a CRSP binding partner can be a second soluble non-CRSP protein or a second CRSP protein molecule of the present 12invention. Alternatively, a CRSP activity is an indirect activity, such as a cellular signaling activity mediated by interaction of the CRSP protein with a second protein a CRSP receptor). As used herein, the term "CRSP receptor" refers to a protein or protein complex, to which a CRSP protein, human CRSP, can bind. A receptor can be a cell surface receptor, a nuclear hormone receptor. CRSP receptors can be isolated by methods known in the art and further described herein. Interaction of a CRSP protein with a CRSP receptor can result in transduction of a signal from the cell surface to the nucleus. The signal transduced can be, an increase in intracellular calcium, an increase in phosphatidylinositol or other molecule, and can result, in phosphorylation of specific proteins, a modulation of gene transcription and any of the other biological activities set forth herein.

In a preferred embodiment, a CRSP activity is at least one or more of the following activities: interaction of a CRSP protein with and/or binding to a second molecule, a protein, such as a CRSP receptor, a soluble form of a CRSP receptor, a receptor for a member of the wnt family of signaling proteins, or a non-CRSP signaling molecule); (ii) interaction of a CRSP protein with an intracellular protein via a membrane-bound CRSP receptor; (iii) complex formation between a soluble CRSP protein and a second soluble CRSP binding partner a non-CRSP protein molecule or a second CRSP protein molecule); (iv) interaction with other extracellular proteins regulation of wnt-dependent cellular adhesion to extracellular matrix components); binding to and eliminating an undesirable molecule a detoxifying activity or defense function); and/or (vi) an enzymatic activity. In yet another preferred embodiment, a CRSP activity is at least one or more of the following activities: (1) modulation of cellular signal transduction, either in vitro or in vivo antagonism of the activity of members of the wnt family of secreted proteins or supression of wntdependent signal transduction); regulation of communication between cells regulation of wnt-dependent cell-cell interactions); regulation of expression of genes whose expression is modulated by binding of CRSP CRSP-1) to a receptor; (4) regulation of gene transcription in a cell involved in development or differentiation, either in vitro or in vivo induction of cellular differentiation); regulation of gene transcription in a cell involved in development or differentiation, wherein at least one gene encodes a differentiation-specific protein; regulation of gene transcription in a cell involved in development or differentaition, wherein at least one gene encodes a second secreted protein; regulation of gene transcription in a cell involved in development or differentiation, wherein at least one gene encodes a signal transduction molecule; regulation of cellular proliferation, either in vitro or in vivo induction of cellular proliferation or inhibition of proliferation as in the case of supression of 13tumorogenesis supression of glioblastoma formation)); formation and maintenance of ordered spatial arrangements of differentiated tissues in vertebrates, both adult and embryonic induction of head formation during vertebrate development or maintenance of hematopoietic progenitor cells); (10) modulation of cell death, such as stimulation of cell survival; (11) regulating cell migration; and/or (12) immune modulation.

As referred to herein, "differentiation-specific proteins" include proteins involved in the transition of a cell from the undifferentiated to the differentiated phenotype. For example, such proteins can be differentiation specific structural proteins or differentiation-specific transcription factors. Such differentiation-specific proteins are generally expressed at higher levels in cells which are making the transition from the undifferentiated to the differentiated phenotype during embryonic development or during regeneration of mature tissue in the adult animal), or are expresed at higher levels in fully-differentiated or terminally-differentiated cells as compared to their undifferentiated counterparts. Also, as referred to herein, "differentiation-specific genes" include nucleic acid molecules which encode differentiation-specific proteins.

Accordingly, another embodiment of the invention features isolated CRSP proteins and polypeptides having a CRSP activity. Preferred CRSP proteins have at least one cysteine-rich region and a CRSP activity. In another preferred embodiment, the CRSP protein has at least one cysteine-rich region, wherein the cysteine-rich region comprises at least one cysteine-rich domain, and a CRSP activity. In another preferred embodiment, the CRSP protein has at least one cysteine-rich region, wherein the cysteine-rich region comprises at least two cysteine-rich domains, and a CRSP activity.

In yet another preferred embodiment, a CRSP protein further comprises a signal sequence. In still another preferred embodiment, a CRSP protein has a cysteine-rich region, a CRSP activity, and an amino acid sequence sufficiently homologous to an amino acid sequence of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO:11.

The human CRSP-1 cDNA, which is approximately 2479 nucleotides in length, encodes a protein which is approximately 350 amino acid residues in length. The human CRSP protein contains an N-terminal signal sequence and a cysteine-rich region comprising two cysteine-rich domains. A CRSP cysteine-rich region can be found at least, for example, from about amino acids 147-284 of SEQ ID NO:2. The CRSP-1 cysteine-rich region comprises a first cysteine-rich domain from about amino acids 147- 195 of SEQ ID NO:2 and a second cysteine-rich domain from about amino acids 201- 284 of SEQ ID NO:2. The human CRSP-1 protein is a secreted protein which further contains a signal sequence at about amino acids 1-23 of SEQ ID NO:2. The prediction -14of such a signal peptide can be made, for example, utilizing the computer algorithm SIGNALP (Henrik, et al. (1997) Protein Engineering 10:1-6).

The human CRSP-2 cDNA, which is approximately 848 nucleotides in length, encodes a protein which is approximately 224 amino acid residues in length. The human CRSP protein contains an N-terminal signal sequence and a cysteine-rich region comprising two cysteine-rich domains. A CRSP cysteine-rich region can be found at least, for example, from about amino acids 41-218 of SEQ ID NO:5. The CRSP-2 cysteine-rich region comprises a first cysteine-rich domain from about amino acids 41of SEQ ID NO:5 and a second cysteine-rich domain from about amino acids 138-218 of SEQ ID NO:5. The human CRSP-2 protein is a secreted protein which further contains a signal sequence at about amino acids 1-19 of SEQ ID The human CRSP-3 cDNA, which is approximately 1529 nucleotides in length, encodes a protein which is approximately 266 amino acid residues in length. The human CRSP protein contains an N-terminal signal sequence and a cysteine-rich region comprising two cysteine-rich domains. A CRSP cysteine-rich region can be found at least, for example, from about amino acids 85-263 of SEQ ID NO:8. The CRSP-3 cysteine-rich region comprises a first cysteine-rich domain from about amino acids 138 of SEQ ID NO:8 and a second cysteine-rich domain from about amino acids 182- 263 of SEQ ID NO:2. The human CRSP-3 protein is a secreted protein which further contains a signal sequence at about amino acids 1-20 of SEQ ID NO:8.

The human CRSP-4 cDNA, which is approximately 702 nucleotides in length, encodes a protein which is approximately 179 amino acid residues in length. The human CRSP protein contains a cysteine-rich region comprising two cysteine-rich domains. A CRSP cysteine-rich region can be found at least, for example, from about amino acids 1-176 of SEQ ID NO: 11. The CRSP-4 cysteine-rich region comprises a first cysteine-rich domain from about amino acids 1-47 of SEQ ID NO: 11 and a second cysteine-rich domain from about amino acids 96-176 of SEQ ID NO: 11.

Various aspects of the invention are described in further detail in the following subsections: I. Isolated Nucleic Acid Molecules One aspect of the invention pertains to isolated nucleic acid molecules that encode CRSP proteins or biologically active portions thereof, as well as nucleic acid fragments sufficient for use as hybridization probes to identify CRSP-encoding nucleic acids CRSP mRNA) and fragments for use as PCR primers for the amplification or mutation of CRSP nucleic acid molecules. As used herein, the term "nucleic acid molecule" is intended to include DNA molecules cDNA or genomic DNA) and RNA molecules mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or doublestranded, but preferably is double-stranded DNA.

An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated CRSP nucleic acid molecule can contain less than about 5 kb, 4kb, 3kb, 2kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the present invention, a nucleic acid molecule having the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO:4, SEQ ID NO:7, or SEQ ID NO:10, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98634, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98452, or a portion thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or portion of the nucleic acid sequence of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7, or SEQ ID NO:10, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98634, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98452 as a hybridization probe, CRSP nucleic acid molecules can be isolated using standard hybridization and cloning techniques as described in Sambrook, Fritsh, E. and Maniatis, T. Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

Moreover, a nucleic acid molecule encompassing all or a portion of SEQ ID NO: 1, SEQ ID NO:4, SEQ ID NO:7, or SEQ ID NO: 10, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98634, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as -16- Accession Number 98633, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98452 can be isolated by the polymerase chain reaction (PCR) using synthetic oligonucleotide primers designed based upon the sequence of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7, or SEQ ID NO: 10, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98634, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98452.

A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis.

Furthermore, oligonucleotides corresponding to CRSP nucleotide sequences can be prepared by standard synthetic techniques, using an automated DNA synthesizer.

In a preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO: 1. The sequence of SEQ ID NO:1 corresponds to the human CRSP-1 cDNA. This cDNA comprises sequences encoding the human CRSP-1 protein "the coding region", from nucleotides 38- 1087), as well as 5' untranslated sequences (nucleotides 1 to 37) and 3' untranslated sequences (nucleotides 1088 to 2479). Alternatively, the nucleic acid molecule can comprise only the coding region of SEQ ID NO: 1 nucleotides 38 to 1087, corresponding to SEQ ID NO:3). A plasmid containing the full-length nucleotide sequence encoding CRSP-I was deposited with the American Type Culture Collection (ATCC), Rockville, Maryland, on June 11, 1997 and assigned Accession Number 98452. A plasmid containing the full-length nucleotide sequence encoding CRSP-I was deposited with the American Type Culture Collection (ATCC), Rockville, Maryland, on January 16, 1998 and assigned Accession Number 98634.

In another-preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO:4. The sequence of SEQ ID NO:4 corresponds to the human CRSP-2 cDNA. This cDNA comprises sequences encoding the human CRSP-2 protein "the coding region", from nucleotides 126-796), as well as 5' untranslated sequences (nucleotides 1 to 125) and 3' untranslated sequences (nucleotides 797 to 848). Alternatively, the nucleic acid molecule can comprise only the coding region of SEQ ID NO:4 nucleotides 126 to 796, corresponding to SEQ ID NO:6).

In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO:7. The sequence of -17- SEQ ID NO:7 corresponds to the human CRSP-3 cDNA. This cDNA comprises sequences encoding the human CRSP-3 protein "the coding region", from nucleotides 93-890), as well as 5' untranslated sequences (nucleotides 1 to 92) and 3' untranslated sequences (nucleotides 891 to 1529). Alternatively, the nucleic acid molecule can comprise only the coding region of SEQ ID NO:7 nucleotides 93 to 890, corresponding to SEQ ID NO:9). A plasmid containing the full-length nucleotide sequence encoding CRSP-3 was deposited with the American Type Culture Collection (ATCC), Rockville, Maryland, on January 16, 1998 and assigned Accession Number 98633.

In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO: 10. The sequence of SEQ ID NO:10 corresponds to the human CRSP-4 cDNA. This cDNA comprises sequences encoding the human CRSP-4 protein "the coding region", from nucleotides 1-537), as.well as 3' untranslated sequences (nucleotides 538 to 702).

Alternatively, the nucleic acid molecule can comprise only the coding region of SEQ ID nucleotides 1 to 537, corresponding to SEQ ID NO:12).

In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of the nucleotide sequence shown in SEQ ID NO: 1, SEQ ID NO:4, SEQ ID NO:7, or SEQ ID NO: 10, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98634, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98452, or a portion of any of these nucleotide sequences. A nucleic acid molecule which is complementary to the nucleotide sequence shown in SEQ ID NO: 1, SEQ ID NO:4, SEQ ID NO:7, or SEQ ID NO: 10, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98634, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98452, is one which is sufficiently complementary to the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7, or SEQ ID NO:10, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98634, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98452, such that it can hybridize to the nucleotide sequence shown in SEQ ID NO: 1, SEQ ID NO:4, SEQ ID NO:7, or SEQ ID or the nucleotide sequence of the DNA insert of the plasmid deposited with 18- ATCC as Accession Number 98634, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98452, thereby forming a stable duplex.

In still another preferred embodiment, an isolated nucleic acid molecule of the present invention comprises a nucleotide sequence which is at least about 30-35%, preferably about 40-45%, more preferably about 50-55%, even more preferably about 60-65%, and even more preferably at least about 70-75%, 80-85%, 90-95% or more homologous to the nucleotide sequences shown in SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7, or SEQ ID NO:10, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98634, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98452, or a portion of any of these nucleotide sequences.

Moreover, the nucleic acid molecule of the invention can comprise only a portion of the nucleic acid sequence of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7, SEQ ID the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98634, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98452, for example a fragment which can be used as a probe or primer or a fragment encoding a biologically active portion of a CRSP protein. The nucleotide sequence determined from the cloning of the human CRSP genes allows for the generation of probes and primers designed for use in identifying and/or cloning CRSP homologues in other cell types, from other tissues, as well as CRSP homologues from other mammals. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, preferably about 25, more preferably about 40, 50 or 75 consecutive nucleotides of a sense sequence of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO: 10, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98634, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98452, of an anti-sense sequence of SEQ ID NO: 1, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO: 10, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98634, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633, or -19the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98452, or of a naturally occurring mutant of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO: 10, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98634, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98452. In an exemplary embodiment, a nucleic acid molecule of the present invention comprises a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising nucleotides 470-2479 of SEQ ID NO: or to a nucleic acid molecule comprising nucleotides 1-475 of SEQ ID NO:4.

Probes based on the human CRSP nucleotide sequence can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. For instance, primers based on the nucleic acid represented in SEQ ID NOS: 1 or 3 can be used in PCR reactions to clone CRSP homologs CRSP-1 homologues). In a preferred embodiment of the invention, CRSP homologs are cloned by PCR amplification RT-PCR) using primers hybridizing to a portion of the nucleotide sequence encoding the CRSP cysteine rich domain. Likewise, probes based on the subject CRSP sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In preferred embodiments, the probe further comprises a label group attached thereto, the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissue which misexpress a CRSP protein, such as by measuring a level of a CRSP-encoding nucleic acid in a sample of cells from a subject detecting CRSP mRNA levels or determining whether a genomic CRSP gene has been mutated or deleted.

A nucleic acid fragment encoding a "biologically active portion of a CRSP protein" can be prepared by isolating a portion of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO:10, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98634, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98634, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98452, which encodes a polypeptide having a CRSP biological activity (the biological activities of the CRSP proteins have previously been described), expressing the encoded portion of the CRSP protein by recombinant expression in vitro) and assessing the activity of the encoded portion of the CRSP protein.

The invention further encompasses nucleic acid molecules that differ from the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO: 10, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98634, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98452, due to degeneracy of the genetic code and thus encode the same CRSP proteins as those encoded by the nucleotide sequence shown in SEQ ID NO: 1, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO: 10, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98634, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98452. In another embodiment, an isolated nucleic acid molecule of the invention has a nueleotide sequence encoding a protein having an amino acid sequence shown in SEQ ID NO:2, SEQ ID NO: 5, SEQ ID NO:8, or SEQ ID NO: 11.

In addition to the human CRSP nucleotide sequences shown in SEQ ID NO: 1, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO: 10, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98634, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98452, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the CRSP proteins may exist within a population the human population). Such genetic polymorphism in the CRSP genes may exist among individuals within a population due to natural allelic variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame encoding a CRSP protein, preferably a mammalia CRSP protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of a CRSP gene. Any and all such nucleotide variations and resulting amino acid polymorphisms in CRSP genes that are the result of natural allelic variation and that do not alter the functional activity of a CRSP protein are intended to be within the scope of the invention.

Moreover, nucleic acid molecules encoding CRSP proteins from other species, and thus which have a nucleotide sequence which differs from the human sequence of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO:10, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98634, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633, or the nucleotide sequence of the DNA insert of the plasmid -21deposited with ATCC as Accession Number 98452, are intended to be within the scope of the invention. For example, a murine CRSP-I cDNA has been identified based of the nucleotide sequence of human CRSP-1. The nucleotide sequence of murine CRSP-1 (SEQ ID NO:16) encodes a CRSP-1 protein having 349 amino acids. The nucleotide and amino acid sequences of murine CRSP-1 are depicted in Figure 8. The coding region of murine CRSP-1 is represented by SEQ ID NO: 18.

Nucleic acid molecules corresponding to natural allelic variants and homologues of the CRSP cDNAs of the invention can be isolated based on their homology to the human CRSP nucleic acids disclosed herein using the human cDNA, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions. Examples of tissues and/or libraries suitable for isolation of the subject nucleic acids include thymus, lymph nodes and inflammatory tissue. cDNA encoding a CRSP protein a CRSP-1 protein) can be obtained by isolating total mRNA-from a cell, a vertebrate cell, a mammalian cell, or a human cell, including embryonic cells. Double stranded cDNAs can then be prepared from the total mRNA, and subsequently inserted into a suitable plasmid or bacteriophage vector using any one of a number of known techniques. The gene encoding a CRSP-1 protein can also be cloned using established polymerase chain reaction techniques in accordance with the nucleotide sequence information provided by the invention. The nucleic acid of the invention can be DNA or RNA or analogs thereof.

Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 15 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO:10, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98634, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98452. In other embodiment, the nucleic acid is at least 30, 50, 100, 250 or 500 nucleotides in length. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other. Preferably, the conditions are such that sequences at least about 70%, more preferably at least about 80%, even more preferably at least about or 90% homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in Current Protocols in Molecular Biology, John Wiley Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent hybridization conditions are hybridization -22in 6X sodium chloride/sodium citrate (SSC) at about 45 0 C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65 0 C. Preferably, an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of SEQ ID NO: I corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature encodes a natural protein).

In addition to naturally-occurring allelic variants of the CRSP sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences of SEQ ID NO: 1, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO:10, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98634, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98452, thereby leading to changes in the amino acid sequence of the encoded CRSP proteins, without altering the functional ability of the CRSP proteins.

For example, nucleotide substitutions leading to amino acid substitutions (particularly conservative amino acid substitutions) at "non-essential" amino acid residues can be made in the sequence of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7, SEQ ID the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98634, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98452. A "nonessential" amino acid residue is a residue that can be altered from the wild-type sequence of CRSP the sequence of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO:11) without altering the biological activity, whereas an "essential" amino acid residue is required for biological activity. For example, amino acid residues that are conserved among the CRSP proteins of the present invention cysteine residues within cysteine-rich domains), are predicted to be particularly unamenable to alteration.

Furthermore, amino acid residues that are conserved between CRSP protein and other proteins having cysteine-rich domains are not likely to be amenable to alteration.

Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding CRSP proteins that contain changes in amino acid residues that are not essential for activity. Such CRSP proteins differ in amino acid sequence from SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO: 11 yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about -23homologous to the amino acid sequence of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO:11. Preferably, the protein encoded by the nucleic acid molecule is at least about 65-70% homologous to SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO:11, more preferably at least about 75-80% homologous to SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO: 11, even more preferably at least about 85-90% homologous to SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO:11, and most preferably at least about 95% homologous to SEQ ID NO:2, SEQ ID SEQ ID NO:8, or SEQ ID NO:11.

An isolated nucleic acid molecule encoding a CRSP protein homologous to the protein of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO:11 can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7, SEQ ID the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98634, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98452, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced into SEQ ID NO: 1, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO:10, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98634, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98452, by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains lysine, arginine, histidine), acidic side chains aspartic acid, glutamic acid), uncharged polar side chains glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains threonine, valine, isoleucine) and aromatic side chains tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in a CRSP protein one not located in a cysteine-rich domain) is preferably replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a CRSP -24coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for CRSP biological activity to identify mutants that retain activity. Following mutagenesis of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO:10, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98634, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98452, the encoded protein can be expressed recombinantly and the activity of the protein can be determined.

In a preferred embodiment, a mutant CRSP protein can be assayed for intracellular calcium, an increase in phosphatidylinositol or other molecule, and can result, in phosphorylation of specific proteins, a modulation of gene transcription and any of the other biological activities set forth herein.

In a preferred embodiment, a mutant CRSP protein can also be assayed for the ability to modulate cellular signal transduction, either in vitro or in vivo; regulate communication between cells; regulate expression of genes whose expression is modulated by binding of CRSP CRSP-1) to a receptor; regulate gene transcription in a cell involved in development or differentiation, either in vitro or in vivo; regulate cellular proliferation, either in vitro or in vivo; form and/or maintain ordered spatial arrangements of differentiated tissues in vertebrates; (7) modulate cell death cell survival); regulate cell migration; and/or modulate immune system function.

In addition to the nucleic acid molecules encoding CRSP proteins described above, another aspect of the invention pertains to isolated nucleic acid molecules which are antisense thereto. An "antisense" nucleic acid comprises a nucleotide sequence which is complementary to a "sense" nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid. The antisense nucleic acid can be complementary to an entire CRSP coding strand, or to only a portion thereof. In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding CRSP. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues the coding region of human CRSP-1 corresponds to SEQ ID NO:3, the coding region of human CRSP-2 corresponds to SEQ ID NO:6, the coding region of human CRSP-3 corresponds to SEQ ID NO:9, the coding region of human CRSP-4 corresponds to SEQ ID NO: 12, and the coding region of human CRSP-like-N corresponds to SEQ ID NO: 15). In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding CRSP. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids also referred to as 5' and 3' untranslated regions).

Given the coding strand sequences encoding CRSP disclosed herein SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9, or SEQ ID NO:12), antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick base pairing.

The antisense nucleic acid molecule can be complementary to the entire coding region of CRSP mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of CRSP mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of CRSP mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, (carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, I-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, uracil-5- oxyacetic acid methylester, uracil-5-oxyacetic acid 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation RNA transcribed from the inserted nucleic acid will be of -26an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a CRSP protein to thereby inhibit expression of the protein, by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention include direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, by linking the antisense nucleic acid molecules to peptides or antibodies which bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an a-anomeric nucleic acid molecule. An oa-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual p-units, the strands run parallel to each other (Gaultier et al. (1987) Nucleic Acids.

Res. 15:6625-6641). The antisense nucleic acid molecule can also comprise a 2'-omethylribonucleotide (Inoue et al. (1987) Nucleic Acids Res. 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue et al. (1987) FEBS Lett. 215:327-330).

In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes hammerhead ribozymes (described in Haselhoff and Gerlach (1988) Nature 334:585-591)) can be used to catalytically cleave CRSP mRNA transcripts to thereby inhibit translation of CRSP mRNA. A ribozyme having specificity for a CRSP-encoding nucleic acid can be designed based upon the nucleotide sequence of a CRSP cDNA disclosed herein SEQ ID NO: 1, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO: 10, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98634, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as -27- Accession Number 98633). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a CRSP-encoding mRNA. See, Cech et al. U.S. Patent No. 4,987,071; and Cech et al. U.S. Patent No. 5,116,742. Alternatively, CRSP mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, Bartel, D. and Szostak, J.W. (1993) Science 261,:1411-1418.

Alternatively, CRSP gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the CRSP the CRSP promoter and/or enhancers) to form triple helical structures that prevent transcription of the CRSP gene in target cells. See generally, Helene, C. (1991) Anticancer Drug Des.

6(6):569-84; Helene, C. et al. (1992) Ann. N.Y. Acad. Sci. 660:27-36; and Maher, L.J.

(1992) Bioassays 14(12):807-15.

In yet another embodiment, the CRSP nucleic acid molecules of the present invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acid molecules can be modified to generate peptide nucleic acids (see Hyrup B. et al. (1996) Bioorganic Medicinal Chemistry 4 5-23). As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics, DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA.and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup B. et al. (1996) supra; Perry-O'Keefe et al. PNAS 93: 14670-675.

PNAs of CRSP nucleic acid molecules can be used therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, for example, inducing transcription or translation arrest or inhibiting replication. PNAs of CRSP nucleic acid molecules can also be used in the analysis of single base pair mutations in a gene, by PNAdirected PCR clamping); as 'artificial restriction enzymes' when used in combination with other enzymes, S1 nucleases (Hyrup B. (1996) supra)); or as probes or primers for DNA sequencing or hybridization (Hyrup B. et al. (1996) supra; Perry- O'Keefe supra).

In another embodiment, PNAs of CRSP can be modified, to enhance their stability or cellular uptake), by attaching lipophilic or other helper groups to PNA, by -28the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of CRSP nucleic acid molecules can be generated which may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, RNAse H and DNA polymerases), to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup B. (1996) supra). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup B. (1996) supra and Finn P.J. et al.

(1996) Nucleic Acids Res. 24 3357-63. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry and modified nucleoside analogs, 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used as a between the PNA and the 5' end of DNA (Mag, M. el al. (1989) Nucleic Acid Res. 17: 5973-88). PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn P.J. et al. (1996) supra). Alternatively, chimeric moleclues can be synthesized with a 5' DNA segment and a 3' PNA segment (Peterser, K.H. et al. (1975) Bioorganic Med. Chem. Lett. 5: 1119-11124).

In other embodiments, the oligonucleotide may include other appended groups such as peptides for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, Letsinger et al. (1989) Proc. Natl. Acad.

Sci. US. 86:6553-6556; Lemaitre et al. (1987) Proc. Natl. Acad. Sci. USA 84:648-652; PCT Publication No. W088/09810, published December 15, 1988) or the blood-brain barrier (see, PCT Publication No. W089/10134, published April 25, 1988). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (See, Krol et al. (1988) BioTechniques 6:958-976) or intercalating agents. (See, Zon (1988) Pharm. Res. 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, a peptide, hybridization triggered cross-linking agent, transport agent, or hybridization-triggered cleavage agent).

II. Isolated CRSP Proteins and Anti-CRSP Antibodies One aspect of the invention pertains to isolated CRSP proteins, and biologically active portions thereof, as well as polypeptide fragments suitable for use as immunogens to raise anti-CRSP antibodies. In one embodiment, native CRSP proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, CRSP proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, a -29- CRSP protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the CRSP protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of CRSP protein in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. In one embodiment, the language "substantially free of cellular material" includes preparations of CRSP protein having less than about 30% (by dry weight) of non-CRSP protein (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-CRSP protein, still more preferably less than about 10% of non-CRSP protein, and most preferably less than about 5% non- CRSP protein. When-the CRSP protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about and most preferably less than about 5% of the volume of the protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of CRSP protein in which the protein is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of CRSP protein having less than about 30% (by dry weight) of chemical precursors or non-CRSP chemicals, more preferably less than about chemical precursors or non-CRSP chemicals, still more preferably less than about chemical precursors or non-CRSP chemicals, and most preferably less than about chemical precursors or non-CRSP chemicals.

Biologically active portions of a CRSP protein include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequence of the CRSP protein, the amino acid sequence shown in SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO: 11, which include less amino acids than the full length CRSP proteins, and exhibit at least one activity of a CRSP protein.

Typically, biologically active portions comprise a domain or motif with at least one activity of the CRSP protein. A biologically active portion of a CRSP protein can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acids in length.

In one embodiment, a biologically active portion of a CRSP protein comprises at least a cysteine-rich region. In another embodiment, a biologically active portion of a CRSP protein comprises at least a cysteine-rich region, wherein the cysteine-rich region includes at least one cysteine-rich domain. In yet another embodiment, a biologically active portion of a CRSP protein comprises at least a signal sequence.

In an alternative embodiment, a biologically active portion of a CRSP protein comprises a CRSP amino acid sequence lacking a signal sequence.

It is to be understood that a preferred biologically active portion of a CRSP protein of the present invention may contain at least one of the above-identified structural domains. A more preferred biologically active portion of a CRSP protein may contain at least two of the above-identified structural domains. An even more preferred biologically active portion of a CRSP protein may contain at least three of the above-identified structural domains. A particularly preferred biologically active portion of a CRSP protein of the present invention may contain at least four of the aboveidentified structural domains.

Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native CRSP protein.

In a preferred embodiment, the CRSP protein has an amino acid sequence shown in SEQ ID NO:2 or an amino acid sequence at least about 55% homologous to SEQ ID NO:2. In another preferred embodiment, the CRSP protein has an amino acid sequence shown in SEQ ID NO:5 or an amino acid sequence at least about 35% homologous to SEQ ID NO:5. In another preferred embodiment, the CRSP protein has an amino acid sequence shown in SEQ ID NO:8 or an amino acid sequence at least about homologous to SEQ ID NO:8. In another preferred embodiment, the CRSP protein has an amino acid sequence shown in SEQ ID NO:11 or an amino acid sequence at least about 35% homologous to SEQ ID NO: 11. In still another preferred embodiment, a CRSP protein of the present invention comprises an amino acid sequence which is at least about 30-35%, preferably about 40-45%, more preferably about 50-55%, even more preferably about 60-65%, and even more preferably at least about 70-75%, 90-95% or more homologous to the amino acid sequences shown in SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO:11.

In other embodiments, the CRSP protein is substantially homologous to SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO:11, and, preferably, retains the functional activity of the protein of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO:11, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail in subsection I above. Accordingly, in another embodiment, the CRSP protein is a protein which comprises an amino acid sequence at least about 60% homologous to the amino acid sequence of SEQ ID NO:2, SEQ ID SEQ ID NO:8, or SEQ ID NO:11 and, preferably, retains the functional activity -31 of the CRSP proteins of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO:11, respectively. Preferably, the protein is at least about 70% homologous to SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO:11, more preferably at least about 80% homologous to SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO:11, even more preferably at least about 90% homologous to SEQ ID NO:2, SEQ ID SEQ ID NO:8, or SEQ ID NO: 11, and most preferably at least about 95% or more homologous to SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO:11.

To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity"). The percent homology between the two sequences is a function of the number of identical positions shared by the sequences homology of identical positions/total of positions x 100). The determination of percent homology between two sequences can be accomplished using a mathematical algorithim. A preferred, non-limiting example of a mathematical algorithim utilized for the comparison of two sequences is the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264-68, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-77. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul, et al. (1990) J.

Mol. Biol. 215:403-10. BLAST nucleotide searches can be performed performed with the NBLAST program, score 100, wordlength 12 to obtain nucleotide sequences homologous to CRSP nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score 50, wordlength 3 to obtain amino acid sequences homologous to CRSP protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Research 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs XBLAST and NBLAST) can be used. See http://www.ncbi.nlm.nih.gov.

Another preferred, non-limiting example of a mathematical algorithim utilized for the comparison of sequences is the algorithm of Myers and Miller, CABIOS (1989). Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for -32comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.

The invention also provides CRSP chimeric or fusion proteins. As used herein, a CRSP "chimeric protein" or "fusion protein" comprises a CRSP polypeptide operatively linked to a non-CRSP polypeptide. A "CRSP polypeptide" refers to a polypeptide having an amino acid sequence corresponding to CRSP, whereas a "non-CRSP polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially homologous to the CRSP protein, a protein which is different from the CRSP protein and which is derived from the same or a different organism. Within a CRSP fusion protein the CRSP polypeptide can correspond to all or a portion of a CRSP protein. In a preferred embodiment, a CRSP fusion protein comprises at least one biologically active portion of a CRSP protein. In another preferred embodiment, a CRSP fusion protein comprises at least two biologically active portions of a CRSP protein. In another preferred embodiment, a CRSP fusion protein comprises at least three biologically active portions of a CRSP protein. Within the fusion protein, the term "operatively linked" is intended to indicate that the CRSP polypeptide and the non-CRSP polypeptide are fused in-frame to each other. The non- CRSP polypeptide can be fused to the N-terminus or C-terminus of the CRSP polypeptide.

For example, in one embodiment, the fusion protein is a GST-CRSP fusion protein in which the CRSP sequences are fused to the C-terminus of the GST sequences.

Such fusion proteins can facilitate the purification of recombinant CRSP.

In another embodiment, the fusion protein is a CRSP protein containing a heterologous signal sequence at its N-terminus. For example, the native CRSP signal sequence about amino acids 1 to 23 of SEQ ID NO:2) can be removed and replaced with a signal sequence from another protein. In certain host cells mammalian host cells), expression and/or secretion of CRSP can be increased through use of a heterologous signal sequence.

In yet another embodiment, the fusion protein is a CRSP-immunoglobulin fusion protein in which the CRSP sequences comprising primarily the CRSP cysteine-rich regions are fused to sequences derived from a member of the immunoglobulin protein family. Soluble derivatives have also been made of cell surface glycoproteins in the immunoglobulin gene superfamily consisting of an extracellular domain of the cell surface glycoprotein fused to an immunoglobulin constant (Fc) region (see Capon, D.J. et al. (1989) Nature 337:525-531 and Capon U.S. Patents 5,116,964 and 5,428,130 [CD4-IgGI constructs]; Linsley, P.S. et al. (1991) J. Exp. Med. 173:721-730 [a CD28- IgGI construct and a B7-1-IgG1 construct]; and Linsley, P.S. et al. (1991) J Exp. Med.

-33- 174:561-569 and U.S. Patent 5,434,131[a CTLA4-IgGl]). Such fusion proteins have proven useful for modulating receptor-ligand interactions. Soluble derivatives of cell surface proteins of the tumor necrosis factor receptor (TNFR) superfamily proteins have been made consisting of an extracellular domain of the cell surface receptor fused to an immunoglobulin constant (Fc) region (See for example Moreland et al. (1997) N. Engl.

J. Med. 337(3):141-147; van der Poll et al. (1997) Blood 89(10):3727-3734; and Ammann et al. (1997) J. Clin. Invest. 99(7):1699-1703.) The CRSP-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a CRSP ligand and a CRSP receptor on the surface of a cell, to thereby suppress CRSP-mediated signal transduction in vivo. The CRSP-immunoglobulin fusion proteins can be used to affect the bioavailability of a CRSP cognate receptor.

Inhibition of the CRSP ligand/CRSP interaction may be useful therapeutically for both the treatment of differentiative or proliferative disorders, as well as modulating promoting or inhibiting) developmental responses, cell adhesion, and/or cell fate.

Moreover, the CRSP-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-CRSP antibodies in a subject, to purify CRSP ligands and in screening assays to identify molecules which inhibit the interaction of CRSP with a CRSP ligand.

Preferably, a CRSP chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers.

Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, Current Protocols in Molecular Biology, eds. Ausubel et al. John Wiley Sons: 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety a GST polypeptide). A CRSPencoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the CRSP protein.

The present invention also pertains to variants of the CRSP proteins which function as either CRSP agonists (mimetics) or as CRSP antagonists. Variants of the -34- CRSP proteins can be generated by mutagenesis, discrete point mutation or truncation of a CRSP protein. An agonist of the CRSP proteins can retain substantially the same, or a subset, of the biological activities of the naturally occurring form of a CRSP protein. An antagonist of a CRSP protein can inhibit one or more of the activities of the naturally occurring form of the CRSP protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the CRSP protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the CRSP protein.

In one embodiment, variants of a CRSP protein which function as either CRSP agonists (mimetics) or as CRSP antagonists can be identified by screening combinatorial libraries of mutants, truncation mutants, of a CRSP protein for CRSP protein agonist or antagonist activity. In one embodiment, a variegated library of CRSP variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of CRSP variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential CRSP sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins for phage display) containing the set of CRSP sequences therein. There are a variety of methods which can be used to produce libraries of potential CRSP variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential CRSP sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (see, Narang; S.A. (1983) Tetrahedron 39:3; Itakura et al. (1984) Annu. Rev.

Biochem. 53:323; Itakura et al. (1984) Science 198:1056; Ike et al. (1983) Nucleic Acid Res. 11:477.

In addition, libraries of fragments of a CRSP protein coding sequence can be used to generate a variegated population of CRSP fragments for screening and subsequent selection of variants of a CRSP protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of a CRSP coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S 1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal, C-terminal and internal fragments of various sizes of the CRSP protein.

Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of CRSP proteins. The most widely used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recrusive ensemble mutagenesis (REM), a new technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify CRSP variants (Arkin and Yourvan (1992) PNAS 89:7811-7815; Delgrave et al. (1993) Protein Engineering 6(3):327-331).

In one embodiment, cell based assays can be exploited to analyze a variegated CRSP library. For example, a library of expression vectors can be transfected into a cell line which ordinarily responds to a particular ligand in a CRSP-dependent manner. The transfected cells are then contacted with the ligand and the effect of expression of the mutant on signaling by the ligand can be detected, by measuring any of a number of immune cell responses. Plasmid DNA can then be recovered from the cells which score for inhibition, or alternatively, potentiation of ligand induction, and the individual clones further characterized.

An isolated CRSP protein, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind CRSP using standard techniques for polyclonal and monoclonal antibody preparation. A full-length CRSP protein can be used or, alternatively, the invention provides antigenic peptide fragments of CRSP for use as immunogens. The antigenic peptide of CRSP comprises at least 8 amino acid residues of the amino acid sequence shown in SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO:11 and encompasses an epitope of CRSP such that an antibody raised against the peptide forms a specific immune complex with CRSP. Preferably, the antigenic peptide comprises at least 10 amino acid residues, more preferably at least amino acid residues, even more preferably at least 20 amino acid residues, and most preferably at least 30 amino acid residues.

-36- Preferred epitopes encompassed by the antigenic peptide are regions of CRSP that are located on the surface of the protein, hydrophilic regions.

A CRSP immunogen typically is used to prepare antibodies by immunizing a suitable subject, rabbit, goat, mouse or other mammal) with the immunogen. An appropriate immunogenic preparation can contain, for example, recombinantly expressed CRSP protein or a chemically synthesized CRSP polypeptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory agent. Immunization of a suitable subject with an immunogenic CRSP preparation induces a polyclonal anti-CRSP antibody response.

Accordingly, another aspect of the invention pertains to anti-CRSP antibodies.

The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, molecules that contain an antigen binding site which specifically binds (immunoreacts with) an antigen, such as CRSP. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab') 2 fragments which can be generated by treating the antibody with an enzyme such as pepsin. The invention provides polyclonal and monoclonal antibodies that bind CRSP. The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of CRSP. A monoclonal antibody composition thus typically displays a single binding affinity for a particular CRSP protein with which it immunoreacts.

Polyclonal anti-CRSP antibodies can be prepared as described above by immunizing a suitable subject with a CRSP immunogen. The anti-CRSP antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized CRSP. If desired, the antibody molecules directed against CRSP can be isolated from the mammal from the blood) and further purified by well known techniques, such as protein A chromatography to obtain the IgG fraction. At an appropriate time after immunization, when the anti-CRSP antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) Nature 256:495-497) (see also, Brown et al. (1981) J. Immunol.

127:539-46; Brown et al. (1980)J. Biol. Chem .255:4980-83; Yeh et al. (1976) PNAS 76:2927-31; and Yeh et al. (1982) Int. J. Cancer 29:269-75), the more recent human B cell hybridoma technique (Kozbor et al. (1983) Immunol Today 4:72), the EBVhybridoma technique (Cole et al. (1985), Monoclonal Antibodies and Cancer Therapy, -37- Alan R. Liss, Inc., pp. 77-96) or trioma techniques. The technology for producing monoclonal antibody hybridomas is well known (see generally R. H. Kenneth, in Monoclonal Antibodies: A New Dimension In Biological Analyses, Plenum Publishing Corp., New York, New York (1980); E. A. Lerner (1981) Yale J. Biol. Med., 54:387-402; M. L. Gefter et al. (1977) Somatic Cell Genet. 3:231-36). Briefly, an immortal cell line (typically a myeloma) is fused to lymphocytes (typically splenocytes) from a mammal immunized with a CRSP immunogen as described above, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds CRSP.

Any of the many well known protocols used for fusing lymphocytes and immortalized cell lines can be applied for the purpose of generating an anti-CRSP monoclonal antibody (see, G. Galfre et al. (1977) Nature 266:55052; Gefter et al.

Somatic Cell Genet., cited supra; Lerner, Yale J. Biol. Med., cited supra; Kenneth, Monoclonal Antibodies, cited supra). Moreover, the ordinarily skilled worker will appreciate that there are many variations of such methods which also would be useful.

Typically, the immortal cell line a myeloma cell line) is derived from the same mammalian species as the lymphocytes. For example, murine hybridomas can be made by fusing lymphocytes from a mouse immunized with an immunogenic preparation of the present invention with an immortalized mouse cell line. Preferred immortal cell lines are mouse myeloma cell lines that are sensitive to culture medium containing hypoxanthine, aminopterin and thymidine ("HAT medium"). Any of a number of myeloma cell lines can be used as a fusion partner according to standard techniques, the P3-NSl/l-Ag4-l, P3-x63-Ag8.653 or Sp2/O-Agl4 myeloma lines. These myeloma lines are available from ATCC. Typically, HAT-sensitive mouse myeloma cells are fused to mouse splenocytes using polyethylene glycol Hybridoma cells resulting from the fusion are then selected using HAT medium, which kills unfused and unproductively fused myeloma cells (unfused splenocytes die after several days because they are not transformed). Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supematants for antibodies that bind CRSP, using a standard ELISA assay.

Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal anti-CRSP antibody can be identified and isolated by screening a recombinant combinatorial immunoglobulin library an antibody phage display library) with CRSP to thereby isolate immunoglobulin library members that bind CRSP.

Kits for generating and screening phage display libraries are commercially available the Pharmacia Recombinant Phage Antibody System, Catalog No. 27-9400-01; and the Stratagene SurfZAPT Phage Display Kit, Catalog No. 240612). Additionally, -38examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, Ladner et al. U.S.

Patent No. 5,223,409; Kang et al. PCT International Publication No. WO 92/18619; Dower et al. PCT International Publication No. WO 91/17271; Winter et al. PCT International Publication WO 92/20791; Markland et al. PCT International Publication No. WO 92/15679; Breitling et al. PCT International Publication WO 93/01288; McCafferty et al. PCT International Publication No. WO 92/01047; Garrard et al. PCT International Publication No. WO 92/09690; Ladner et al. PCT International Publication No. WO 90/02809; Fuchs et al. (1991) Bio/Technology 9:1370-1372; Hay et al. (1992) Hum. Antibod. Hybridomas 3:81-85; Huse et al. (1989) Science 246:1275-1281; Griffiths et al. (1993) EMBOJ 12:725-734; Hawkins et al. (1992) J. Mol. Biol. 226:889- 896; Clarkson et al. (1991) Nature 352:624-628; Gram et al. (1992) PNAS 89:3576- 3580; Garrad et al. (1991) Bio/Technology 9:1373-1377; Hoogenboom et al. (1991) Nuc.

Acid Res. 19:4133-4137; Barbas et al. (1991) PNAS 88:7978-7982; and McCafferty et al. Nature (1990) 348:552-554.

Additionally, recombinant anti-CRSP antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in Robinson et al. International Application No. PCT/US86/02269; Akira, et al. European Patent Application 184,187; Taniguchi, European Patent Application 171,496; Morrison et al. European Patent Application 173,494; Neuberger et al. PCT International Publication No. WO 86/01533; Cabilly et al. U.S. Patent No. 4,816,567; Cabilly et al.

European Patent Application 125,023; Better et al. (1988) Science 240:1041-1043; Liu et al. (1987) PNAS 84:3439-3443; Liu et al. (1987) J. Immunol. 139:3521-3526; Sun et al. (1987) PNAS 84:214-218; Nishimura et al. (1987) Cane. Res. 47:999-1005; Wood et al. (1985) Nature 314:446-449; and Shaw et al. (1988) J. Natl. Cancer Inst. 80:1553- 1559); Morrison, S. L. (1985) Science 229:1202-1207; Oi et al. (1986) BioTechniques 4:214; Winter U.S. Patent 5,225,539; Jones et al. (1986) Nature 321:552-525; Verhoeyan et al. (1988) Science 239:1534; and Beidler et al. (1988) J. Immunol.

141:4053-4060.

An anti-CRSP antibody monoclonal antibody) can be used to isolate CRSP by standard techniques, such as affinity chromatography or immunoprecipitation. An anti-CRSP antibody can facilitate the purification of natural CRSP from cells and of recombinantly produced CRSP expressed in host cells. Moreover, an anti-CRSP antibody can be used to detect CRSP protein in a cellular lysate or cell -39supernatant) in order to evaluate the abundance and pattern of expression of the CRSP protein. Anti-CRSP antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, P-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include 1251, 1311 35 S or 3

H.

III. Recombinant Expression Vectors and Host Cells Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding CRSP (or a portion thereof). As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors nonepisomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome.

Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form ofplasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to includes promoters, enhancers and other expression control elements polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein CRSP proteins, mutant forms of CRSP, fusion proteins, etc.).

The recombinant expression vectors of the invention can be designed for expression of CRSP in prokaryotic or eukaryotic cells. For example, CRSP can be expressed in bacterial cells such as E. coli, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in E. coli with vectors containing constitutive or inducible promotors directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion -41 moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase.

Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith, D.B.

and Johnson, K.S. (1988) Gene 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRITS (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Purified fusion proteins can be utilized in CRSP activity assays, in CRSP ligand binding direct assays or competitive assays described in detail below), to generate antibodies specific for CRSP proteins, as examples. In a preferred embodiment, a CRSP fusion expressed in a retroviral expression vector of the present invention can be utilized to infect bone marrow cells which are subsequently transplanted into irradiated recipients. The pathology of the subject recipient is then examined after sufficient time has passed (e.g six (6).weeks).

Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amann et al., (1988) Gene 69:301-315) and pET 1 Id (Studier et al., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California (1990) 60-89). Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET 1 Id vector relies on transcription from a T7 gnl0-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gnl). This viral polymerase is supplied by host strains BL21(DE3) or HMS 174(DE3) from a resident X prophage harboring a T7 gnl gene under the transcriptional control of the lacUV promoter.

One strategy to maximize recombinant protein expression in E. coli is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California (1990) 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in E. coli (Wada et al., (1992) Nucleic Acids Res. 20:2111-2118).

Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the CRSP expression vector is a yeast expression vector.

Examples of vectors for expression in yeast S. cerivisae include pYepSecl (Baldari, et al., (1987) Embo J. 6:229-234), pMFa (Kurjan and Herskowitz, (1982) Cell 30:933- -42- 943), pJRY88 (Schultz et al., (1987) Gene 54:113-123), pYES2 (Invitrogen Corporation, San Diego, CA), and picZ (InVitrogen Corp, San Diego, CA).

Alternatively, CRSP can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells Sf 9 cells) include the pAc series (Smith et al. (1983) Mol. Cell Biol.

3:2156-2165) and the pVL series (Lucklow and Summers (1989) Virology 170:31-39).

In yqt another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, B. (1987) Nature 329:840) and pMT2PC (Kaufman et al. (1987) EMBOJ. 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements.

For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook, Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type tissue-specific regulatory elements are used to express the nucleic acid). Tissuespecific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert et al.

(1987) Genes Dev. 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) Adv. Immunol. 43:235-275), in particular promoters ofT cell receptors (Winoto and Baltimore (1989) EMBO J. 8:729-733) and immunoglobulins (Banerji et al. (1983) Cell 33:729-740; Queen and Baltimore (1983) Cell 33:741-748), neuron-specific promoters the neurofilament promoter; Byrne and Ruddle (1989) PNAS 86:5473-5477), pancreas-specific promoters (Edlund et al. (1985) Science 230:912-916), and mammary gland-specific promoters milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990) Science 249:374-379) and the a-fetoprotein promoter (Campes and Tilghman (1989) Genes Dev. 3:537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an -43- RNA molecule which is antisense to CRSP mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub, H. et al., Antisense RNA as a molecular tool for genetic analysis, Reviews Trends in Genetics, Vol. 1(1) 1986.

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, CRSP protein can be expressed in bacterial cells such as E. coli, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), and oaher laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred -44selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding CRSP or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection cells that have incorporated the selectable marker gene will survive, while the other cells die).

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce express) CRSP protein. Accordingly, the invention further provides methods for producing CRSP protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding CRSP has been introduced) in a suitable medium such that CRSP protein is produced. In another embodiment, the method further comprises isolating CRSP from the medium or the host cell.

The host cells of the invention can also be used to produce nonhuman transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which CRSP-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous CRSP sequences have been introduced into their genome or homologous recombinant animals in which endogenous CRSP sequences have been altered. Such animals are useful for studying the function and/or activity of CRSP and for identifying and/or evaluating modulators of CRSP activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous CRSP gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing CRSPencoding nucleic acid into the male pronuclei of a fertilized oocyte, by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. The human CRSP cDNA sequence of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7, or SEQ ID NO:10 can be introduced as a transgene into the genome of a non-human animal. Alternatively, a nonhuman homologue of a human CRSP gene, such as a mouse CRSP gene, can be isolated based on hybridization to the human CRSP cDNA (described further in subsection I above) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably linked to the CRSP transgene to direct expression of CRSP protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos.

4,736,866 and 4,870,009, both by Leder et al., U.S. Patent No. 4,873,191 by Wagner et al. and in Hogan, Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the CRSP transgene in its genome and/or expression of CRSP mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene encoding CRSP can further be bred to other transgenic animals carrying other transgenes.

To create a homologous recombinant animal, a vector is prepared which contains at least a portion of a CRSP gene into which a deletion, addition or substitution has been introduced to thereby alter, functionally disrupt, the CRSP gene. The CRSP gene can be a human gene the cDNA of SEQ ID NO:3, SEQ ID NO: 6, SEQ ID NO:9 or SEQ ID NO:12), but more preferably, is a non-human homologue of a human CRSP gene. For example, a mouse CRSP gene of SEQ ID NO: 16 can be used to construct a homologous recombination vector suitable for altering an endogenous CRSP gene in the mouse genome. In a preferred embodiment, the vector is designed such that, upon homologous recombination, the endogenous CRSP gene is functionally disrupted no longer encodes a functional protein; also referred to as a "knock out" vector).

Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous CRSP gene is mutated or otherwise altered but still encodes functional protein the upstream regulatory region can be altered to thereby alter the expression of the endogenous CRSP protein). In the homologous recombination vector, the altered portion of the CRSP gene is flanked at its 5' and 3' ends by additional nucleic acid of the CRSP gene to allow for homologous recombination to occur between the exogenous CRSP gene carried by the vector and an endogenous CRSP gene in an -46embryonic stem cell. The additional flanking CRSP nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the vector (see Thomas, K.R. and Capecchi, M. R. (1987) Cell 51:503 for a description of homologous recombination vectors). The vector is introduced into an embryonic stem cell line by electroporation) and cells in which the introduced CRSP gene has homologously recombined with the endogenous CRSP gene are selected (see Li, E.

et al. (1992) Cell 69:915). The selected cells are then injected into a blastocyst of an animal a mouse) to form aggregation chimeras (see Bradley, A. in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, E.J. Robertson, ed. (IRL, Oxford, 1987) pp. 113-152). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, A. (1991) Current Opinion in Biotechnology 2:823-829 and in PCT International Publication Nos.: WO 90/11354 by Le Mouellec et al.; WO 91/01140 by Smithies et al.; WO 92/0968 by Zijlstra et al.; and WO 93/04169 by Berns et al.

In another embodiment, transgenic non-humans animals can be produced which contain selected systems which allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage PI. For a description of the cre/loxP recombinase system, see, Lakso et al. (1992) PNAS 89:6232-6236. Another example of a recombinase system is the FLP recombinase system of Saccharomyces cerevisiae (O'Gorman et al. (1991) Science 251:1351-1355. If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, I. et al. (1997) Nature 385:810- 813. In brief, a cell, a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G o phase. The quiescent cell can then be fused, through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The recontructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to -47pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell, the somatic cell, is isolated.

IV. Pharmaceutical Compositions The CRSP nucleic acid molecules, CRSP proteins, and anti-CRSP antibodies (also referred to herein as "active compounds") of the invention can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, intravenous, intradermal, subcutaneous, oral inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage -48and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound a CRSP protein or anti-CRSP antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following irgredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

-49- For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.

Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid.

Methods for preparation of such formulations will be apparent to those skilled in the art.

The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose 50 therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD5OIED50. Compounds which exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see U.S. Patent 5,328,470) or by stereotactic injection (see Chen et al. (1994) PNAS 91:3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

V. Uses and Methods of the Invention The molecules of the present invention nucleic acid molecules, proteins, protein homologues, and antibodies described herein) can be used in one or more of the following methods: a) screening assays; b) predictive medicine diagnostic assays, prognostic assays, monitoring clinical trials, and pharmacogenetics); and c) methodls of treatment therapeutic and prophylactic). As described herein, a CRSP protein of -51 the invention has one or more of the following activities: intracellular calcium, an increase in phosphatidylinositol or other molecule, and can result, in phosphorylation of specific proteins, a modulation of gene transcription and any of the other biological activities set forth herein.

In a preferred embodiment, a CRSP activity is at least one or more of the following activities: interaction of a CRSP protein with and/or binding to a second molecule, a protein, such as a CRSP CRSP-1) receptor, a soluble form of a CRSP receptor, a receptor for a member of the wnt family of signaling proteins, or a non-CRSP signaling molecule); (ii) interaction of a CRSP protein with an intracellular protein via a membrane-bound CRSP receptor; (iii) complex formation between a soluble CRSP protein and a second soluble CRSP binding partner a non-CRSP protein molecule or a second CRSP protein molecule); (iv) interaction with other extracellular proteins regulation of wnt-dependent cellular adhesion to extracellular matrix components); binding to and eliminating an undesirable molecule a detoxifying activity or defense function); and/or (vi) an enzymatic activity, and can can thus be used in, for example, modulation of cellular signal transduction, either in vitro or in vivo antagonism of the activity of members of the wnt family of secreted proteins or supression of wnt-dependent signal transduction); regulation of communication between cells regulation of wnt-dependent cell-cell interactions); regulation of expression of genes whose expression is modulated by binding of CRSP CRSP-1) to a receptor; regulation of gene transcription in a cell involved in development or differentiation, either in vitro or in vivo induction of cellular differentiation); regulation of gene transcription in a cell involved in development or differentiation, wherein at least one gene encodes a differentiation-specific protein; (6) regulation of gene transcription in a cell involved in development or differentaition, wherein at least one gene encodes a second secreted protein; regulation of gene transcription in a cell involved in development or differentiation, wherein at least one gene encodes a signal transduction molecule; regulation of cellular proliferation, either in vitro or in vivo induction of cellular proliferation or inhibition of proliferation as in the case of supression of tumorogenesis supression of glioblastoma formation)); formation and maintenance of ordered spatial arrangements of differentiated tissues in vertebrates, both adult and embryonic induction of head formation during vertebrate development or maintenance of hematopoietic progenitor cells); (10) modulation of cell death, such as stimulation of cell survival; (11) regulating cell migration; and/or (12) immune modulation.

Accordingly one embodiment of the present invention involves a method of use a diagnostic assay, prognostic assay, or a prophylactic/therapeutic method of -52treatment) wherein a molecule of the present invention a CRSP protein, CRSP nucleic acid, or a CRSP modulator) is used, for example, to diagnose, prognose and/or treat a disease and/or condition in which any of the aforementioned activities activities (vi) and (12) in the above paragraph) is indicated. In another embodiment, the present invention involves a method of use a diagnostic assay, prognostic assay, or a prophylactic/therapeutic method of treatment) wherein a molecule of the present invention a CRSP protein, CRSP nucleic acid, or a CRSP modulator) is used, for example, for the diagnosis, prognosis, and/or treatment of subjects, preferably a human subject, in which any of the aforementioned activities is pathologically perturbed. In a preferred embodiment, the methods of use diagnostic assays, prognostic assays, or prophylactic/therapeutic methods of treatment) involve administering to a subject, preferably a human subject, a molecule of the present invention a CRSP protein, CRSP nucleic acid, or a CRSP modulator) for the diagnosis, prognosis, and/or therapeutic treatment. In another embodiment, the methods of use diagnostic assays, prognostic assays, or prophylactic/therapeutic methods of treatment) involve administering to a human subject a molecule of the present invention a CRSP protein, CRSP nucleic acid, or a CRSP modulator).

Other embodiments of the invention pertain to the use of isolated nucleic acid molecules of the invention can be used, for example, to express CRSP protein via a recombinant expression vector in a host cell in gene therapy applications), to detect CRSP mRNA in a biological sample) or a genetic alteration in a CRSP gene, and to modulate CRSP activity, as described further below. In addition, the CRSP proteins can be used to screen drugs or compounds which modulate the CRSP activity as well as to treat disorders characterized by insufficient or excessive production of CRSP protein or production of CRSP protein forms which have decreased or aberrant activity compared to CRSP wild type protein developmental disorders or proliferative diseases such as cancer as well as diseases, conditions or disorders characterized by abnormal cell differentiation and/or survival, an abnormal extracellular structure, or an abnormality in a defense mechanism). Moreover, the anti-CRSP antibodies of the invention can be used to detect and isolate CRSP proteins, regulate the bioavailability of CRSP proteins, and modulate CRSP activity. The term "an aberrant activity", as applied to an activity of a protein such as CRSP CRSP-1), refers to an activity which differs from the activity of the wild-type or native protein or which differs from the activity of the protein in a healthy subject. An activity of a protein can be aberrant because it is stronger than the activity of its native counterpart. Alternatively, an activity can be aberrant because it is weaker or absent related to the activity of its native counterpart. An aberrant activity can also be a change in an activity. For example an -53 aberrant protein can interact with a different protein relative to its native counterpart. A cell can have an aberrant CRSP CRSP-1) activity due to overexpression or underexpression of the gene encoding CRSP.

A. Screening Assays: The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, candidate or test compounds or agents peptides, peptidomimetics, small molecules or other drugs) which bind to CRSP proteins or have a stimulatory or inhibitory effect on, for example, CRSP expression or CRSP activity.

Modulators can include, for example, CRSP agonist and/or CRSP antagonists. The term "agonist", as used herein, is meant to refer to an agent that mimics or upregulates (e.g.

potentiates or supplements) a CRSP CRSP-1) bioactivity. A CRSP agonist can be a compound which mimics a bioactivity of a CRSP protein, such as transduction of a signal from a CRSP receptor, by, interacting with a CRSP-1 receptor. A CRSP agonist can also be a compound that upregulates expression of a CRSP gene. A CRSP agonist can also be a compound which modulates the expression or activity of a protein which is located downstream of a CRSP receptor, thereby mimicking or enhancing the effect of binding of CRSP to a CRSP receptor.

"Antagonist" as used herein is meant to refer to an agent that inhibits, decreases or suppresses a CRSP CRSP-1) bioactivity. An antagonist can be a compound which decreases signalling from a CRSP protein, a compound that is capable of binding to CRSP-1 or to a CRSP-I receptor. A preferred CRSP antagonist inhibits the interaction between a CRSP protein and another molecule, such as a CRSP receptor.

Alternatively, a CRSP antagonist can be a compound that downregulates expression of a CRSP gene. A CRSP antagonist can also be a compound which modulates the expression or activity of a protein which is located downstream of a CRSP receptor, thereby antagonizing the effect of binding of CRSP to a CRSP receptor.

In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of a CRSP protein or polypeptide or biologically active portion thereof. In another embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of a CRSP receptor. The test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one- -54compound' library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, K.S. (1997) Anticancer Drug Des. 12:145).

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt et al. (1993) Proc. Natl. Acad. Sci. U.S.A. 90:6909; Erb et al. (1994) Proc. Natl. Acad. Sci. USA 91:11422; Zuckermann et al. (1994). J. Med Chem. 37:2678; Cho et al. (1993) Science 261:1303; Carrell et al. (1994) Angew. Chem.

Int. Ed. Engl. 33:2059; Carell et al. (1994) Angew. Chem. Int. Ed. Engl. 33:2061; and in Gallop et al. (1994) J. Med Chem. 37:1233.

Libraries of compounds may be presented in solution Houghten (1992) Biotechniques 13:412-421), or on beads (Lam (1991) Nature 354:82-84), chips (Fodor (1993) Nature 364:555-556), bacteria (Ladner USP 5,223,409), spores (Ladner USP '409), plasmids (Cull et al. (1992) Proc Natl Acad Sci USA 89:1865-1869) or on phage (Scott and Smith (1990) Science 249:386-390); (Devlin (1990) Science 249:404-406); (Cwirla et al. (1990) Proc. Natl. Acad. Sci. 87:6378-6382); (Felici (1991) J. Mol. Biol.

222:301-310); (Ladner supra.).

In one embodiment, an assay is a cell-based-assay in which a cell which expresses a CRSP receptor on the cell surface is contacted with a test compound and the ability of the test compound to bind to a CRSP receptor determined. The cell, for example, can be of mammalian origin or a yeast cell. Determining the ability of the test compound to bind to a CRSP receptor can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the CRSP receptor can be determined by detecting the labeled compound in a complex. For example, test compounds can be labeled with 125s, 35S, 14C, or 3

H,

either directly or indirectly, and the radioisotope detected by direct counting of radioemmission or by scintillation counting. Alternatively, test compounds can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product.

It is also within the scope of this invention to determine the ability of a test compound to interact with a CRSP receptor without the labeling of any of the interactants. For example, a microphysiometer can be used to detect the interaction of a test compound with a CRSP receptor without the labeling of either the test compound or the receptor. McConnell, H. M. et al. (1992) Science 257:1906-1912. As used herein, a "microphysiometer" Cytosensor

T

is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indicator of the interaction between ligand and receptor.

In a preferred embodiment, the assay comprises contacting a cell which expresses a CRSP receptor on the cell surface with a CRSP protein or biologicallyactive portion thereof, to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a CRSP receptor, wherein determining the ability of the test compound to interact with a CRSP receptor comprises determining the ability of the test compound to preferentially bind to the CRSP receptor as compared to the ability of CRSP, or a biologically active portion thereof, to bind to the receptor.

In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a CRSP target molecule with a test compound and determining the ability of the test comlound to modulate stimulate or inhibit) the activity of the CRSP target molecule. Determining the ability of the test compound to modulate the activity of a CRSP target molecule can be accomplished, for example, by determining the ability of the CRSP protein to bind to or interact with the CRSP target molecule.

Determining the ability of the CRSP protein to bind to or interact with a CRSP target molecule can be accomplished by one of the methods described above for determining direct binding. In a preferred embodiment, determining the ability of the CRSP protein to bind to or interact with a CRSP target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target intracellular Ca 2 diacylglycerol, IP 3 etc.), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising a CRSP-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, luciferase), or detecting a cellular response, for example, development, differentiation or rate of proliferation.

In yet another embodiment, an assay of the present invention is a cell-free assay in which a CRSP protein or biologically active portion thereof is contacted with a test compound and the ability of the test compound to bind to the CRSP protein or biologically active portion thereof is determined. Binding of the test compound to the CRSP protein can be determined either directly or indirectly as described above. In a preferred embodiment, the assay includes contacting the CRSP protein or biologically active portion thereof with a known compound which binds CRSP to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a CRSP protein, wherein determining the ability of -56the test compound to interact with a CRSP protein comprises determining the ability of the test compound to preferentially bind to CRSP or biologically active portion thereof as compared to the known compound.

In another embodiment, the assay is a cell-free assay in which a CRSP protein or biologically active portion thereof is contacted with a test compound and the ability of the test compound to modulate stimulate or inhibit) the activity of the CRSP protein or biologically active portion thereof is determined. Determining the ability of the test compound to modulate the activity of a CRSP protein can be accomplished, for example, by determining the ability of the CRSP protein to bind to a CRSP target molecule by one of the methods described above for determining direct binding.

Determining the ability of the CRSP protein to bind to a CRSP target molecule can also be accomplished using a technology such as real-time Biomolocular Interaction Analysis (BIA). Sjolander, S. and Urbaniczky, C. (1991) Anal. Chem. 63:2338-2345 and Szabo et al. (1995) Curr. Opin. Struct. Biol. 5:699-705. As used herein, "BIA" is a technology for studying biospecific interactions in real time, without labeling any of the interactants BIAcorem). Changes in the optical phenomenon surface plasmon resonance (SPR) can be used as an indication of real-time reactions between biological molecules.

In an alternative embodiment, determining the ability of the test compound to modulate the activity of a CRSP protein can be accomplished by determining the ability of the CRSP protein to further modulate the activity of a CRSP target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as previously described.

In yet another embodiment, the cell-free assay involves contacting a CRSP protein or biologically active portion thereof with a known compound which binds the CRSP protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with the CRSP protein, wherein determining the ability of the test compound to interact with the CRSP protein comprises determining the ability of the CRSP protein to preferentially bind to or modulate the activity of a CRSP target molecule.

In many drug screening programs which test libraries of compounds and natural extracts, high throughput assays are desirable in order to maximize the number of compounds surveyed in a given period of time. Assays which are performed in cell-free systems, such as may be derived with purified or semi-purified proteins, are often preferred as "primary" screens in that they can be generated to permit rapid development and relatively easy detection of an alteration in a molecular target which is mediated by a test compound. Moreover, the effects of cellular toxicity and/or bioavailability of the test compound can be generally ignored in the in vitro system, the assay instead being -57focused primarily on the effect of the drug on the molecular target as may be manifest in an alteration of binding affinity with upstream or downstream elements. Accordingly, in an exemplary screening assay of the present invention, the compound of interest is contacted with a CRSP CRSP-1) protein or a CRSP CRSP-1) binding partner, a receptor. The receptor can be soluble or the receptor can be present on a cell surface. To the mixture of the compound and the CRSP protein or CRSP binding partner is then added a composition containing a CRSP binding partner or a CRSP protein, respectively. Detection and quantification of complexes of CRSP proteins and CRSP binding partners provide a means for determining a compound's efficacy at inhibiting (or potentiating) complex formation between CRSP and a binding partner.

The efficacy of the compound can be assessed by generating dose response curves from data obtained using various concentrations of the test compound. Moreover, a control assay can also be performed to provide a baseline for comparison. In the control assay, isolated and purified CRSP polypeptide or binding partner is added to a composition containing the CRSP binding partner or CRSP polypeptide, and the formation of a complex is quantitated in the absence of the test compound.

The cell-free assays of the present invention are amenable to use of both soluble and/or membrane-bound forms of isolated proteins CRSP proteins or biologically active portions thereof or CRSP target molecules). In the case of cell-free assays in which a membrane-bound form an isolated protein is used a CRSP target molecule or receptor) it may be desirable to utilize a solubilizing agent such that the membranebound form of the isolated protein is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, ndodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-Nmethylglucamide, Triton® X-100, Triton® X-114, Thesit®, Isotridecypoly(ethylene glycol ether),, 3-[(3-cholamidopropyl)dimethylamminio]- -propane sulfonate (CHAPS), 3 -[(3-cholamidopropyl)dimethylamminio]-2-hydroxy-1 -propane sulfonate (CHAPSO), or N-dodecyl=N,N-dimethyl-3-ammonio- 1-propane sulfonate.

In more than one embodiment of the above assay methods of the present invention, it may be desirable to immobilize either CRSP or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to a CRSP protein, or interaction of a CRSP protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, -test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows one or both of the proteins to be bound to a -58matrix. For example, glutathione-S-transferase/ CRSP fusion proteins or glutathione-Stransferase/target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or CRSP protein, and the mixture incubated under conditions conducive to complex formation at physiological conditions for salt and pH). Following incubation, the beads or microtitre plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of CRSP binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either a CRSP protein or a CRSP target molecule can be immobilized utilizing conjugation of biotin and streptavidin.

Biotinylated CRSP protein or target molecules can be prepared from biotin-NHS (Nhydroxy-succinimide) using techniques well known in the art biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with CRSP protein or target molecules but which do not interfere with binding of the CRSP protein to its target molecule can be derivatized to the wells of the plate, and unbound target or CRSP protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the CRSP protein or target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the CRSP protein or target molecule.

In another embodiment, modulators of CRSP expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of CRSP mRNA or protein in the cell is determined. The level of expression of CRSP mRNA or protein in the presence of the candidate compound is compared to the level of expression of CRSP mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of CRSP expression based on this comparison. For example, when expression of CRSP mRNA or protein is greater (statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of CRSP mRNA or protein expression. Alternatively, when expression of CRSP mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of CRSP mRNA or protein -59expression. The level of CRSP mRNA or protein expression in the cells can be determined by methods described herein for detecting CRSP mRNA or protein.

In yet another aspect of the invention, the CRSP proteins can be used as "bait proteins" in a two-hybrid assay or three-hybrid assay (see, U.S. Patent No.

5,283,317; Zervos et al. (1993) Cell 72:223-232; Madura et al. (1993) J. Biol. Chem.

268:12046-12054; Bartel et al. (1993) Biotechniques 14:920-924; Iwabuchi et al.

(1993) Oncogene 8:1693-1696; and Brent W094/10300), to identify other proteins, which bind to or interact with CRSP ("CRSP-binding proteins" or "CRSP-bp") and modulate CRSP activity. Such CRSP-binding proteins are also likely to be involved in the propagation of signals by the CRSP proteins as, for example, downstream elements of a CRSP-mediated signaling pathway. Alternatively, such CRSP-binding proteins are likely to be cell-surface molecules associated with non-CRSP expressing cells, wherein such CRSP-binding proteins are involved in signal transduction.

The two-hybrid'system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for a CRSP protein is fused to a gene encoding the DNA binding domain of a known transcription factor GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, in vivo, forming a CRSPdependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the CRSP protein.

This invention further pertains to novel agents identified by the above-described screening assays and to processes for producing such agents by use of these assays.

Accordingly, in one embodiment, the present invention includes a compound or agent obtainable by a method comprising the steps of any one of the aformentioned screening assays cell-based assays or cell-free assays). For example, in one embodiment, the invention includes a compound or agent obtainable by a method comprising contacting a cell which expresses a CRSP target molecule with a test compound and the determining the ability of the test compound to bind to, or modulate the activity of, the CRSP target molecule. In another embodiment, the invention includes a compound or agent obtainable by a method comprising contacting a cell which expresses a CRSP target molecule with a CRSP protein or biologically-active portion thereof, to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with, or modulate the activity of, the CRSP target molecule. In another embodiment, the invention includes a compound or agent obtainable by a method comprising contacting a CRSP protein or biologically active portion thereof with a test compound and determining the ability of the test compound to bind to, or modulate stimulate or inhibit) the activity of, the CRSP protein or biologically active portion thereof. In yet another embodiment, the present invention included a compound or agent obtainable by a method comprising contacting a CRSP protein or biologically active portion thereof with a known compound which binds the CRSP protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with, or modulate the activity of the CRSP protein.

Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent identified as described herein a CRSP modulating agent, an antisense CRSP nucleic acid molecule, a CRSP-specific antibody, or a CRSP-binding partner) can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal model to determine the mechanism of action of such an agent.

The present inventon also pertains to uses of novel agents identified by the above-described screening assays for diagnoses, prognoses, and treatments as described herein. Accordingly, it is within the scope of the present invention to use such agents in the design, formulation, synthesis, manufacture, and/or production of a drug or pharmaceutical composition for use in diagnosis, prognosis, or treatment, as described herein. For example, in one embodiment, the present invention includes a method of synthesizing or producing a drug or pharmaceutical composition by reference to the structure and/or properties of a compound obtainable by one of the above-described screening assays. For example, a drug or pharmaceutical composition can be synthesized based on the structure and/or properties of a compound obtained by a method in which a cell which expresses a CRSP target molecule is contacted with a test compound and the ability of the test compound to bind to, or modulate the activity of, the CRSP target molecule is determined. In another exemplary embodiment, the present invention includes a method of synthesizing or producing a drug or pharmaceutical composition based on the structure and/or properties of a compound obtainable by a method in which a CRSP protein or biologically active portion thereof is contacted with a test compound and the ability of the test compound to bind to, or modulate -61stimulate or inhibit) the activity of, the CRSP protein or biologically active portion thereof is determined.

B. Detection Assays Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. For example, these sequences can be used to: map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. Theseapplications are described in the subsections below.

1. Chromosome Mapping Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the CRSP nucleotide sequences, described herein, can be used to map the location of the CRSP genes on a chromosome. The mapping of the CRSP sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.

Briefly, CRSP genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the CRSP nucleotide sequences. Computer analysis of the CRSP sequences can be used to predict primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the CRSP sequences will yield an amplified fragment.

Somatic cell hybrids are prepared by fusing somatic cells from different mammals human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but human cells can, the one human chromosome that contains the gene encoding the needed enzyme, will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. (D'Eustachio P. et al. (1983) Science 220:919-924). Somatic cell hybrids -62containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions.

PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the CRSP nucleotide sequences to design oligonucleotide primers, sublocalization can be achieved with panels of fragments from specific chromosomes. Other mapping strategies which can similarly be used to map a 9o, Ip, or Iv sequence to its chromosome include in situ hybridization (described in Fan, Y. et al. (1990) PNAS, 87:6223-27), pre-screening with labeled flowsorted chromosomes, and pre-selection by hybridization to chromosome specific cDNA libraries.

Fluorescence in situ hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical such as colcemid that disrupts the mitotic spindle.

The chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases will suffice to get good results at a reasonable amount of time. For a review of this technique, see Verma et al., Human Chromosomes: A Manual of Basic Techniques (Pergamon Press, New York 1988).

Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. (Such data are found, for example, in V. McKusick, Mendelian Inheritance in Man, available on-line through Johns Hopkins University Welch Medical Library). The relationship between a gene and a disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, for example, Egeland, J. et al. (1987) Nature, 325:783-787.

-63- Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the CRSP gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease.

Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence.

Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

2. Tissue Typing The CRSP sequences of the present invention can also be used to identify individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The sequences of the present invention are useful as additional DNA markers for RFLP (described in U.S. Patent 5,272,057).

Furthermore, the sequences of the present invention can be used to provide an alternative technique which determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the CRSP nucleotide sequences described herein can be used to prepare two PCR primers from the 5' and 3' ends of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.

Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the present invention can be used to obtain such identification sequences from individuals and from tissue. The CRSP nucleotide sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the -64noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7, or SEQ ID can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers which each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9, or SEQ ID NO: 12 are used, a more appropriate number of primers for positive individual identification would be 500-2,000.

If a panel of reagents from CRSP nucleotide sequences described herein is used to generate a unique identification database for an individual, those same reagents can later be used to identify tissue from that individual. Using the unique identification database, positive identification of the individual, living or dead, can be made from extremely small tissue samples.

3. Use of Partial CRSP Sequences in Forensic Biology DNA-based identification techniques can also be used in forensic biology.

Forensic biology is a scientific field employing genetic typing of biological evidence found at a crime scene as a means for positively identifying, for example, a perpetrator of a crime. To make such an identification, PCR technology can be used to amplify DNA sequences taken from very small biological samples such as tissues, hair or skin, or body fluids, blood, saliva, or semen found at a crime scene. The amplified sequence can then be compared to a standard, thereby allowing identification of the origin of the biological sample.

The sequences of the present invention can be used to provide polynucleotide reagents, PCR primers, targeted to specific loci in the human genome, which can enhance the reliability of DNA-based forensic identifications by, for example, providing another "identification marker" another DNA sequence that is unique to a particular individual). As mentioned above, actual base sequence information can be used for identification as an accurate alternative to patterns formed by restriction enzyme generated fragments. Sequences targeted to noncoding regions of SEQ ID NOs: 1, SEQ ID NO:4, SEQ ID NO:7, or SEQ ID NO:10 are particularly appropriate for this use as greater numbers of polymorphisms occur in the noncoding regions, making it easier to differentiate individuals using this technique. Examples of polynucleotide reagents include the CRSP nucleotide sequences or portions thereof, fragments derived from the noncoding regions of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7, or SEQ ID NO:10, having a length of at least 20 bases, preferably at least 30 bases.

The CRSP nucleotide sequences described herein can further be used to provide polynucleotide reagents, labeled or labelable probes which can be used in, for example, an in situ hybridization technique, to identify a specific tissue, brain tissue. This can be very useful in cases where a forensic pathologist is presented with a tissue of unknown origin. Panels of such CRSP probes can be used to identify tissue by species and/or by organ type.

In a similar fashion, these reagents, CRSP primers or probes can be used to screen tissue culture for contamination screen for the presence of a mixture of different types of cells in a culture).

C. Predictive Medicine: The present invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, and monitoring clinical trails are used for prognostic (predictive) purposes to thereby treat an individual prophylactically.

Accordingly, one aspect of the present invention relates to diagnostic assays for determining CRSP protein and/or nucleic acid expression as well as CRSP activity, in the context of a biological sample blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant CRSP expression or activity, such as aberrant cell proliferation, differentiation, and/or survival resulting for example in a neurodegenerative disease or cancer. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with CRSP protein, nucleic acid expression or activity. For example, mutations in a CRSP gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby phophylactically treat an individual prior to the onset of a disorder characterized by or associated with CRSP protein, nucleic acid expression or activity.

Another aspect of the invention pertains to monitoring the influence of agents drugs, compounds) on the expression or activity of CRSP in clinical trials.

These and other agents are described in further detail in the following sections.

1. Diagnostic Assays An exemplary method for detecting the presence or absence of CRSP protein or nucleic acid in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting CRSP protein or nucleic acid mRNA, genomic DNA) that encodes CRSP protein such that the presence of CRSP protein or nucleic acid is detected in the biological sample. A preferred agent for detecting CRSP mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to CRSP mRNA or genomic DNA.

-66- The nucleic acid probe can be, for example, a full-length CRSP nucleic acid, such as the nucleic acid of SEQ ID NO: 1, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO:10, the DNA insert of the plasmid deposited with ATCC as Accession Number 98634, the DNA insert of the plasmid deposited with ATCC as Accession Number 98633, the DNA insert of the plasmid deposited with ATCC as Accession Number 98452, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to CRSP mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

A preferred agent for detecting CRSP protein is an antibody capable of binding to CRSP protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof Fab or F(ab') 2 can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect CRSP mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection-of CRSP mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of CRSP protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. In vitro techniques for detection of CRSP genomic DNA include Southern hybridizations. Furthermore, in vivo techniques for detection of CRSP protein include introducing into a subject a labeled anti-CRSP antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a serum sample isolated by conventional means from a subject.

In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a -67compound or agent capable of detecting CRSP protein, mRNA, or genomic DNA, such that the presence of CRSP protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of CRSP protein, mRNA or genomic DNA in the control sample with the presence of CRSP protein, mRNA or genomic DNA in the test sample.

The invention also encompasses kits for detecting the presence of CRSP in a biological sample. For example, the kit can comprise a labeled compound or agent capable of detecting CRSP protein or mRNA in a biological sample; means for determining the amount of CRSP in the sample; and means for comparing the amount of CRSP in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect CRSP protein or nucleic acid.

2. Prognostic Assays The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant CRSP expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with CRSP protein, nucleic acid expression or activity such as a proliferative disorder, a differentiative or developmental disorder, a hematopoietic disorder as well as diseases, conditions or disorders characterized by abnormal cell survival, abnormal extracellular structure, or an abnormality in a defense mechanism. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a differentiative or proliferative disease cancer). Thus, the present invention provides a method for identifying a disease or disorder associated with aberrant CRSP expression or activity in which a test sample is obtained from a subject and CRSP protein or nucleic acid (e.g, mRNA, genomic DNA) is detected, wherein the presence of CRSP protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant CRSP expression or activity. As used herein, a "test sample" refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid serum), cell sample, or tissue.

Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant CRSP expression or activity. For example, such methods can be used to determine whether a subject can be effectively -68treated with an agent for a disorder, such as a proliferative disorder, a differentiative or developmental disorder, a hematopoietic disorder, as well disorders characterized by abnormal cell survival, an abnormal extracellular structure, or an abnormality in a defense mechanism. Alternatively, such methods can be used to determine whether a subject can be effectively treated with an agent for a differentiative or proliferative disease cancer). Thus, the present invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant CRSP expression or activity in which a test sample is obtained and CRSP protein or nucleic acid expression or activity is detected wherein the abundance of CRSP protein or nucleic acid expression or activity is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant CRSP expression or activity.) The methods of the invention can also be used to detect genetic alterations in a CRSP gene, thereby determining if a subject with the altered gene is at risk for a disorder characterized by aberrant development, aberrant cellular differentiation, aberrant cellular proliferation or an aberrant hematopoietic response. In preferred embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic alteration characterized by at least one of an alteration affecting the integrity of a gene encoding a CRSP-protein, or the mis-expression of the CRSP gene. For example, such genetic alterations can be detected by ascertaining the existence of at least one of 1) a deletion of one or more nucleotides from a CRSP gene; 2) an addition of one or more nucleotides to a CRSP gene; 3) a substitution of one or more nucleotides of a CRSP gene, 4) a chromosomal rearrangement of a CRSP gene; an alteration in the level of a messenger RNA transcript of a CRSP gene, 6) aberrant modification of a CRSP gene, such as of the methylation pattern of the genomic DNA, 7) the presence of a non-wild type splicing pattern of a messenger RNA transcript of a CRSP gene, 8) a non-wild type level of a CRSP-protein, 9) allelic loss of a CRSP gene, and 10) inappropriate post-translational modification of a CRSP-protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting alterations in a CRSP gene. A preferred biological sample is a tissue or serum sample isolated by conventional means from a subject.

In certain embodiments, detection of the alteration involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, U.S. Patent Nos.

4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, Landegran et al. (1988) Science 241:1077-1080; and Nakazawa et al. (1994) PNAS 91:360-364), the latter of which can be particularly useful for detecting point mutations in the CRSP-gene (see Abravaya et al. (1995) -69- Nucleic Acids Res .23:675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a CRSP gene under conditions such that hybridization and amplification of the CRSP-gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

Alternative amplification methods include: self sustained sequence replication (Guatelli, J.C. et al., 1990, Proc. Natl. Acad. Sci. USA 87:1874-1878), transcriptional amplification system (Kwoh, D.Y. et al., 1989, Proc. Natl. Acad. Sci. USA 86:1173- 1177), Q-Beta Replicase (Lizardi, P.M. et all, 1988, Bio/Technology 6:1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

In an alternative embodiment, mutations in a CRSP gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (see, for example, U.S. Patent No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

In other embodiments, genetic mutations in CRSP can be identified by hybridizing a sample and control nucleic acids, DNA or RNA, to high density arrays containing hundreds or thousands of oligonucleotides probes (Cronin, M.T. et al.

(1996) Human Mutation 7: 244-255; Kozal, M.J. et al. (1996) Nature Medicine 2: 753- 759). For example, genetic mutations in CRSP can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin, M.T. et al. supra.

Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential ovelapping probes. This step allows the identification of point mutations. This step is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the CRSP gene and detect mutations by comparing the sequence of the sample CRSP with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert ((1977) PNAS 74:560) or Sanger ((1977) PNAS 74:5463). It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays ((1995) Biotechniques 19:448), including sequencing by mass spectrometry (see, PCT International Publication No. WO 94/16101; Cohen etal. (1996) Adv. Chromatogr. 36:127-162; and Griffin et al. (1993) Appl. Biochem. Biotechnol. 38:147-159).

Other methods for detecting mutations in the CRSP gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes (Myers et al. (1985) Science 230:1242). In general, the art technique of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type CRSP sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent which cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S 1 nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation.

See, for example, Cotton et al. (1988) Proc. Natl Acad Sci USA 85:4397; Saleeba et al.

(1992) Methods Enzymol. 217:286-295. In a preferred embodiment, the control DNA or RNA can be labeled for detection.

In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in CRSP cDNAs obtained from samples of cells. For example, the mutY enzyme ofE. coli cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches (Hsu et al. (1994) Carcinogenesis 15:1657-1662). According to an exemplary embodiment, a probe based on a CRSP -71 sequence, a wild-type CRSP sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, for example, U.S. Patent No. 5,459,039.

In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in CRSP genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids (Orita et al. (1989) Proc Natl. Acad. Sci USA: 86:2766, see also Cotton (1993) Mutat Res 285:125-144; and Hayashi (1992) Genet Anal Tech Appl 9:73-79). Single-stranded DNA fragments of sample and control CRSP nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In a preferred embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility (Keen et al. (1991) Trends Genet In yet another embodiment the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE) (Myers et al. (1985) Nature 313:495). When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA (Rosenbaum and Reissner (1987) Biophys Chem 265:12753).

Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions which permit hybridization only if a perfect match is found (Saiki et al. (1986) Nature 324:163); Saiki et al. (1989) Proc. Natl Acad Sci USA 86:6230). Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

Alternatively, allele specific amplification technology which depends on selective PCR amplification may be used in conjunction with the instant invention.

-72- Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization) (Gibbs et al. (1989) Nucleic Acids Res. 17:2437-2448) or at the extreme 3 end of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (Prossner (1993) Tibtech 11:238). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection (Gasparini et al. (1992) Mol. Cell Probes It is anticipated that in certain embodiments amplification may also be performed using Taq ligase for amplification (Barany (1991) Proc. Natl. Acad Sci USA 88:189). In such cases, ligation will occur only if there is a perfect match at the 3' end of the 5' sequence making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

The methods described herein may be performed, for example, by utilizing prepackaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a CRSP gene.

Furthermore, any cell type or tissue in which CRSP is expressed may be utilized in the prognostic assays described herein.

3. Monitoring of Effects During Clinical Trials Monitoring the influence of agents drugs, compounds) on the expression or activity of CRSP modulation of cellular signal transduction, regulation of gene transcription in a cell irivolved in development or differentiation, regulation of cellular proliferation) can be applied not only in basic drug screening, but also in clinical trials.

For example, the effectiveness of an agent determined by a screening assay as described herein to increase CRSP gene expression, protein levels, or upregulate CRSP activity, can be monitored in clinical trails of subjects exhibiting decreased CRSP gene expression, protein levels, or downregulated CRSP activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease CRSP gene expression, protein levels, or downregulate CRSP activity, can be monitored in clinical trails of sabjects exhibiting increased CRSP gene expression, protein levels, or upregulated CRSP activity. In such clinical trials, the expression or activity of CRSP and, preferably, other genes that have been implicated in, for example, a proliferative disorder can be used as a "read out" or markers of the phenotype of a particular cell.

For example, and not by way of limitation, genes, including CRSP, that are modulated in cells by treatment with an agent compound, drug or small molecule) -73which modulates CRSP activity identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on proliferative disorders, developmental or differentiative disorder, hematopoietic disorder as well disorders characterized by abnormal cell differentiation and/or survival, an abnormal extracellular structure, or an abnormality in a defense mechanism, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of CRSP and other genes implicated in the proliferative disorder, developmental or differentiative disorder, hematopoietic disorder as well as disorders characterized by abnormal cell differentiation and/or survival, an abnormal extracellular structure, or an abnormality in a defense mechanism, respectively. The levels of gene expression a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of CRSP or other genes. In this way, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during treatment of the individual with the agent.

In a preferred embodiment, the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of a CRSP protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the CRSP protein, mRNA, or genomic DNA in the post-administration samples; comparing the level of expression or activity of the CRSP protein, mRNA, or genomic DNA in the preadministration sample with the CRSP protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of CRSP to higher levels than detected, to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of CRSP to lower levels than detected, i.e. to decrease the effectiveness of the agent. According to such an embodiment, CRSP expression or activity may be used as an indicator of the effectiveness of an agent, even in the absence of an observable phenotypic response.

-74- C. Methods of Treatment: The present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant CRSP expression or activity. With regards to both prophylactic and therapeutic methods of treatment, such treatments may be specifically tailored or modified, based on knowledge obtained from the field of pharmacogenomics.

"Pharmacogenomics", as used herein, refers to the application of genomics technologies such as gene sequencing, statistical genetics, and gene expression analysis to drugs in clinical development and on the market. More specifically, the term refers the study of how a patient's genes determine his or her response to a drug a patient's "drug response phenotype", or "drug response genotype".) Thus, another aspect of the invention provides methods for tailoring an individual's prophylactic or therapeutic treatment with either the CRSP molecules of the present invention or CRSP modulators according to that individual's drug response genotype. Pharmacogenomics allows a clinician or physician to target prophylactic or therapeutic treatments to patients who will most benefit from the treatment and to avoid treatment of patients who will experience toxic drug-related side effects.

1. Prophylactic Methods In one aspect, the invention provides a method for preventing in a subject, a disease or condition associated with an aberrant CRSP expression or activity, by administering to the subject an agent which modulates CRSP expression or at least one CRSP activity. Subjects at risk for a disease which is caused or contributed to by aberrant CRSP expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the CRSP aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending on the type of CRSP aberrancy, for example, a CRSP agonist or CRSP antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein. The prophylactic methods of the present invention are further discussed in the following subsec:tions.

2. Therapeutic Methods Another aspect of the invention pertains to methods of modulating CRSP expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of CRSP protein activity associated with the cell. An agent that modulates CRSP protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring target molecule of a CRSP protein, a peptide, a CRSP peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more CRSP protein activity. Examples of such stimulatory agents include active CRSP protein and a nucleic acid molecule encoding CRSP that has been introduced into the cell. In another embodiment, the agent inhibits one or more CRSP protein activity.

Examples of such inhibitory agents include antisense CRSP nucleic acid molecules and anti-CRSP antibodies. These modulatory methods can be performed in vitro by culturing the cell with the agent) or, alternatively, in vivo by administering the agent to a subject). As such, the present invention provides methods of treating an individual afflicted with a disease or-disorder characterized by aberrant expression or activity of a CRSP protein or nucleic acid molecule. In one embodiment, the method involves administering an agent an agent identified by a screening assay described herein), or combination of agents that modulates upregulates or downregulates) CRSP expression or activity. In another embodiment, the method involves administering a CRSP protein or nucleic acid molecule as therapy to compensate for reduced or aberrant CRSP expression or activity.

Stimulation of CRSP activity is desirable in situations in which CRSP is abnormally downregulated and/or in which increased CRSP activity is likely to have a beneficial effect. Likewise, inhibition of CRSP activity is desirable in situations in which CRSP is abnormally upregulated and/or in which decreased CRSP activity is likely to have a beneficial effect. One example of such a situation is where a subject has a disorder characterized by aberrant development or cellular differentiation. Another example of such a situation is where the subject has a proliferative disease cancer) or a disorder characterized by an aberrant hematopoietic response. Yet another example of such a situation is where it is desireable to acheive tissue regeneration in a subject where a subject has undergone brain or spinal cord injury and it is desirable to regenerate neuronal tissue in a regulated manner.) Accordingly, in one embodiment, the disease is a disease characterized by an abnormal cell proliferation, differentiation, and/or survival. For example, the disease can be a hyper-or hypoproliferative disease. The invention also provides methods for treating diseases characterized by an abnormal cell proliferation, differentiation, and/or survival in a subject, which are not characterized by an abnormal CRSP activity CRSP-1 activity). In fact, since CRSP is likely to be capable of modulating the proliferative state of a cell state of proliferation, differentiation, and or survival of a -76cell), CRSP can regulate disease wherein the abnormal proliferative state of a cell results from a defect other than an abnormal CRSP activity.

Hyperproliferative diseases can be treated with CRSP CRSP-1) therapeutics include neoplastic and hyperplastic diseases, such as various forms of cancers and leukemias, and fibroproliferative disorders. Other hyperproliferative diseases that can be treated or prevented with the subject CRSP therapeutics CRSP- 1 therapeutics) include malignant conditions, premalignant conditions, and benign conditions. The condition to be treated or prevented can be a solid tumor, such as a tumor arising in an epithelial tissue. Accordingly, treatment of such a cancer could comprise administration to the subject of a CRSP therapeutic decreasing the interaction of CRSP with a CRSP receptor. Other cancers that can be treated or prevented with a CRSP protein include sarcomas and carcinomas, lung cancer, cancer of the colon, prostate, breast, ovary, esophagus, lung cancer, melanoma, seminoma, and squamous adenocarcinoma. Additional solid tumors within the scope of the invention include those that can be found in a medical textbook.

The condition to be treated or prevented can also be a soluble tumor, such as leukemia, either chronic or acute, including chronic or acute myelogenous leukemia, chronic or acute lymphocytic leukemia, promyelocytic leukemia, monocytic leukemia, myelomonocytic leukemia, and erythroleukemia. Yet other proliferative disorders that can be treated with a CRSP therapeutic of the invention include heavy chain disease, multiple myeloma, lymphoma, Hodgkin's lymphoma and non-Hodgkin's lymphoma, and Waldenstroem's macroglobulemia.

Diseases or conditions characterized by a solid or soluble tumor can be treated by administrating a CRSP therapeutic either locally or systemically, such that aberrant cell proliferation is inhibited or decreased. Methods for administering the compounds of the invention are further described below.

The invention also provides methods for preventing the formation and/or development of tumors. For example, the development of a tumor can be preceded by the presence of a specific lesion, such as a pre-neoplastic lesion, hyperplasia, metaplasia, and dysplasia, which can be detected, by cytologic methods. Such lesions can be found, in epithelial tissue. Thus, the invention provides a method for inhibiting progression of such a lesion into a neoplastic lesion, comprising administering to the subject having a preneoplastic lesion an amount of a CRSP-1 therapeutic sufficient to inhibit progression of the preneoplastic lesion into a neoplastic lesion.

The invention also provides for methods for treating or preventing diseases or conditions in which proliferation of cells is desired. For example, CRSP therapeutics can be used to stimulate tissue repair or wound healing, such as after surgery or to -77stimulate tissue healing from burns. Other diseases in which proliferation of cells is desired are hypoproliferative diseases, diseases characterized by an abnormally low proliferation of certain cells.

In yet another embodiment, the invention provides a method for treating or preventing diseases or conditions characterized by aberrant cell differentiation.

Accordingly, the invention provides methods for stimulating cellular differentiation in conditions characterized by an inhibition of normal cell differentiation which may or may not be accompanied by excessive proliferation. Alternatively, CRSP therapeutics can be used to inhibit differentiation of specific cells.

In a preferred method, the aberrantly proliferating and/or differentiating cell is a cell present in the nervous system. A role for CRSP in the nervous system is suggested at least in part from the fact that human CRSP-l is expressed in human fetal brain.

Accordingly, the invention provides methods for treating diseases or conditions associated with a central or peripheral nervous system. For example, the invention provides methods for treating lesions of the nervous system associated with an aberrant proliferation, differentiation or survival of any of the following cells: neurons, Schwann cells, glial cells, and other types of neural cells. Disorders of the nervous system include, but are not limited to: spinal cord injuries, brain injuries, lesions associated with surgery, ischemic lesions, malignant lesions, infectious lesions, degenerative lesions (Parkinson's disease, Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis), demyelating diseases (multiple sclerosis, human immunodeficiency associated myelopathy, transverse myelopathy, progressive multifocal leukoencephalopathy, pontine myelinolysis), motor neuron injuries, progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-Londe syndrome), poliomyelitis, and hereditary motorsensory neuropathy (Charcot-Marie- Tooth disease).

In another embodiment, the invention provides a method for enhancing the survival and/or stimulating proliferation and/or differentiation of cells and tissues in vitro. In a preferred embodiment, CRSP therapeutics are used to promote tissue regeneration and/or repair to treat nerve injury). For example, tissues from a subject can be obtained and grown in vitro in the presence of a CRSP therapeutic, such that the tissue cells are stimulated to proliferate and/or differentiate. The tissue can then be readministered to the subject.

Among the approaches which may be used to ameliorate disease symptoms involving an aberrant CRSP activity and/or an abnormal cell proliferation, differentiation, and/or survival, are, for example, antisense, ribozyme, and triple helix -78molecules described above. Examples of suitable compounds include the antagonists, agonists or homologues described in detail above.

Yet other CRSP therapeutics consist of a first peptide comprising a CRSP peptide capable of binding to a CRSP receptor, and a second peptide which is cytotoxic.

Such therapeutics can be used to specifically target and lyse cells expressing or overexpressing a receptor for CRSP.

3. Pharmacogenomics The CRSP molecules of the present invention, as well as agents, or modulators which have a stimulatory or inhibitory effect on CRSP activity CRSP gene expression) as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders proliferative or developmental disorders) associated with aberrant CRSP activity. In conjunction with such treatment, pharmacogenomics the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, a physician or clinician may consider applying knowledge obtained in relevant pharmacogenomics studies in determining whether to administer a CRSP molecule or CRSP modulator as well as tailoring the dosage and/or therapeutic regimen of treatment with a CRSP molecule or CRSP modulator.

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See Eichelbaum, Clin Exp Pharmacol Physiol, 1996, 23(10-11) :983- 985 and Linder, Clin Chem, 1997, 43(2):254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare genetic defects or as naturally-occurring polymorphisms. For example, glucose-6-phosphate dehydrogenase deficiency (G6PD) is a common inherited enzymopathy in which the main clinical complication is haemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

One pharmacogenomics approach to identifying genes that predict drug response, known as "a genome-wide association", relies primarily on a high-resolution map of the human genome consisting of already known gene-related markers a "biallelic" gene marker map which consists of 60,000-100,000 polymorphic or variable -79sites on the human genome, each of which has two variants.) Such a high-resolution genetic map can be compared to a map of the genome of each of a statistically significant number of patients taking part in a Phase II/III drug trial to identify markers associated with a particular observed drug response or side effect. Alternatively, such a high resolution map can be generated from a combination of some ten-million known single nucleotide polymorphisms (SNPs) in the human genome. As used herein, a "SNP" is a common alteration that occurs in a single nucleotide base in a stretch of DNA. For example, a SNP may occur once per every 1000 bases of DNA. A SNP may be involved in a disease process, however, the vast majority may not be diseaseassociated. Given a genetic map based on the occurrence of such SNPs, individuals can be grouped into genetic categories depending on a particular pattern of SNPs in their individual genome. In such a manner, treatment regimens can be tailored to groups of genetically similar individuals, taking into account traits that may be common among such genetically similar individuals.

Alternatively, a method termed the "candidate gene approach", can be utilized to identify genes that predict drug response. According to this method, if a gene that encodes a drugs target is known a CRSP protein or CRSP receptor of the present invention), all common variants of that gene can be fairly easily identified in the population and it can be determined if having one version of the gene versus another is associated with a particular drug response.

As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C 19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug.

These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses.

If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. The other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

Alternatively, a method termed the "gene expression profiling", can be utilized to identify genes that predict drug response. For example, the gene expression of an animal dosed with a drug a CRSP molecule or CRSP modulator of the present invention) can give an indication whether gene pathways related to toxicity have been turned on.

Information generated from more than one of the above pharmacogenomics approaches can be used to determine appropriate dosage and treatment regimens for prophylactic or therapeutic treatment an individual. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a CRSP molecule or CRSP modulator, such as a modulator identified by one of the exemplary screening assays described herein.

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are hereby incorporated by reference.

EXAMPLES

Example 1: Isolation And Characterization of Human CRSP-1 cDNA In this example, the isolation and characterization of the gene encoding human CRSP-1 (also referred to as "CRISPY-I" or "TANGO 59") is described.

Isolation of the human CRSP-1 cDNA The invention is based at least in part on the discovery of a human gene encoding a secreted protein, referred to herein as Cysteine Rich Secreted Protein-I (CRSP-1). A partial cDNA was isolated using a Signal Sequence Trap method. This methodology takes advantage of the fact that molecules such as CRSP have an amino terminal signal sequence which directs certain secreted and membrane-bound proteins through the cellular secretory apparatus.

Briefly, a randomly primed cDNA library using mRNA prepared from human fetal brain tissue (Clontech, Palo Alto CA) was made by using the Stratagene-ZAPcDNA Synthesis T M kit, (catalog #20041). The cDNA was ligated into the mammalian expression vector pTrap adjacent to a cDNA encoding placental alkaline phosphatase lacking a secretory signal. The plasmids were transformed into E. coli and DNA was prepared using the Wizard T M DNA purification kit (Promega). DNA was transfected into COS-7 cells with lipofectamine T M (Gibco-BRL). After 48 hours incubation the COS cell supernatants were assayed for alkaline phosphatase on a Wallac Micro-Beta scintillation -81 counter using the Phospha-Light T M kit (Tropix Inc. Catalog #BP300). The individual plasmid DNAs scoring positive in the COS cell Alkaline Phosphatase secretion assay were further analyzed by DNA sequencing using standard procedures.

Using a partial cDNA isolated by the above-described method, a full length cDNA encoding human CRSP-I was cloned. The nucleotide sequence encoding the full length human CRSP-1 protein is shown in Figure 1 and is set forth as SEQ ID NO: 1.

The full length protein encoded by this nucleic acid is comprised of about 350 amino acids and has the amino acid sequence shown in Figure 1 and set forth as SEQ ID NO:2.

The coding portion (open reading frame) of SEQ ID NO: is set forth as SEQ ID NO:3.

DNA for the clone jthKb075al0 was deposited with the ATCC as Accession No. 98634.

Analysis of Human CRSP- Determination of the hydrophobicity profile of human CRSP-1 having the amino acid sequence set forth in SEQ ID NO:2 indicated the presence of a hydrophobic region from about amino acid 1 to about amino acid 23 of SEQ ID NO:2. Further analysis of the amino acid sequence SEQ ID NO:2 using signal peptide prediction programs predicted the presence of a signal peptide from about amino acid I to about amino acid 19, 21, or 23 of SEQ ID NO:2. Accordingly, the mature CRSP-1 protein includes about 327, 329, or 331 amino acids spanning from about amino acid 20, 22, or 24 to about amino acid 350 of SEQ ID NO:2. The presence of the signal sequence, in addition to the fact that CRSP-1 has been identified using a Signal Sequence Trap system, indicates that CRSP-1 is a secreted protein. Furthermore, the prediction of such a signal peptide and signal peptide cleavage site can be made, for example, utilizing the computer algorithm SIGNALP (Henrik, et al. (1997) Protein Engineering 10:1-6).

Furthermore, when the cDNA encoding human CRSP-I was expressed in bacterial cells with a C-terminal FLAG tag, the FLAG-tagged CRSP-1 protein product was found to be secreted in to the cellular medium.

Examination of the cDNA sequence depicted in Figure 1 shows that human CRSP-1 is particularly rich in cysteine residues. As shown in Figure 1, CRSP-1 contains 20 cysteine residues located between amino acid 147 and amino acid 284 of SEQ ID NO: 2. These cysteine residues can possibly form 10 disulfide bridges.

A BLAST search (Altschul et al. (1990) J. Mol. Biol. 215:403) of the nucleotide and the amino acid sequences of CRSP-1 has revealed that CRSP-1 is significantly similar to a chicken cDNA encoding a protein of unknown function having GenBank Accession No. D26311. This cDNA was isolated from a chicken lens cDNA library and was shown to be expressed in lens fibers and lens epithelium, but not in neural retina nor in liver cells. (Sawada et al. (1996) Int. J. Dev. Biol. 40:531). CRSP-1 and the chicken -82protein have 56% amino acid sequence identity and 72% amino acid sequence similarity.

The amino acid sequence similarity between the chicken protein and human CRSP-1 is particularly high in the cysteine-rich domain of CRSP-1 which is located between amino acids 147 and 284 of SEQ ID NO: 2. In particular, the 20 cysteine residues of CRSP-1 located in this region are present in the chicken protein (see Figure 3).

Two genes recently identified in a screen for suppressors of glioblastoma formation (Ligon et al., 1997 Oncogene 14 1075-1081) also show significant homology to hCRSP-1. These genes, RIG ("Regulated In Glioblastoma") and RIG-like 7-1 (GenBank Accession Nos. U32331 and AF034208, respectively), were identified in a differential screen for mRNAs regulated by the introduction of a normal copy of chromosome 10 into a glioblastoma cell line harboring a deletion in chromosome 10 that promotes tumorigenesis. A schematic diagram summarizing the relationship between the sequences of the CRSP-1 and the RIG genes presented as Figure 9. The indicated region of identity between CRSP-1, RIG and RIG-like 7-1 comprises a region of the 3' UTR of the human CRSP-1 mRNA. This cDNA was initially isolated in the described differential screen and subsequently used to isolate full length RIG and RIG-like 7-1 messages as depicted. RIG-like 7-1 is highly homologous (96.8% similar as determined using the Lipman-Pearson protein alignment program, Ktuple: 2; Gap Penalty: 4, Gap Length Penalty: 12; and 64.7% homologous using the Wilbur Lipman DNA alignment program, Ktuple: 3; Gap Penalty: 3; Window: 20) to CRSP-1 although the encoded protein lacks the N-terminal signal sequence and is not therefore predicted to be a secreted protein. The full length RIG mRNA only displays homology to CRSP-1 in the region of the initial cDNA. These data associate CRSP-1 with human glioblastoma and suggest that CRSP-1 may be important in the suppression of the tumorigenic phenotype.

A role in glioblastoma is also consistent with the high level of CRSP-1 mRNA expression observed in human brain tissue. In addition, the co-localization of the CRSP- 1, RIG and RIG-like genes to a region of chromosome 11 (1 pl5.1) implicated in the development of human malignant astrocytoma (Ligon et al. 1997 Oncogene 14 1075- 1081) further indicates a role for these genes in tumorogenesis.

Human CRSP-1 protein has also some amino acid sequence similarity to metallothionein, particularly in the cyteine-rich domain.

Tissue Distribution of CRSP-1 mRNA This Example describes the tissue distribution of CRSP-1 mRNA, as determined by Northern blot hybridization.

Northern blot hybridizations with the various RNA samples were performed under standard conditions and washed under stringent conditions, 0.2xSSC at 65 0

C.

-83- In each sample, the probe hybridized to a single RNA of about 2.5 kb. The results of hybridization of the probe to various mRNA samples are described below.

Hybridization of a Clontech Fetal Multiple Tissue Northern (MTN) blot (Clontech, LaJolla, CA) containing RNA from fetal brain, lung, liver, and kidney indicated the presence of high levels of CRSP-1 mRNA in fetal brain, lung, and slightly lower levels of CRSP-1 mRNA in fetal kidney. However, no significant level of CRSP- 1 mRNA was found in fetal liver.

Hybridization of a Clontech human Multiple Tissue Northern (MTN) blot (Clontech, LaJolla, CA) containing RNA from adult heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas with a human CRSP-I probe indicated the presence of high levels of CRSP-I mRNA in heart, slightly lower levels in brain, and much lower levels in placenta and lung. Some CRSP-1 mRNA was also found in adult skeletal muscle. However, no significant levels of CRSP-1 mRNA was observed in adult liver, kidney, or pancreas. Interestingly, the chicken gene which is homologous to CRSP-I was not expressed at detectable levels in liver either (Sawada et al. (1996) Int. J.

Dev. Biol. 40:531).

Further hybridization of a Clontech human Multiple Tissue Northern (MTN) blot (Clontech, LaJolla, CA) including RNA from adult spinal cord revealed high levels of expression of CRSP-1 in mRNA isolated from adult spinal cord.

In situ analysis further revealed the following expression patterns when tissue sections were hybridized with CRSP-1 probes. CRSP-1 mRNA was expressed in heart, lung, aorta, eye (retina and lens), and brain (cortex) in 14.5 day mouse embryos. CRSP- 1 mRNA was expressed in heart, lung, eye (retina and lens), brain (cortical), and cartilage (foot, trachea, larynx, head, sternum, and spinal column) in 1.5 day post natal mouse tissues. CRSP-1 mRNA was expressed in brain (cortex, hippocampus, brainstem), heart (atria only), eye (retina and lens outer layer) in adult mouse tissues.

Thus, CRSP-1 is expressed in a tissue specific manner, with the strongest expression observed in brain, heart, and spinal cord.

CRSP-1 protein expression data Constructs Expression constructs for two forms of CRSP-1 were prepared using the mammalian expression vector pMET-stop. Form-1 comprised a cDNA incorporating the complete 350aa CRSP-1 protein coding sequence (CRSP-1flag.long) and form-2 comprised the entire CRSP-1 protein coding sequence except for the final 18 amino acids (CRSP-1flag.short). A C-terminal sequence encoding the FLAG epitope (DYKDDDDK) was added to both CRSP- forms for ease of detection and purification.

-84- CRSP-lflag cDNAs were generated by PCR from a full length CRSP-1 cDNA template and ligated into pMET-stop using EcoR and Sal restriction sites.

Trial transfection small scale expression Expression constructs for CRSP-lflag.long and CRSP-lflag.short were transfected into 293T cells using 10 pl of lipofectamine (GIBCO/BRL) and 2 pg of DNA per well of a 6-well plate of cells which were 70-80% confluent. After 5 hours at 37*C, cells were fed with lml of 20%FCS/DMEM. After incubation overnight at 37 0

C,

cells were conditioned in Iml OptiMEM for 48 hours at 37 0 C. Samples of supernatant and cell pellets were solubilized in boiling SDS-PAGE gel buffer, run out on a 4-20% SDS-PAGE gel, transferred to a nylon membrane and probed with the anti-FLAG monoclonal antibody M2. Samples from both supematant and pellet samples showed significant immunoreactivity within a molecular weight range of 40-65 kDa on autoradiographic film using a HRP conjugated secondary antibody and ECL detection reagents. Thus, both forms of CRSP-I tested are secreted from 293T cells thereby confirming experimentally that CRSP-1 is a secreted protein. It should be noted that the molecular weights of both forms of CRSP-1 tested are greater than predicted from the amino acid sequence, suggesting that the CRSP-l proteins secreted by 293T cells may be glycosylated. This is consistent with the presence of four potential sites for N-linked glycosylation in the CRSP-1 protein.

Large scale CRSP-1 protein production For scale-up of CRSP-lflag.long protein expression, 30 x 150mM plates of 293T cells at 70-80% confluence were transfected with 27 pg DNA, 100 pl lipofectamine in 18ml OptiMEM for 5 hours at 37 0 C. 18 ml of 10%FCS/DMEM was added to each plate and incubated overnight at 37 0 C. 24 hours after the start of transfection, transfection supernatant was aspirated and 35 mls OptiMEM was added to each plate and the plates incubated at 37 0 C for 72 hours. Conditioned medium was harvested, spun at 4000 rpm for 30 min. at 4 0 C, and filtered through a 0.45 micron filter unit. 1100 ml was passed over a 1.6 x 10 cm anti-FLAG M2 affinity column pre-equilibrated in PBS pH7.4 buffer at a flow rate of 2.0 ml per minute. After washing with 200 ml of PBS pH 7.4 buffer, bound material was eluted by a step of 200 mM Glycine pH 3.0 buffer and 0.5 ml fractions collected. Upon elution, a significant protein peak was detected by absorbance at 280nm. Samples corresponding to conditioned medium, flow through and eluted fractions were analyzed by Coomassie blue and silver stained SDS-PAGE and by western blot analysis as described above. Significant immunoreactivity within a molecular weight range of 40-65 kDa was detected in conditioned medium and eluted fractions but not in the flow through sample, indicating that the secreted CRSP- Iflag.long protein bound to the affinity column specifically and was eluted efficiently by the described conditions. Coomassie blue staining of SDS-PAGE gels suggested that the predominant immunoreactive protein constituted >90% of the protein present in the bound and eluted protein peak. Peak fractions of eluted protein were pooled and dialysed against Phosphate Buffered Saline resulting in a 4 ml volume of recombinant CRSP-lflag.long protein at a concentration of approximately 1mg/ml.

Example 2: Isolation And Characterization of Human CRSP-2. CRSP-3, and CRSP-4 cDNA To identify novel proteins related to CRSP-1, the human CRSP-1 amino acid sequence was used to search the private and dbEST databases using TBLASTN (WashUversion, 2.0, BLOSUM62 search matrix). From this search, four distinct partial protein sequences were identified which displayed significant homology to human CRSP-1. These sequences were designated as partial sequences for the novel hCRSPs; hCRSP-2, h-CRSP-3, h-CRSP-4 and h-CRSP-like-n.

hCRSP-2 partial protein sequence was derived from a single dbEST clone with accession number AA565546. This clone was subsequently obtained from the IMAGE collection and sequenced fully to define the entire hCRSP-2 sequence depicted in Figure 2.

hCRSP-3 partial protein sequence was derived from a jthKb075al 0 clone with sequence identification code jthKb075al 0. This clone was sequenced further and this sequence information combined with additional sequences from dbEST using the assembly program Phrap Green, U. Washington) to define the entire hCRSP-3 sequence depicted in Figure 3. DNA for the clone jthKb075al 0 was deposited with the ATCC as Accession No. 98633. Northern blot analysis of various tissues using a probe specific for hCRSP-3 revealed that CRSP-3 mRNA expression was restricted to placenta. CRSP-3 mRNA expression has not yet been demonstrated in other normal adult human tissues.

A murine and Xenopus homologue of CRSP-3 has recently been described called dkk-1 ("dickkopf', German, thickhead) which is proposed to encode a secreted signaling molecule (Nature, 391, 357-368). dkk-1 is described as a powerful inducer of head formation during early Xenopus development, its mechanism of action apparently involving inhibition of the wnt family of secreted factors.

Given the homology between CRSP-3 and dkk-1, it is suggested that hCRSP-3 may display profound head-inducing activity during early human embryonic -86development. Furthermore,the mechanisms of action of dkk-1 is thought to involve antagonism of members of the wnt family of secreted proteins. Overexpression of wnt proteins has been associated with certain malignancies. For example, activation of wnt- 1 expression by proviral insertion of MMTV causes breast cancer in the mouse (see Cadigan and Nusse, Genes and Dev., 1997 11 3286-3305). Therefore, at least CRSP-3, and potentially other CRSP family members, may also play a role in the suppression of wnt signaling in cancer.

h-CRSP-4 partial protein sequence was derived from a single dbEST clone with accession number W55979. This clone was subsequently obtained from the IMAGE collection and sequenced fully to define a hCRSP-4 sequence depicted in Figure 4.

Northern blot analysis of various tissues using a probe specific for hCRSP-4 revealed that CRSP-4 mRNA was expressed in several adult human tissues. CRSP-4 mRNA expression was highest in heart, brain, placenta, lung, and skeletal muscle.

h-CRSP-like-n-partial protein sequence was derived from a single dbEST clone with accession number AA397836. This clone was subsequently obtained from the IMAGE collection and sequenced fully to define the entire hCRSP-like-n sequence depicted in Figure Structure of the CRSP Family proteins An alignment of the amino acid sequences of human CRSP-1, human CRSP-2, human CRSP-3, and human CRSP-4 is shown in Figure 6. Amino acid residues which are conserved between human CRSP family members are boxed. The 20 conserved cysteine residues are indicated by an asterix. The cysteine-rich domains are indicated as CRD-1 and CRD-2. The domain structure of the full length CRSP proteins of the present invention are depicted in Figure 7. The amino acid and nucleotide homology between CRSP family members is as follows in Tables 1 and 2.

Table 1: CRSP-1 CRSP-2 CRSP-3 CRSP-4 mdkk-l xdkk-1 CLFEST CRSP-1 100 16.0 18.6 15.1 18.5 16.5 53.0 CRSP-2 100 33.7 35.2 32.6 33.7 16.2 CRSP-3 100 33.1 80.2 53.5 17.4 CRSP-4 _100 30.5 33.7 12.5 -87- Amino acid percent homologies were determined using the ALIGN program, (version (GCG software package) using a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4.

Table 2: CRSP-1 CRSP-2 CRSP-3 CRSP-4 mdkk-1 xdkk-1 CLFEST CRSP-1 100 30.0 37.2 34.7 31.5 45.4 58.8 CRSP-2 100 43.0 35.9 38.8 38.4 36.7 CRSP-3 100 59.3 66.4 53.7 32.1 CRSP-4 _100 38.8 38.4 36.7 Nucleotide percent homologies were determined using the using the Wilbur Lipman DNA alignment program, Ktuple: 3; Gap Penalty: 3; Window: Equivalents Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that that prior art forms part of the common general knowledge in Australia.

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

-88- SEQUENCE LISTING GENERAL INFORMATION:

APPLICANT:

NAME: MILLENNIUM BIOTHERAPEUTICS, INC.

STREET: 620 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MASSACHUSETTS COUNTRY: US POSTAL CODE: 02319

TELEPHONE:

TELEFAX:

(ii) TITLE OF INVENTION: NOVEL CRSP PROTEIN AND NUCLEIC ACID MOLECULES AND USES THEREFOR (iii) NUMBER OF SEQUENCES: 18 (iv) CORRESPONDENCE ADDRESS: ADDRESSEE: LAHIVE COCKFIELD, LLP STREET: 28 STATE STREET CITY: BOSTON STATE: MASSACHUSETTS COUNTRY: US ZIP: 02109 COMPUTER READABLE FORM: MEDIUM TYPE: Floppy disk COMPUTER: IBM PC compatible OPERATING SYSTEM: PC-DOS/MS-DOS SOFTWARE: PatentIn Release Version #1.25 (vi) CURRENT APPLICATION DATA: APPLICATION NUMBER: PCT/US98/ FILING DATE: 16 APRIL 1998

CLASSIFICATION:

(vii) PRIOR APPLICATION DATA: APPLICATION NUMBER: US 08/843,704 FILING DATE: 16 APRIL 1997 APPLICATION NUMBER: US 08/842,898 FILING DATE: 17 APRIL 1997 APPLICATION NUMBER: 60/071,589 FILING DATE: 15 JANUARY 1998 APPLICATION NUMBER: 09/009,802 FILING DATE: 20 JANUARY 1998 (viii) ATTORNEY/AGENT INFORMATION: NAME: MANDRAGOURAS, AMY E.

REGISTRATION NUMBER: 36,207 REFERENCE/DOCKET NUMBER: MEI-008CPPC -89- (ix) TELECOMMUNICATION INFORMATION: TELEPHONE: (617)227-7400 TELEFAX: (617)742-4214 INFORMATION FOR SEQ ID NO:1: SEQUENCE CHARACTERISTICS: LENGTH: 2479 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: NAME/KEY: CDS LOCATION: 38..1087 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: GGCACGAGGG GGCGGCGGCT GCGGGCGCAG AGCGGAG ATG CAG CGG CTT GGG GCC Met Gin Arg Leu Gly Ala ACC CTG CTG Thr Leu Leu CCC GCT CCG Pro Ala Pro AGC TAC CCG Ser Tyr Pro

TGC

Cys CTG CTG CTG GCG Leu Leu Leu Ala

GCG

Ala 15 GCG GTC CCC ACG Ala Val Pro Thr GCC CCC GCG Ala Pro Ala CCG GCT CTC Pro Ala Leu ACG GCG ACC TCG Thr Ala Thr Ser

GCT

Ala 30 CCA GTC AAG CCC Pro Val Lys Pro

GGC

Gly 103 151 199 CAG GAG GAG Gin Glu Glu ACC CTC AAT GAG Thr Leu Asn Glu

ATG

Met TTC CGC GAG GTT Phe Arg Glu Val

GAG

Glu 55 GAA CTG ATG GAG Glu Leu Met Glu

GAC

Asp 60 ACG CAG CAC AAA Thr Gin His Lys

TTG

Leu 65 CGC AGC GCG GTG Arg Ser Ala Val

GAA

Glu 247 295 GAG ATG GAG GCA Glu Met Glu Ala

GAA

Glu GAA GCT GCT GCT Glu Ala Ala Ala

AAA

Lys 80 GCA TCA TCA GAA Ala Ser Ser Glu GTG AAC Val Asn CTG GCA AAC TTA CCT CCC AGC TAT CAC AAT GAG ACC AAC Leu Ala Asn Leu Pro Pro Ser Tyr His Asn Glu Thr Asn ACA GAC ACG Thr Asp Thr 100 CAC AAG ATA His Lys Ile 343 AAC GTT GGA AAT Asn Val Gly Asn 105 AAT ACC ATC CAT GTG CAC CGA GAA Asn Thr Ile His Val His Arg Glu 110

ATT

Ile 115 90 ACC AAC Thr Asn 120 AAC CAG ACT GGA Asn Gin Thr Gly

CAA

Gin 125 ATG GTC TTT TCA GAG ACA GTT ATC ACA Met Val Phe Ser Glu Thr Val Ile Thr 130

TCT

Ser 135 GTG GGA GAC GAA Val Gly Asp Glu

GAA

Giu 140 GGC AGA AGG AGC Gly Arg Arg Ser

CAC

His 145 GAG TGC ATC ATC Giu Cys Ile Ile

GAC

Asp 150 GAG GAC TGT GGG Giu Asp Cys Gly

CCC

Pro 155 AGC ATO TAC TGC Ser Met Tyr Cys

CAG

Gin 160 TTT GCC AGC ?TC Phe Ala Ser Phe CAG TAC Gin Tyr 165 GAC AGT Asp Ser 487 535 583 ACC TOC CAG Thr Cys Gin GAG TGC TGT Giu Cys Cys 185

CCA

Pro 170 TGC CGG GGC CAG Cys Arg Gly Gin

AGG

Arg 175 ATG CTC TGC ACC Met Leu Cys Thr

CGG

Arg 180 GGA GAC CAG CTG Gly Asp Gin Leu

TGT

Cys 190 GTC TGG GGT CAC Val Trp Gly His

TGC

Cys 195 ACC AAA ATG Thr Lys Met GCC ACC Ala Thr 200 AGG GGC AGO~ AAT Arg Gly Ser Asn

GGG

Gly 205 ACC ATC TGT GAC Thr Ile Cys Asp

AAC

Asn 210 CAG AGG GAC TGC Gin Arg Asp Cys

CAG

Gin 215 CCG GGG CTG TGC Pro Giy Leu Cys

TGT

Cys 220 GCC TTC CAG AGA Ala Phe Gin Arg

GGC

Gly 225 CTG CTG TTC CCT Leu Leu Phe Pro

GTG

Val 230 679 727 775 TGC ACA CCC CTG Cys Thr Pro Leu CGG CTT CTG GAC Arg Leu Leu Asp -250

CCC

Pro 235 GTG GAG GGC GAG Val Giu Gly Glu

CTT

Leu 240 TGC CAT GAC CCC Cys His Asp Pro GCC AGC Ala Ser 245 CTC ATC ACC TGG Leu Ile Thr Trp

GAG

Giu 255 CTA GAG CCT GAT Leu Glu Pro Asp GGA GCC TTG Gly Ala Leu 260 CAC AGC CAC His Ser His 823 871 GAC CGA TGC Asp Arg Cys 265 CCT TGT GCC AGT Pro Cys Ala Ser

GGC

Gly 270 CTC CTC TOC CAG Leu Leu Cys Gin

CCC

Pro 275 AGC CTG Ser Leu 280 GTG TAT GTG TGC Val Tyr Val Cys

AAG

Lys 285 CCG ACC TTC GTG Pro Thr Phe Val

GGG

Gly 290 AGC CGT GAC CAA Ser Arg Asp Gin

GAT

Asp 295 GGG GAG ATC CTG Gly Giu Ile Leu

CTG

Le *u 300 CCC AGA GAG GTC Pro Arg Glu Val CCC GAT Pro Asp 305 GAG TAT GAA Ciu Tyr Giu

GTT

Val 310 919 967 1015 GGC AGC TTC ATG Cly Ser Phe Met

GAG

Ciu 315 GAG CTG CGC CAG Clu Val Arg Gin

GAG

Glu 320 CTG GAG GAC CTG Leu Giu Asp Leu GAG AGG Glu Arg 325 AGC CTG ACT Ser Leu Thr

GAA

Clu 330 GAG ATG GCG CTG Glu Met Ala Leu

AGG

Arg 335 GAG CCT GCC GCT Glu Pro Ala Ala GCC CCC GCT Aia Ala Ala 340 1063 91 GCA CTG CTG GGA AGO GAA GAG ATT TAGATCTGGA CCAGGCTGTG GGTAGATGTG Ala Leu Leu Gly Arg Glu Glu Ile 1117 345 350 CAATAGAAAT AGCTAATTTA

TCTTCCTACA

CATTTGTTCA

AGGCAGGGTT

CTCTACCAGT

GAGATGGAAA

CCCTGCTTTG

TTCCATGGGC

TOCATTACAT

AGCATTTTCA

TTCTCCTCGT

CACAGCTAGT

CCACTAcccc

GATTTTTCTT

TAAAAGTAAA

AATGAAGACA

GTATATGACT

GGCGAGGATT

CCACGTGGAG

CGAACACTGA

ACCATGTATT

1 TCTTTGAGT

CTTCAACTGC

TCTTCTTCCC

GCTCCCCCAG

AAACTGCAGG

TGGCAGACAG

CAATGTGGAG

CAAACATCAA

ATAGGTAAGC

GTGTTTAT'rC

TATCCAAGAT

CCATCAGGGA

GAAGACCAGA

ACACCAGCCT

TTGAGGCATG

CTACTGTTAG

ATGATATTGA

GAGCGTAGCA

ATAAATGAAA

AAAATCAAAC

ACTCTACGCC

CATCCAGAGT

TTTAAATTAT

TAAAAAAAAA

TTTCCCCANG

AGTAAGTTTC

GCTGTTCTCC

AGCAGTTTGC

CCGTTTGTTC

TCTCCCTCTG

CCTGGCAAAA

TGTGCCTTCA

ATCCAGCAGT

CAATTCCCTC

TTTCAGAGGC

GCAGTTTCAT

TGGTGCCACC

CACATCTGGA

GAACAGCAGT

CACTGTCCCT

TACAGGTTAA

TTTGCAAAAT

CGAGCAGGGC

ACTCCACAAA

TCT'rAAAGTT

GTATAAACAT

TGTGTGCTTT AAGCGTGGGC CCCTCTGGCT TGACAGCATG AGGCTTCACA GTCTGGTGCT CACCCCTGTC CAGATTATTG TACATGGCTT TGATAATTGT ATTGGTTTTG GGGAAATGTG ATGCAACAAA TGAATTTTCC GCTGTTGCAG ATGAAATGTT GTTGCTCAGC TCCTACCTCT TCTCAGCACA GCCTGGGGAG TCAGAGACTG CAAGCTGCTT CTGGTTGTGA. CTCTAAGCTC AAAAGTGCTC CCCAAAAGGA ATTAAGGTCA AACTAATTCT GTTCTCACAG TGTGGGGCAG CTTTGGCAGT TGCA'ITAGTA CCTGCAGAAA CAGTACTTAG CACTTAGCAG CAACTGAAGA TGTGTGAAAC ATGGTTGTAA TGATGTTTTC AGGTGTCATG TAAAGTTGCA CATGATTGTA AAGTTGCATT TAGAAATCAA AAAAAA AA

TGACCAGGCT

AGGTGTTGTG

TGGGAGAGTC

GCTGC'rTTGC

TTGAGGGGAG

GAGAAGAGTG

ACGCAGTTCT

CTGTTCACCC

GTGCCAGGGC

GGGGTCATTG

GCCCAAGTCA

AGTGCTCTCT

AGGAGAATGG

CACATCCCTC

CCGTCCTTCT

ACTTTGAAAG

GTAATTGTAG

CAATTATCAA

TATGCGACTG

GACTGTTGCC

TAAGCATGCT

GCATAAATCA

1177 1237 1297 1357 1417 1477 1537 1597 1657 1717 1777 1837 1897 1957 2017 2077 2137 2197 2257 2317 2377 2437 2479 92 INFORMATION FOR SEQ ID NO:2: SEQUENCE CHARACTERISTICS: LENGTH: 350 amino acids TYPE: amino acid TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Gin Arg Leu Gly Ala Thr Leu Leu Cys 1 Val Lys Giu Leu 65 Ala Glu Arg Ser His 145 Phe Leu Gly Asp Pro Pro Met Arg Ser Thr Glu Giu 130 Giu Al a Cys His Asn 210 Thr Gly Phe Ser Ser Asn Ile Thr Cys Ser Thr Cys 195 Gin Ala Pro Arg Ala Giu Thr 100 His Val Ile Phe Arg 180 Thr Arg 5 Pro Al a Giu Val1 Val Asp Lys Ile Ile Gin 165 Asp Lys Asp Ala Leu Val1 Giu 70 Asn Thr Ile Thr Asp 150 Tyr Ser Met Cl's Pro Ser Giu 55 Giu Leu Asn Thr Ser 135 Giu Thr Giu Ala Gin 215 Ala Tyr 40 Giu Met Ala Val Asn 120 Val Asp Cys Cys Thr 200 Pro Pro 25 Pro Leu Giu Asn Gly 105 Asn Gly Cys Gin Cys 185 Arg Gly Thr Gin Met Aila Leu 90 Asn Gin Asp Gly Pro 170 Gly Gly Leu Leu Al a Glu Giu Glu 75 Pro Asn Thr Giu Pro 155 Cys Asp Ser Cys Leu Thr Giu Asp Giu Pro Thr Gly Giu 140 Ser Arg Gin Asn Cys 220 Leu Ser Ala Thr Ala Ser Ile Gin 125 Gly Met Gly Leu Gly 205 Ala Al a Ala Thr Gin Al a Tyr His 110 Met Arg Tyr Gin Cl's 190 Thr Phe Ala Pro Leu His Ala His Val Val Arg Cys Arg 175 Val Ile Gin Ala Val Asn Lys Lys Asn His Phe Ser Gin 160 Met Trp Cys Arg Gly Leu Leu Phe Pro Val Cys Thr Pro Leu Pro Val Giu Gly Glu Leu 225 230 235 240 -93- Cys His Asp Pro Ala Ser Arg Leu Leu Asp Leu Ile Thr Trp Glu Leu 245 250 255 Glu Pro Asp Gly Ala Leu Asp Arg Cys Pro Cys Ala Ser Gly Leu Leu 260 265 270 Cys Gin Pro His Ser His Ser Leu Val Tyr Val Cys Lys Pro Thr Phe 275 280 285 Val Gly Ser Arg Asp Gin Asp Gly Glu Ile Leu Leu Pro Arg Glu Val 290 295 300 Pro Asp Glu Tyr Glu Val Gly Ser Phe Met Glu Glu Val Arg Gin Glu 305 310 315 320 Leu Glu Asp Leu Glu Arg Ser Leu Thr Glu Glu Met Ala Leu Arg Glu 325 330 335 Pro Ala Ala Ala Ala Ala Ala Leu Leu Gly Arg Glu Glu Ile 340 345 350 INFORMATION FOR SEQ ID NO:3: SEQUENCE CHARACTERISTICS: LENGTH: 1050 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: NAME/KEY: CDS LOCATION: 1..1050 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: ATG CAG CGG CTT GGG GCC ACC CTG CTG TGC CTG CTG CTG GCG GCG GCG 48 Met Gin Arg Leu Gly Ala Thr Leu Leu Cys Leu Leu Leu Ala Ala Ala 1 5 10 GTC CCC ACG GCC CCC GCG CCC GCT CCG ACG GCG ACC TCG GCT CCA GTC 96 Val Pro Thr Ala Pro Ala Pro Ala Pro Thr Ala Thr Ser Ala Pro Val 20 25 AAG CCC GGC CCG GCT CTC AGC TAC CCG CAG GAG GAG GCC ACC CTC AAT 144 Lys Pro Gly Pro Ala Leu Ser Tyr Pro Gin Glu Glu Ala rhr Leu Asn 40 GAG ATG TTC CGC GAG GTT GAG GAA CTG ATG GAG GAC ACG CAG CAC AAA 192 Glu Met Phe Arg Glu Val Glu Glu Leu Met Glu Asp Thr Gin His Lys 55 94

TTG

Leu CGC AGC GCG GTG GAA GAG ATG GAG GCA Arg Ser Ala Val. Giu Glu Met Glu Ala

GAA

Glu 75 GAA GCT GCT GCT Glu Ala Ala Ala

AAA

Lys 240 288 GCA TCA TCA GAA GTG AAC CTG GCA AAC Ala Ser Ser Giu Val Asn Leu Ala Asn

TTA

Leu 90 CCT CCC AGC TAT Pro Pro Ser Tyr CAC AAT His Asn GAG ACC AAC Glu Thr Asn

ACA

Thr 100 GAC ACG AAC GTT Asp Thr Asn Val

GGA

Gly 105 AAT AAT ACC ATC Asn Asn Thr Ile CAT GTG CAC His Val His 110 ATG GTC TTT Met Val Phe 336 CGA GAA ATT CAC AAG ATA ACC AAC AAC CAG ACT GGA Arg Glu Ile His Lys Ile Thr Asn Asn Gln Thr Gly 115 120

CAA

Gin 125 TCA GAG Ser Giu 130 ACA GTT ATC ACA Thr Val Ile Thr

TCT

Ser 135 GTG GGA GAC GAA Val Giy Asp Glu GAA GGC AGA AGG Glu Gly Arg Arg 140 AGC ATG TAC TGC Ser Met Tyr Cys

AGC

Ser

CAG

Gin 160

CAC

His 145 GAG TGC ATC ATC Olu Cys Ile Ile

GAC

Asp 150 GAG GAC TGT 000 Glu Asp Cys Gly

CCC

Pro S5 432 480 528 TTT GCC AGC TTC Phe Ala Ser Phe

CAG

Gin 165 TAC ACC TGC CAG Tyr Thr Cys Gin

CCA

Pro 170 TGC COG GGC CAG Cys Arg Gly Gin AGO ATG Arg Met 175 CTC TGC ACC Leu Cys Thr GOT CAC TGC Gly His Cys 195 GAC AGT GAG TGC Asp Ser Giu Cys

TOT

Cys 185 GGA GAC CAG, CTG Gly Asp Gin Leu TGT GTC TG Cys Val Trp 190 ACC ATC TGT Thr Ile Cys 576 624 ACC AAA ATG 0CC Thr Lys Met Ala

ACC

Thr 200 AGG GGC AGC AAT Arg Gly Ser Asn

GG

Gly 205 GAC AAC Asp Asn 210 CAG AGG GAC TGC Gin Arg Asp Cys

CAG

Gin 215 CCG 000 CTG TGC Pro Gly Leu Cys

TOT

Cys 220 0CC TTC CAG AGA Ala Phe Gin Arg

GGC

Gly 225 CTG CTG TTC CCT Leu Leu Phe Pro

GTG

Val 230 TGC ACA CCC CTG Cys Thr Pro Leu

CCC

Pro 235 GTG GAG GGC GAG Val Glu Gly Giu

CTT

Leu 240 672 720 768 TGC CAT GAC CCC Cys His Asp Pro 0CC Al a 245 AGC CGO CTT CTG Ser Arg Leu Leu

GAC

Asp 250 CTC ATC ACC TG Leu Ile Thr Trp, GAG CTA Olu Leu 255 GAG CCT OAT Glu Pro Asp TGC CAG CCC Cys Gin Pro 275

GGA

Gly 260 0CC TTO GAC CGA Ala Leu Asp Arg

TGC

Cys 265 CCT TOT 0CC AGT Pro Cys Ala Ser GOC CTC CTC Gly Leu Leu 270 CCG ACC TTC Pro Thr Phe 816 864 CAC AGC CAC AGC His Ser His Ser

CTO

Leu 280 GTO TAT GTO TGC Val Tyr Val Cys

AAG

Lys 285 GTG GGG AGC CGT Val Gly Ser Arg 290 GAC CAA GAT GGG GAG Asp Gin Asp Gly Glu 295 ATC CTG CTG Ile Leu Leu 300 CCC AGA GAG GTC Pro Arg Glu Val

CCC

Pro 305 GAT GAG TAT GAA Asp Glu Tyr Glu

GTT

Val 310 GGC AGC TTC ATG Gly Ser Phe Met

GAG

Glu 315 GAG GTG CGC CAG Glu Val Arg Gin

GAG

Glu 320 912 960 1008 1050 CTG GAG GAC CTG Leu Glu Asp Leu

GAG

Glu 325 AGG AGC CTG ACT Arg Ser Leu Thr

GAA

Glu 330 GAG ATG GCG CTG Glu Met Ala Leu AGG GAG Arg Glu 335 CCT GCG GCT Pro Ala Ala

GCC

Ala 340 GCC GCT GCA CTG Ala Ala Ala Leu

CTG

Leu 345 GGA AGG GAA GAG Gly Arg Glu Glu

ATT

Ile 350 INFORMATION FOR SEQ ID NO:4: SEQUENCE CHARACTERISTICS: LENGTH: 848 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: NAME/KEY: CDS LOCATION: 125..796 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: GAATTCGGCA CGAGAGACGA CGTGCTGAGC TGCCAGCTTA GTGGAAGCTC TGCTCTGGGT GGAGAGCAGC CTCGCTTTGG TGACGCACAG TGCTGGGACC CTCCAGGAGC CCCGGGATTG AAGG ATG GTG GCG GCC GTC CTG CTG GGG CTG AGC TGG CTC TGC TCT CCC Met Val Ala Ala Val Leu Leu Gly Leu Ser Trp Leu Cys Ser Pro 1 5 10 CTG GGA GCT CTG GTC CTG GAC TTC AAC AAC ATC AGG AGC TCT GCT GAC Leu Gly Ala Leu Val Leu Asp Phe Asn Asn Ile Arg Ser Ser Ala Asp 20 25 CTG CAT GGG GCC CGG AAG GGC TCA CAG TGC CTG TCT GAC ACG GAC TGC Leu His Gly Ala Arg Lys Gly Ser Gin Cys Leu Ser Asp Thr Asp Cys 40 AAT ACC AGA AAG TTC TGC CTC CAG CCC CGC GAT GAG AAG CCG TTC TGT Asn Thr Arg Lys Phe Cys Leu Gin Pro Arg Asp Glu Lys Pro Phe Cys 55 120 169 217 265 313 96 GCT ACA TGT Ala Thr Cys COT G TTG Arg Gly Leu CGG AGO AOG TOC Arg Arg Arg Cys 70 GTG AAC GAT OTT Val Asn Asp Val CAG CGA OAT Gin Arg Asp TOT ACT ACG Cys Thr Thr 90 GCC ATG TGC Ala Met Cys ATG OAA GAT Met Oiu Asp

TGC

Cys CCT GGG ACA CTC Pro Gly Thr Leu

TOT

Cys 85 GCA ACC CCA ATA Ala Thr Pro Ile

TTA

Leu 100 GAA AGO CAG CTT Olu Arg Gin Leu

GAT

Asp 105 GAO CAA OAT GOC Giu Gin Asp Gly ACA CAT Thr His 110 457 OCA GAA OGA Ala Glu Gly AAO CCA AOT Lys Pro Ser 130

ACA

Thr 115 ACT 000 CAC CCA Thr Giy His Pro

GTC

Val 120 CAG OAA AAC CAA Gin Glu Asn Gin CCC AAA AGO Pro Lys Arg 125 GAG OGA GAA Giu Gly Giu ATT AAG AAA TCA Ile Lys Lys Ser

CAA

Gin 135 GGC AGO AAO OGA Giy Arg Lys Giy

CAA

Gin 140 AOT TOT Ser Cys 145 CTO AGA AC'S TTT Leu Arg Thr Phe

GAC

Asp

ISO

TOT GGC CCT OGA Cys Gly Pro Gly

CTT

Leu 155 TOC TOT OCT COT Cys Cys Ala Arg 505 553 601 649 697

CAT

His 160 TTT TOG ACO AAA Phe Trp Thr Lys

ATT

Ile 165 TOT AAG CCA GTC Cys Lys Pro Val CTTr Leu 170 TTG GAG OGA CAG Leu Giu Oly Gin

OTC

Val 175 TGC TCC AGA AGA Cys Ser Arg Arg 000 Oly 180 CAT AAA GAC ACT His Lys Asp Thr

OCT

Al a 185 CAA OCT CCA GAA Gin Ala Pro Giu ATC TTC Ile Phe 190 CAG COT Gin Arg TOC GAC Cys Asp 195 TOT GOC CCT GGA Cys Gly Pro Gly

CTA

Leu 200 CTO TOT COA AGC Leu Cys Arg Ser CAA TTG ACC Gin Leu Thr 205 ATA GAA AAG Ile Giu Lys 745 AGC AAT CGG CAG CAT OCT COA TTA AGA OTA TOCC Ser Asn Arg Oin His Ala Arg Leu Arg Val Cys G 210 215 CTA TAAATATTTC AAAATAAAGA AGAATCCACA TTGCAAAA Leu INFORMATION FOR SEQ ID NO:S: Wi SEQUENCE CHARACTERISTICS: CA) LENGTH: 224 amino acids TYPE: amino acid TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID 110:5: lin

AAA

Lys 220 793 848 AAAAA AA~ fll f 97 Met Val Ala Ala Val Leu Leu Gly Leu Ser Trp, Leu Cys Ser Pro Leu Gly His Thr Thr Pro Thr Giu Pro Cys 145 Phe Ser Arg Asn Ala Gly Arg Cys Gly Pro Gly Ser 130 Leu Trp, Arg Cl's Arg 210 Leu Ala Lys Arg Thr Ile Thr 115 Ile Arg Thr Arg Asp 195 Gin Val 20 Arg Phe Gly Leu Leu 100 Thr Lys Thr Lys Gly 180 Cys His Leu Lys Cys Leu Cys Giu Gly Lys Phe Ile 165 His Gly Ala Asp Gly Leu Arg 70 Val Arg His Ser Asp 150 Cys Lys Pro Arg Phe Ser Gin 55 Arg Asn Gin Pro Gin 135 Cys Lys Asp Gly Leu 215 Asn Gin 40 Pro Arg Asp Leu Val 120 Gly Gly Pro Thr Leu 200 Arg Asn 25 Cys Arg Cys Val Asp 105 Gin Arg Pro Val Ala 185 Leu Val Ile Leu Asp Gin Cys 90 Glu Giu Lys Gly Lett 170 Gin Cys Cys Arg Ser Giu Arg 75 Thr Gin Asn Gly Leu 155 Leu Al a Arg Gin Ser Asp Lys Asp Thr Asp Gin Gin 140 Cys Giu Pro Ser Lys 220 Ser Thr Pro Ala Met Gly Pro 125 Glu Cys Gly Glu Gin 205 Ile Ala Asp Phe Met Giu Thr 110 Lys Gly Ala Gin Ile 190 Leu Glu Asp Leu Cys Asn Cys Ala Cys Cl's Asp Ala His Ala Arg Lys Glu Ser Arg His 160 Val Cl's 175 Phe Gin Thr Ser Lys Leu INFORMATION FOR SEQ ID NO:6: Wi SEQUENCE CHARACTERISTICS: LENGTH: 672 base pairs TYPE: nucleic acid STR.ANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA 98 (ix) FEATURE: NAME/KEY: CDS LOCATION: 1. .672 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: ATG GTG GCG 0CC GTC CTG CTG GGG CTG Met Val Ala Ala Val Leu Leu Gly Leu

AGC

Ser TOG CTC TGC TCT CCC CTG Leu Trp Leu Cys Ser Pro is GGA GCT CTG Gly Ala Leu CAT 000 0CC His Gly Ala

GTC

Val CTG GAC TTC AAC Leu Asp Phe Asn

AAC

Asn 25 ATC AGO AGC TCT Ile Arg Ser Ser OCT GAC CTG Ala Asp Leu GAC TGC AAT Asp Cys Asn COG AAG GOC TCA Arg Lys Gly Ser

CAG

Gin 40 TGC CTG TCT GAC Cys Leu Ser Asp

ACO

Thr 144 192 ACC AGA Thr Arg AAO TTC TGC Lys Phe Cys CTC CAG Leu Gin 55 CCC CGC OAT GAG Pro Arg Asp Giu

AAG

Lys CCO TTC TOT OCT Pro Phe Cys Ala

ACA

Thr 65 TOT COT OGG TTO Cys Arg Oly Leu

CG

Arg 70 AGO AGO TOC CAG Arg Arg Cys Gin OAT 0CC ATO TOC Asp Ala Met Cys

TOC

Cys 240 CCT 000 ACA CTC Pro Gly Thr Leu

TOT

Cys OTO AAC OAT OTT Val Asn Asp Val

TOT

Cys 90 ACT ACO ATO GAA Thr Thr Met Glu OAT OCA Asp Ala 288 336 ACC CCA ATA Thr Pro Ile

TTA

Leu 100 GAA AGO CAG CTT Oiu Arg Oln Leu

OAT

Asp 105 GAO CAA OAT OGC Giu Gin Asp Gly ACA CAT OCA Thr His Ala 110 AAA AGO AAO Lys Arg Lys OAA GGA ACA Oiu Oly Thr 115 CCA AOT ATT Pro Ser le 130 ACT 000 CAC CCA Thr Oly His Pro

GTC

Val 120 CAG OAA AAC CAA Gin Olu Asn Gin

CCC

Pro 125 384 432 AAG AAA TCA Lys Lys Ser

CAA

Gin 135 GGC AGO AAO GGA Oly Arg Lys Oly

CAA

Gin 140 GAO OGA OAA AGT Glu Oly Glu Ser

TOT

Cys 145 CTO AGA ACT TTT Leu Axg Thr Phe

GAC

Asp 150 TOT 0CC CCT GGA Cys Oly Pro Gly CTr Leu 155 TOC TOT OCT CGT Cys Cys Ala Arg

CAT

His 160 480 528 TTT TOO ACO AAA Phe Trp, Thr Lys

ATT

Ile 165 TOT AAO CCA OTC Cys Lys Pro Val

CTT

Leu 170 TTG GAO GGA CAG Leu Olu Giy Gin OTC TGC Vai Cys 175 TCC AGA AGA Ser Arg Arg 000 Gly 180 CAT AAA GAC ACT His Lys Asp Thr

OCT

Ala 185 CAA OCT CCA GAA Gin Ala Pro Giu ATC TTC CAG Ile Phe Gin 190 576 99 CGT TGC GAC Arg Cys Asp 195 TGT GGC CCT GGA Cys Gly Pro Gly

CTA

Leu 200 CTG TGT CGA AGC Leu Cys Arg Ser

CAA

Gin 205 TTG ACC AGC Leu Thr Ser 624 AAT CGG Asn Arg 210 CAG CAT GCT CGA Gin His Ala Arg

TTA

Leu 215 AGA GTA TGC CAA Arg Val Cys Gin

AAA

Lys 220 ATA GAA AAG CTA Ile Glu Lys Leu INFORMATION FOR SEQ ID NO:7: SEQUENCE CHARACTERISTICS: LENGTH: 1529 base pairs TYPE: nucleic acid STR.A1DEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: NAMEIJKEY: CDS LOCATION: 93. .890 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: CCGGACGCGT GGGCGGCACG GTTTCGTGGG GACCCAGGCT TGCAAAGTGA CGGTCATTTT CTCTTTCTTT CTCCCTCTTG AGTCCTTCTG AG ATG ATG GCT CTG GGC GCA GCG Met Met Ala Leu Gly Ala Ala GGA GCT ACC CGG GTC TTT GTC GCG ATG GTA GCG GCG Gly Ala Thr Arg Val Phe Val Ala Met Val Ala Ala

GCT

Al a CTC GGC GGC Leu Gly Gly 113 161 209 CAC CCT His Pro CTG CTG GGA GTG Leu Leu Gly Val

AGC

Ser 30 GCC ACC TTG AAC Ala Thr Leu Asn

TCG

Ser GTT CTC AAT TCC Val Leu Asn Ser

AAC

Asn GCT ATC AAG AAC CTG CCC CCA CCG CTG GGC GGC GCT GCG GGG Ala Ile Lys Asn Leu Pro Pro Pro Leu Gly Gly Ala Ala Gly

CAC

His 257 305 CCA GGC TCT GCA GTC AGC GCC GCG CCG GGA ATC CTG TAC CCG Pro Gly Ser Ala Val Ser Ala Ala Pro Gly Ile Leu Tyr Pro GOC GGG Gly Gly AAT AAG TAC Asn Lys Tyr GAC GAG GAG Asp Giu Glu

CAG

Gln ACC ATT GAC AAC TAC CAG CCG TAC CCG Thr Ile Asp Asn Tyr Gin Pro Tyr Pro TGC GCA GAG Cys Ala Giu ACC CGC GGA Thr Arg Gly 353 401 TOC GGC ACT GAT GAG TAC TGC GCT AGT Cys Gly Thr Asp Giu Tyr Cys Ala Ser 95

CCC

Pro 100 -100- GGG GAC GCA GGC GTG CAA ATC TGT CTC Leu GCC TGC AGO AAG CGC CGA AAA 449 Gly Asp 105 Ala Gly Val Gin Ile Cys Ala Cys Arg 115 Lys Arg Arg Lys

CGC

Arg 120 TGC ATG COT CAC Cys Met Arg His

GCT

Ala 125 ATG TGC TGC Met Cys Cys CCC GGG Pro Gly 130 AAT TAC TGC Asn Tyr Cys AAA AAT Lys Asn 135 ATT GAG Ile Glu 150 497 545 OGA ATA TOC OTG Gly Ile Cys Val

TCT

Ser 140 TCT GAT CAA AAT Ser Asp Gin Asn

CAT

His 145 TTC CGA OGA GAA Phe Arg Gly Glu GAA ACC ATC Glu Thr Ile TAT TCC AGA Tyr Ser Arg 170

ACT

Thr 155 GAA AGC TTT GOT Giu Ser Phe Gly

AAT

Asn 160 GAT CAT AOC ACC Asp His Ser Thr TTG OAT 000 Leu Asp Gly 165 ACC AAA GGA Thr Lys Gly AGA ACC ACC TTG Arg Thr Thr Leu

TCT

Ser 175 TCA AAA ATG TAT Ser Lys Met Tyr

CAC

His IS0 CAA GAA Gin Glu 185 GOT TCT OTT TOT Gly Ser Val Cys

CTC

Leu 190 COO TCA TCA GAC Arg Ser Ser Asp

TGT

Cys 195 GCC TCA GGA TTO Ala Ser Gly Leu 593 641 689 737 785

TGT

Cys 200 TOT OCT AGA CAC Cys Ala Arg His

TTC

Phe 205 TOG TCC AAG ATC Trp Ser Lys Ile

TOT

Cys 210 AAA CCT GTC CTG Lys Pro Val Leu

AAA

Lys 215 OAA GOT CAA OTG Giu Gly Gin Val

TOT

Cys 220 ACC AAG CAT AGO Thr Lys His Arg

AGA

Arg 225 AAA GOC TCT CAT Lys Gly Ser His GGA CTA Gly Leu 230 GAA ATA TTC Giu Ile Phe CAG AAA OAT Gin Lys Asp 250 CAG AGA CAC Gin Arg His 265 CAG COT Gin Arg 235 TOT TAC TOT Cys Tyr Cys

GGA

Gly 240 GAA GOT CTG TCT Glu Gly Leu Ser TOC COG ATA Cys Arg Ile 245 CAC ACT TOT His Thr Cys 833 881 CAC CAT CAA 0CC His His Gin Ala

AGT

Ser 255 AAT TCT TCT AGO Asn Ser Ser Arg

CTT

Leu 260 TAAACCAGCT ATCCAAAATG CAGTOAACTC C77TTATATA 930 ATAGATOCTA TOAAAACCTT TTATGACCTT CATCAACTCA ATCCTAAGGA TATACAAGTT CTGTGGTTTC AGTTAAOCAT TCCAATAACA CCTTCCAAAA ACCTGGAGTG TAAGAGCTTT GTTTCTTTAT GGAACTCCCC TGTGATTGCA GTAAATTACT GTATTGTAAA TTCTCAGTGT GGCACTTACC TGTAAATGCA ATGAAACTTT TAATTATTTT TCTAAAOGTG CTGCACTGCC TATrTTCCT CTTGTTATGT AAATTTTTGT ACACATTOAT TGTTATCTTG ACTGACAAAT ATTCTATATT GAACTGAAGT AAATCATTTC AGCTTATAGT TCTTAAAAGC ATAACCCTTr 990 1050 1110 1170 1230 1290 101 ACCCCATTTN ATTCTAGAGT CNAGAACGCA AGGATCTCTT GGAATGACAA ATGATAGGTA CCTAAAATGT AACATGAAAA TACTAGCTTA TTTTCTGAAA TGTACTATCT TAATGCTTAA ATTATA TTT C CCT=TAGGCT GTGATAGTTT TTGAAATAAA ATTTAACATT TAATATCATG AAATGKTATA AGTAGACATA AAAAAA AAAAA AGGGCGGCCG CTAGACTAG 1350 1410 1470 1529 INFORMATION FOR SEQ ID NO:B8: Wi SEQUENCE CHARACTERISTICS: LENGTH: 266 amino acids TYPE: amino acid TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: Met Met Ala Leu Gly Ala Ala Gly Ala Thr Arg Val Phe Val 1 Val Ala Met Ala Ala Ala Leu Guy Gly His Pro 25 Ala Leu Gly Val Leu Asn Ser Leu Gly Gly Val Leu Asn Ser Asn 40 Ile Lys Asn Leu Ser Ser Ala Thr Pro Pro Pro Ala Ala Pro Ala Ala Gly His 55 Gly Pro Gly Ser Ala Val Thr 65 Gln Ile Leu Tyr Pro Gly 70 Asn Lys Tyr Gin 75 Ci's Ile Asp Asn Tyr Pro Tyr Pro Ci's Thr Ala Giu Asp Glu Gly Thr Asp Glu Tyr Ci's Ala Ser Ala Cys Arg 115 Pro Gly Asn Pro 100 Arg Gly Gly Asp 105 Ci's Gly Val Gin Lys Arg Arg Ly'sArg 120 Gly Met Arg His Ala 125 Ser Ile Ci's Leu 110 Met Cys Ci's Asp Gin Asn Tyr Ci's Ly's 130 His Phe Asn 135 Glu Ile Ci's Val Ser 140 Glu Arg Gly Giu 145 Ile 150 Glu Thr Ile Thr 155 Ser Phe Gly Asn 160 Asp His Ser Thr Leu Asp Gly Tyr Ser Arg Arg Thr Thr Leu Ser Ser 165 170 175 102- Lys Met Tyr His Thr Lys Gly Gin Glu Gly Ser Val Cys Leu Arg Ser 180 185 190 Ser Asp Cys Ala Ser Gly Leu Cys Cys Ala Arg His Phe Trp Ser Lys 195 200 205 Ile Cys Lys Pro Val Leu Lys Glu Gly Gin Val Cys Thr Lys His Arg 210 215 220 Arg Lys Gly Ser His Gly Leu Glu Ile Phe Gin Arg Cys Tyr Cys Gly 225 230 235 240 Glu Gly Leu Ser Cys Arg Ile Gin Lys Asp His His Gin Ala Ser Asn 245 250 255 Ser Ser Arg Leu His Thr Cys Gin Arg His 260 265 INFORMATION FOR SEQ ID NO:9: SEQUENCE CHARACTERISTICS: LENGTH: 798 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: NAME/KEY: CDS LOCATION: 1..798 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: ATG ATG GCT CTG GGC GCA GCG GGA GCT ACC CGG GTC TTT GTC GCG ATG 48 Met Met Ala Leu Gly Ala Ala Gly Ala Thr Arg Val Phe Val Ala Met 1 5 10 GTA GCG GCG GCT CTC GGC GGC CAC CCT CTG CTG GGA GTG AGC GCC ACC 96 Val Ala Ala Ala Leu Gly Gly His Pro Leu Leu Gly Val Ser Ala Thr 25 TTG AAC TCG GTT CTC AAT TCC AAC GCT ATC AAG AAC CTG CCC CCA CCG 144 Leu Asn Ser Val Leu Asn Ser Asn Ala Ile Lys Asn Leu Pro Pro Pro 35 40 CTG GGC GGC GCT GCG GGG CAC CCA GGC TCT GCA GTC AGC GCC GCG CCG 192 Leu Gly Gly Ala Ala Gly His Pro Gly Ser Ala Val Ser Ala Ala Pro 55 GGA ATC CTG TAC CCG GGC GGG AAT AAG TAC CAG ACC ATT GAC AAC TAC 240 Gly Ile Leu Tyr Pro Gly Gly Asn Lys Tyr Gin Thr Ile Asp Asn Tyr 70 75 103- CAG CCG TAC CCG TGC GCA GAG GAC GAG Gin Pro Tyr Pro Cys Ala Giu Asp Giu

GAG

Giu 90 TGC GGC ACT GAT Cys Gly Thr Asp GAG TAC Glu Tyr 288 TGC GCT ACT Cys Ala Ser

CCC

Pro 100 ACC CGC GGA GGG Thr Arg Gly Gly

GAC

Asp 105 GCA GGC GTG CAA Ala Cly Val Gin ATC TGT CTC Ile Cys Leu 110 ATG TGC TGC Met Cys Cys GCC TGC AGG Ala Cys Arg 115 CCC GGG AAT Pro Gly Asn 130 AAG CGC CGA AAA Lys Arg Arg Lys

CC

Arg 120 TGC ATG CGT CAC Cys Met Arg His

GCT

Ala 125 336 384 432 TAC TGC AAA Tyr Cys Lys

AAT

Asn 135 GGA ATA TGC GTG Gly Ile Cys Val

TCT

Ser 140 TCT GAT CAA AAT Ser Asp Gin Asn

CAT

His 145 TTC CGA GCA GAA Phe Arg Gly Ciu

ATT

Ile 150 GAG CAA ACC ATC Glu Giu Thr Ile

ACT

Thr 155 GAA ACC TTT GCT Giu Ser Phe Gly

AAT

Asn 160 480 528 GAT CAT AGC ACC Asp His Ser Thr

TTQ

Leu 165 CAT GGG TAT TCC Asp Gly Tyr Ser

AGA

Arg 170 AGA ACC ACC TTG Arg Thr Thr Leu TCT TCA Ser Ser 175 AAA ATG TAT Lys Met Tyr TCA GAC TCT Ser Asp Cys 195 ATC TGT AAA Ile Cys*Lys 210

CAC

His 180 ACC AAA CCA CAA Thr Lys Gly Gin

GAA

Glu 185 GGT TCT GTT TGT Gly Ser Val Cys CTC CGG TCA Leu Arg Ser 190 TGG TCC AAG Trp Ser Lys GCC TCA GGA TTG Ala Ser Gly Leu

TCT

Cys 200 TCT GCT AGA CAC Cys Ala Arg His

TTC

Phe 205 576 624 672 CCT GTC CTG Pro Val Leu

AAA

Lys 215 GAA GCT CAA GTG Ciu Cly Gin Val

TGT

Cys 220 ACC AAG CAT AG Thr Lys His Arg

AGA

Arg 225 AAA CCC TCT CAT Lys Gly Ser His

GGA

Cly 230 CTA GAA ATA TrC Leu Ciu Ile Phe

CAC

Gin 235 CGT TGT TAC TCT Axg Cys Tyr Cys

GGA

Gly 240 720 768 GAA GGT CTC TCT Ciu Gly Leu Ser

TGC

Cys 245 CCC ATA CAG AAA Arg Ile Gin Lys

GAT

Asp 250 CAC CAT CAA GCC His His Gin Ala ACT AAT Ser Asn 255 TCT TCT AGC Ser Ser Arg CAC ACT TGT CAG His Thr Cys Gin AGA CAC Arg His 265 798 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 702 base pairs TYPE: nucleic acid STRANDEDNESS: single 104 TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE:

NAME/KEY:

LOCATION:

CDS

1. .537 (xi) SEQUENCE DESCRIPTION: SEQ ID

GAA

Giu 1 TTC GGC ACG Phe Gly Thr

AGG

Arg 5 GTT GGG AGG TAT Val Giy Arg Tyr

TGC

Cys 10 CAC AGT CCC CAC His Ser Pro His CAA GGA Gin Gly TCA TCG GCC Ser Ser Ala

TGC

Cys ATG GTG TGT CGG Met Val Cys Arg

AGA

Arg 25 AAA AAG AAG CGC Lys Lys Lys Arg TGC CAC CGA Cys His Arg ATC TGT ATC Ile Cys Ile GAT GGC ATG TGC TGC Asp Gly Met Cys Cys CCC AGT ACC CGC TGC AAT AAT Pro Ser Thr Arg Cys Asn Asn 40

GGC

Gly CCA GTT Pro Val ACT GAA AGC ATC Thr Giu Ser Ile

TTA

Leu ACC CCT CAC ATC CCG GCT CTG GAT GGT Thr Pro His Ile Pro Ala Leu Asp Gly

ACT

Thr CGG CAC AGA GAT Arg His Arg Asp

CGA

Arg 70 AAC CAC GGT CAT TAC TCA AAC CAT GAC Asn His Gly His Tyr Ser Asn His Asp

TTG

Leu GGA TGG CAG AAT Gly Trp Gin Asn

CTA

Leu GGA AGA CCA CAC ACT AAG ATG TCA CAT Gly Arg Pro His Thr Lys Met Ser His 90 ATA AAA Ile Lys GGG CAT GAA Gly His Giu

GGA

Giy 100 GAC CCC TGC CTA Asp Pro Cys Leu

CGA

Arg 105 TCA TCA GAC TGC ATT GAA GGG Ser Ser Asp Cys Ile Giu Gly 110 TTT TGC TGT GCT CGT CAT TTC Phe Cys Cys Aia Arg His Phe 115

TGG

Tip, 120 ACC AAA ATC TGC AAA CCA GTG CTC Thr Lys Ile Cys Lys Pro Val Leu 125 CAT CAG His Gin 130 GGG GAA GTC TGT Gly Glu Val Cys

ACC

Thr 135 AAA CAA CGC AAG AAG GGT TCT CAT GGG Lys Gin Arg Lys Lys Gly Ser His Gly 140 432

CTG

Leu 145 GAA ATT TTC CAG CGT TGC GAC TGT GCG AAG GGC CTG TCT TGC Giu Ile Phe Gin Arg Cys Asp Cys Ala Lys Gly Leu Ser Cys 150 155 GTA TGG AAA GAT GCC ACC TAC TCC TCC AAA GCC AGA CTC CAT Val Tip Lys Asp Ala Thr Tyr Ser Ser Lys Ala Arg Leu His 165 170 GTG TGT Val. Cys 175 105 CAG AAA ATT TGATCACCAT TGAGGAACAT CATCAATTGC AGACTGTGAA 577 Gin Lys Ile GTTGTGTATT TAATGCATTA TAGCATGGTG GAAAATAAGG TTCAGATGCA GAAGAATGGC 637 TAAAATAAGA AACGTGATAA GAATATAGAT GATCACAAAA AAAAAA AAAAGATGCG 697 GCCGC 702 INFORMATION FOR SEQ ID NO:1i: Wi SEQUENCE CHARACTERISTICS: LENGTH: 179 amino acids TYPE: amino acid TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:i1: Giu Phe Giy Thr Arg Val Giy Arg Tyr Cys His Ser Pro His Gin Gly 1 5 10 ser ser Ala cys met Val Cys Arg Arg Lys Lys Lys Arg Cys His Arg 25 Asp Gly Met Cys Cys Pro Ser Thr Arg Cys Asn Asn Giy Ile Cys Ile 40 Pro Val Thr Giu Ser Ile Leu Thr Pro His Ile Pro Ala Leu Asp Giy so 55 Thr Arg His Arg Asp Arg Asn His Gly His Tyr Ser Asn His Asp Leu 65 70 75 Giy Trp Gin Asn Leu Giy Arg Pro His Thr Lys Met Ser His Ile Lys 90 Giy His Giu Giy Asp Pro Cys Leu Arg Ser Ser Asp Cys Ile Giu Gly 100 105 110 Phe Cys Cys Ala Arg His Phe Trp Thr Lys Ile Cys Lys Pro Val Leu 115 120 125 His Gin Giy Giu Val Cys Thr Lys Gin Arg Lys Lys Gly Ser His Giy 130 135 140 Leu Giu Ile Phe Gin Arg Cys Asp Cys Ala Lys Giy Leu Ser Cys Lys 145 I50 155 160 Val Trp Lys Asp Ala Thr Tyr Ser Ser Lys Ala Arg Leu His Val. Cys 165 170 175 Gin Lys le -106- INFORMATION FOR SEQ ID NO:12: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 537 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE:

NAME/KEY:

LOCATION:

CDS

1. .537 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GAA

Glu 1 TTC GGC ACG Phe Gly Thr AGG GT T Arg Val GGG AGG TAT Gly Arg Tyr

TGC

Cys 10 CAC AGT CCC CAC CAA GGA His Ser Pro His Gin Gly TCA TCG GCC Ser Ser Ala GAT GOC ATG Asp Gly Met

TGC

Cys ATG GTG TGT CGG Met Val Cys Arg

AGA

Arg 25 AAA AAG AAG CGC Lys Lys Lys Arg TGC CAC CGA Cys His Arg ATC TGT ATC Ile Cys Ile TGC TGC CCC AGT Cys Cys Pro Ser

ACC

Thr 40 CGC TGC AAT Arg Cys Asn AAT GGC Asn Gly CCA GTT Pro Val ACT GAA AGC ATC Thr Giu Ser Ile

TTA

Leu 55 ACC CCT CAC ATC Thr Pro His Ile

CCG

Pro GCT CTG GAT GGT Ala Leu Asp Gly 144 192 240 288

ACT

Thr CGG CAC AGA Arg His Arg GAT CGA Asp Arg 70 CTA GGA Leu Gly AAC CAC GGT CAT Asn His Gly His

TAC

Tyr 75 TCA AAC CAT GAC Ser Asn His Asp

TTG

Leu GGA TGG CAG AAT Gly Trp Gin Asn AGA CCA CAC Arg Pro His

ACT

Thr 90 AAG ATG TCA CAT Lys Met Ser His ATA AAA Ile Lys GGG CAT GAA Gly His Glu TTT TGC TGT Phe Cys Cys 115 GAC CCC TOC CTA Asp Pro Cys Leu

CGA

Arg 105 TCA TCA GAC TGC Ser Ser Asp Cys ATT GAA GGG Ile Giu Gly 110 CCA GTG CTC Pro Val Leu 336 384 GCT CGT CAT TTC Ala Arg His Phe

TGG

Trp 120 ACC AAA ATC TGC Thr Lys Ile Cys

AAA

Lys 125 CAT CAG His Gin 130 GGG GAA GTC TGT Gly Glu Val Cys

ACC

Thr 135 AAA CAA CGC AAG AAG GGT TCT CAT GGG Lys Gin Arg Lys Lys Gly Ser His Gly 140 432 107- CTG GAA ATT TTC CAG CGT TGC GAC TGT GCC AAG Leu Glu Ile Phe Gin Arg Cys Asp Cys Ala Lys 145 150 155 GTA TGG AAA GAT GCC ACC TAC TCC TCC AAA CC Val Trp Lys Asp Ala Thr Tyr Ser Ser Lys Ala 165 170 GGC CTG TCT TGC Cly Leu Ser Cys

AAA

Lys 160 AGA CTC CAT Arg Leu His GTG TGT Val Cys 175 480 528 537 CAC AAA ATT Gin Lys Ile INFORMATION FOR SEQ ID NO:13: SEQUENCE CHARACTERISTICS: LENGTH: 928 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: NAME/KEY: CDS LOCATION: 75. .800 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: CTCGAGGCCA AAATTCGGCA CGAGGCCGGG CTGTGGTCTA GCATAAAGGC GGAGCCCAGA AGAAGGGGCG GGGT ATG Met 1 OGA GAA GCC Gly Glu Ala

TCC

Ser 5 CCA CCT CC Pro Pro Ala CCC GCA AGO CGG Pro Ala Arg Arg CAT CTG CTG His Leu Leu CTC CTC CTG CTG Val Leu Leu Leu

CTC

Leu 20 CTC TCT ACC CTG Leu Ser Thr Leu

GTG

Val ATC CCC TCC Ile Pro Ser 110 158 206 OCT GCA Ala Ala OCT CCT ATC CAT Ala Pro Ile His

CAT

Asp 35 GCT GAC GCC CAA Ala Asp Ala Gin

GAG

Glu AGC TCC TTG COT Ser Ser Leu Cly

CTC

Leu 45 ACA GOC CTC CAG Thr Gly Leu Gin

AC

Ser 50 CTA CTC CAA GGC TrC ACC CCA CTT TTC Leu Leu Gin Cly Phe Ser Arg Leu Phe AAA OCT AAC CTC Lys Ciy Asn Leu

CTT

Leu CGG GGC ATA GAC Arg Gly Ile Asp TTA TTC TCT CC Leu Phe Ser Ala CCC ATO Pro Met GAC TTC CGG Asp Phe Arg

GCC

Cly CTC CCT CCC AAC Leu Pro Gly Asn

TAC

Tyr 85 CAC AAA GAG GAG His Lys Ciu Giu AAC CAG GAG Asn Gln Glu 108 CAC CAG CTG His Gin Leu GGG AAC AAC ACC Gly Asn Asn Thr

CTC

Leu 100 TCC AGC CAC CTC CAG ATC GAC AAG Ser Ser His Leu Gin Ile Asp Lys 105 398 ATG ACC Met Thr 110 GAC AAC AAG ACA Asp Asn Lys Thr

GGA

Gly 115 GAG GTG CTG ATC Giu Val Leu Ile

TCC

Ser 120 GAG AAT GTG GTG Giu Asn Val Val 446

GCA

Ala 125 TCC ATT CAA CCA Ser Ile Gin Pro

GCG

Al a 130 GAG GGG AGC TTC Giu Gly Ser Phe

GAG

Giu 135 GOT GAT TTG AAG Gly Asp Leu Lys

GTA

Val 140 CCC AGO ATG GAG Pro Arg Met Giu

GAG

Giu 145 AAG GAG GCC CTG Lys Giu Ala Leu

GTA

Val 150 CCC ATC CAG AAG Pro Ile Gin Lys GCC ACG Ala Thr 155 GAC AGC TTC Asp Ser Phe AAG CTG CCA Lys Leu Pro 175

CAC

His 160 ACA GAA CTC CAT Thr Giu Leu His

CCC

Pro 165 CGG GTG GCC TTC Arg Val Ala Phe TOG ATC ATT Trp Ile Ile 170 GGC GGC CAC Gly Gly His 590 638 CGG CG%. AGO TCC Arg Arg Arg Ser

CAC

His 180 CAG GAT GCC CTG Gin Asp Ala Leu

GAG

Giu 185 TGG CTC Trp Leu 190 AGC GAG AAG CGA Ser Giu Lys Arg

CAC

His 195 CGC CTG CAG GCC Arg Leu Gin Ala

ATC

Ile 200 CGG GAT GGA CTC Arg Asp Gly Leu

CGC

Arg 205 AAG GO ACC CAC Lys Giy Thr His

AAG

Lys 210 GAC GTC CTA GAA Asp Val Leu Glu

GAG

Giu 215 GGG ACC GAG AGC Gly Thr Giu Ser

TCC

Ser 220 TCC CAC TCC AGO Ser His Ser Arg

CTG

Leu 225 TCC CCC CGA AAG Ser Pro Arg Lys

ACC

Thr 230 CAC TTA CTG TAC His Leu Leu Tyr ATC CTC Ile Leu 235 686 734 782 830 890 92 B AGG CCC TCT Arg Pro Ser COG CAG CTG Arg Gin Leu 240 TAGGGGTGGG GACCOGGAG CACCTGCCTG TAGCCCCCAT CAGACCCTGC CCCAAGCACC ATATGGAAAT AAAGTTCTTT CTTACATCTA AAAAAA AAAAAAATTG GCGOCCGC INFORMATION FOR SEQ ID NO:14: i)SEQUENCE CHARACTERISTICS: LENGTH: 242 amino acids TYPE: amino acid TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: 109 Met 1 Len Ile I0 Gin Leu 65 Leu Asn Lys Pro Gin 145 Thr Arg Lys His Leu 225 Gin Giy Leu His Ser Arg Pro Asn Thr Aia 130 Lys Gin Arg Arg Lys 210 Ser Len Giu Ala Ser Pro Pro Ala Pro 5 Leu Asp Len Gly Giy Thr Giy Glu Gin Leu Ser His 195 Asp Pro Len Ala Leu Ile Asn Len 100 Glu Gly Ala His His 180 Arg Val Arg Leu Ser Asp Ala Gin Gly Asp Ser 70 Tyr His Ser Ser Val Len Ser Phe Leu Vai 150 Pro Arg 165 Gin Asp Leu Gin Len Gin Lys Thr 230 Thr Gin Phe 55 Len Lys His Ile Gin 135 Pro Val Ala Ala Gin 215 His Len Gin 40 Ser Phe Gin Len Ser 120 Gly Ile Al a Len Ile 200 Gly Len Val 25 Ser Arg Ser Gin Gin 105 Giu Asp Gin Phe Gin lBS Arg Thr Leu Aia Ile Ser Len Al a Asn 90 Ile Asn Len Lys Trp 170 Gly Asp Gin Tyr Arg Pro Len Phe Pro 75 Gin Asp Val Lys Ala 155 Ile Gly Gly Ser Ile 235 Arg Ser Gly Len Met Gin Lys Val Val 140 Thr Ile His Len Ser 220 Len His Al a Leu Lys Asp His Met Ala 125 Pro Asp Lys Trp Arg 205 Ser Arg Len Ala Thr Gly Phe Gin Thr 110 Ser Arg Ser Len Len 190 Lys His Pro Len Vai Ala Pro Gly Len Asn Len Arg Gly Leu Giy Asp Asn Ile Gin Met Giu Phe His 160 Pro Arg 175 Ser Gin Gly Thr Ser Arg Ser Arg 240 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 726 base pairs TYPE: nncieic acid STRANDEDNESS: single -110- TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: NAME/KEY: CDS LOCATION: 1. .726 (xi) SEQUENCE DESCRIPTION: SEQ ID ATG GGA GAA GCC Met Gly Glu Ala

TCC

Ser CCA CCT GCC CCC GCA AGG CGG CAT CTG CTG GTC Pro Pro Ala Pro Ala Arg Arg His Leu Leu Val CTG CTG CTG Leu Leu Leu CTC TCT ACC CTG GTG ATC CCC TCC GCT Leu Ser Thr Leu Val Ile Pro Ser Ala GCA GCT CCT Ala Ala Pro ACA GGC CTC Thr Gly Leu ATC CAT GAT GCT GAC GCC CAA GAG Ile His Asp Ala Asp Ala Gin Glu -40 AGC TCC TTG GGT Ser Ser Leu Gly

CTC

Leu CAG AGC Gin Ser CTA CTC CAA GGC Leu Leu Gin Cly

TTC

Phe 55 AGC CGA CTT TTC Ser Arg Leu Phe

CTG

Leu AAA GGT AAC CTG Lys Gly Asn Leu 144 192 240 288

CTT

Leu CGG GGC ATA GAC Arg Cly Ile Asp

AGC

Ser 70 TTA TTC TCT CC Leu Phe Ser Ala

CCC

Pro 75 ATG CAC TTC CCC Met Asp Phe Arg

GGC

Gly CTC CCT CGG AAC Leu Pro Gly Asn

TAC

Tyr CAC AAA GAG GAG His Lys Glu Glu

AAC

Asn 90 GAG GAG CAC GAG Gin Giu His Gin CTG GGG Leu Gly AAc AAC ACC Asn Asn Thr AAG ACA CGA Lys Thr Gly 115

CTC

Leu 100 TCC AGC CAC CTC Ser Ser His Leu

GAG

Gin 105 ATC GAC AAG ATG Ile Asp Lys Met ACC GAC AAC Thr Asp Asn 110 TCC ATT CAA Ser Ile Gin 336 384 GAG GTG CTG ATC Giu Val Leu Ile

TCC

Ser 120 GAG AAT GTG GTG Glu Asn Val Val

GCA

Ala 125 CCA CC Pro Ala 130 GAG CCC AGC TTC Ciu Gly Ser Phe

GAG

Giu 135 GGT CAT TTC AAG Gly Asp Leu Lys

GTA

Val 140 CCC AGG ATG GAG Pro Arg Met Giu

GAG

Glu 145 AAG GAG CCC CTC Lys Giu Ala Len

GTA

Val 150 CCC ATC CAG AAG CCC ACG GAC AGC TTC Pro Ile Gin Lys Ala Thr Asp Ser Phe

CAC

His 160 480 528 ACA GAA CTC CAT Thr Giu Leu His

CCC

Pro 165 CCC GTG CCC TTC TGC ATC ATT AAG CTG Arg Val Ala Phe Trp Ile Ile Lys Leu 170 CGA CCC Pro Arg 175 -111- CGG AGG TCC Arg Arg Ser

CAC

His 180 CAG GAT GCC CTG GAG GGC GGC CAC TGG Gin Asp Ala Leu Glu Gly Gly His Trp 185 CTC AGC GAG Leu Ser Glu 190 AAG GGG ACC Lys Gly Thr 576 AAG CGA CAC Lys Arg His 195 CAC AAG GAC His Lys Asp 210 CGC CTG CAG GCC Arg Leu Gin Ala

ATC

Ile 200 CGG GAT GGA CTC Arg Asp Gly Leu

CGC

Arg 205 624 672 GTC CTA GAA Val Leu Glu

GAG

Glu 215 GGG ACC GAG AGC Gly Thr Glu Ser

TCC

Ser 220 TCC CAC TCC AGG Ser His Ser Arg

CTG

Leu 225 TCC CCC CGA AAG Ser Pro Arg Lys

ACC

Thr 230 CAC TTA CTG TAC His Leu Leu Tyr

ATC

Ile 235 CTC AGG CCC TCT Leu Arg Pro Ser

CGG

Arg 240 720 726 CAG CTG Gin Leu INFORMATION FOR SEQ ID NO:16: SEQUENCE CHARACTERISTICS: LENGTH: 2381 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: NAME/KEY: CDS LOCATION: 110..1156 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: FGTCGACCCA CGCGTCCGCT GTGGCAGCCC AGCTACCGGT CGTGACCAGA TCCAGCTTGC AGCTCAGCTT TGTTCATTCG AATTGGGCGG CGGCCAGCGC GGAACAAAC ATG CAG Met Gin 1 CGG CTC GGG GGT ATT TTG CTG TGT ACA CTG CTG GCG GCG GCG GTC CCC Arg Leu Gly Gly Ile Leu Leu Cys Thr Leu Leu Ala Ala Ala Val Pro 10 ACT GCT CCT GCT CCT TCC CCG ACG GTC ACT TGG ACT CCG GCG GAG CCG Thr Ala Pro Ala Pro Ser Pro Thr Val Thr Trp Thr Pro Ala Glu Pro 25 GGC CCA GCT CTC AAC TAC CCT CAG GAG GAA GCT ACG CTC AAT GAG ATG Gly Pro Ala Leu Asn Tyr Pro Gin Glu Glu Ala Thr Leu Asn Glu Met 40 45 115 163 211 259 -112- TTT CGA GAG GTG GAG Phe Arg Glu Val Glu GAG CTG ATG GAA GAC ACT CAG CAC Glu Leu Met Glu Asp Thr Gin His 60 AGT GCC GTG Ser Ala Val TCT GAG GTG Ser Giu Val GAG GAG ATG GAG Giu Giu Met Giu AAC CTG GCA AGC Asn Leu Ala Ser GCG GAA GAA GCA GCT GCT Ala Giu Giu Ala Ala Ala 75 TTA CCT CCC AAC TAT CAC Leu Pro Pro Asn Tyr His 90 AAA CTG CGC Lys Leu Arg AAA ACG TCC Lys Thr Ser AAT GAG ACC Asn Giu Thr 307 355 403 AGC ACG Ser Thr 100 GAG ACC AGG GTG Giu Thr Arg Val

GGA

Gly 105 AAT AAC ACA GTC Asn Asn Thr Val

CAT

His 110 GTG CAC CAG GAA Val His Gin Glu

GTT

Val 115 CAC AAG ATA ACC His Lys Ile Thr

AAC

Asn 120 AAC CAG AGT GGA Asn Gin Ser Gly

CAG

Gin 125 GTG GTC TTT TCT Val Val Phe Ser

GAG

Glu 130 451 499 547 ACA GTC ATT ACA Thr Val Ile Thr TC P Ser 135 GTA GGG GAT GAA Val Gly Asp Glu

GAA

Glu 140 GGC AAG AGG AGC Gly Lys Arg Ser CAT GAA His Giu 145 TGT ATC ATT Cys Ile Ile AGC TTC AAG Ser Phe Lys 165

GAT

Asp 150 GAA GAC TGT GG Glu Asp Cys Gly

CCC

Pro 155 ACC AGG TAC TGC Thr Arg Tyr Cys CAG TrC TCC Gin Phe Ser 160 ATG CTA TGC Met Leu Cys 595 643 TAC ACC TOC CAG Tyr Thr Cys Gin

CCA

Pro 170 TGC CGG GAC CAG Cys Arg Asp Gin

CAG

Gin 175 ACC CGA Thr Arg 180 GAC AGT GAG TGC Asp Ser Glu Cys

TGT

Cys 185 GGA GAC CAG CTG Gly Asp Gin Leu

TOT

Cys 190 GCC TGG GOT CAC Ala Trp Gly His

TGC

Cys 195 ACC CAA AAG GCC Thr Gin Lys Ala

ACC

Thr 200 AAA GOT GGC AAT Lys Gly Gly Asn

GG

Giy 205 ACC ATC TGT GAC Thr Ile Cys Asp

AAC

Asn 210 691 739 787 CAG AGG GAT TGC Gin Arg Asp Cys

CAG

Gin 215 CCT GGC CTG TOT Pro Gly Leu Cys

TOT

Cys 220 GCC TTC CAA AGA Ala Phe Gin Arg GGC CTG Gly Leu 225 CTG TTC CCC Leu Phe Pro

GTG

Vai 230 TGC ACA CCC CTG Cys Thr Pro Leu

CCC

Pro 235 GTG GAG GGA GAG Val Glu Gly Giu CTC TGC CAT Leu Cys His 240 GAC CCC ACC Asp Pro Thr 245 AGC CAG CTG CTG Ser Gin Leu Leu

GAT

Asp 250 CTC ATC ACC TOG GAA CTG GAG CCT Leu Ile Thr Trp Giu Leu Giu Pro 255 GAA GGA G].u Gly 260 GCT TTG GAC CGA Ala Leu Asp Arg

TGC

Cys 265 CCC TGC 0CC AGT Pro Cys Ala Ser

GGC

Gly 270 CTC CTA TGC CAG Leu Leu Cys Gin 113-

CCA

Pro 275

AGC

Ser CAC AGC CAC AGT His Ser His Ser

CTG

Leu 280

GAG

Glu GTG TAC ATG TGC Val Tyr Met Cys

AAG

Lys 285

CCC

Pro CCA GCC TTC GTG Pro Ala Phe Val

GGC

Gly 290 CAT GAC CAC His Asp His

AGT

Ser 295

GTT

Val GAG AGC CAG Glu Ser Gin

CTG

Leu 300

GAA

Glu AGO GAG 0CC Arg Glu Ala CCG GAT Pro Asp 305 GAG TAC GAA Glu Tyr Glua GAC CTG GAG Asp Leu Glu 325 CCT GTG GAG Pro Val Glu 340

GAT

Asp 310

CGG

Arg GGC TTC ATA Gly Phe Ile

GG

Gly 315

GAG

Glu GTG CGC CAG Val Arg Gin GAG CTG GAA Glu Leu Glu 320 GGG CCT GCC Gly Pro Ala 979 1027 1075 1123 1176 AGC CTA GCC Ser Leu Ala

CAG

Gin 330

GAG

Glu ATG GCA TTT GAG Met Ala Phe Giu TCA CTA GGC GGA Ser Leu Gly Gly 345 GAG GAG ATT Giu Glu Ile TAGGCCCAGA CCCAGCTGAG

TC.ACTGGTAG

GGAATGGCCG

ACATTTCTTC

CAGCGGTGAG

ATTTGTTTGA

ACAGGGAGGA.

GTCTTGCGCC

CCTCCCACAT

AGCCACGCCC

GCCCCATGCT

TGGAGGGAGT

GGTCAGGCTG

ACCGACTGCT

TGCAGGAAGT

CTTAGCAACA

TGTAGAGTAC

TGACGGTTTC

ATGTGCAATA

CAGCTCCTTC

CAGCCGCCCT

TCGTCCCTCG

AGGGAGAGGA

GGATGCCTGC

GCTCCCATGG

ATTCATCCCT

CCTCTTGCTC

CTCTCTCTCA

GAAATCCTTT

ACTTGCATGT

TCAATACCTC

ATACTTGGCT

ATGGAAAGCC

AGCTGTGACA

AGGTGCCAGG

GAAATGGCTA

CCAGTAGCTT

GCTTCTCTGA

CTGTTGCTAG

TGGGAAGGGG

CTTGCAGACG

GCTGAGGCAG

GTGT=CAGC

ACCACAGCCT

ACCCCATACC

GGTTTAATTA

CCCTCTAACG

TGAAAGCCAG

AATTGTAGGG

TTCTCAGTC

TACAGACAGA

AACTATTACC

ATTTATTTTC

TTCCTCTGGC

CTTGGGAAAG

AAACGCTGTC

TGAAGTCTGC

TGGACTTGGC

TGGCTACACA

TCCTACCTCA

AGGAGGGGAC

AGCCTCTGTG

TTTTCTCCTT

TTCGTAOCAG

TGCTCGGAGT

CTAGGATTGT

ACACCGAGAA

AGAAGGCTGG

ATTCTGTATC

CCAGGAGTGT

TTGACAAGGT

ACAGGCATGG

TTGTTCTTCA

TCATGATGGA

AAAATGTAAC

AGAGCTATGC

CTGTCAGCAC

CAGAGGGGAC

CCAGCGACAG

CAAGGCACGC

TGTGGTGGAC

GCAGTTCGTG

GAATGAAATT

GTCACAACCA

GCTGGATGTC

TATCCAGAGT

CCCCAAGTGT

ACAGTGCAGT

CGGGTAAGGG

TGGATGGAAG

TTTGGGGGAT

CTTTGCTTTT

TGCTCTGTGG

AGCCCTTCAT

TTCTCTCAGA

TCCTTCCAAA

CTGCCACTAA

ACTGTCTTCC

TAAATTAATT

TGCAAAGTCG

AGCCAGGTTG

AGGCCTCAGA

TATTAAAATT

1236 1296 1356 1416 1476 1536 1596 1656 1716 1776 1836 1896 1956 2016 2076 2136 2196 -114- GAAAGTTGCA CACATTTGTA TAAGCATGCC TTTCTCCTGA GTTTTAAATT ATATGTATAC 2256 ACAAACATGT GGCCCTCAAA GATCATGCAC AAACCACTAC TCTTTGCTAA TTCTTGGACT 2316 TTTCTCTTTG ATTTTCAATA AATACAAATC CCCTTCATGC AAAAAAAAAA AAAAAGGGCG 2376 GCCGC 2381 INFORMATION FOR SEQ ID NO:17: SEQUENCE CHARACTERISTICS: LENGTH: 349 amino acids TYPE: amino acid TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: Met Gin Arg Leu Gly Gly Ile Leu Leu Cys Thr Leu Leu Ala Ala Ala 1 5 10 Val Pro Thr Ala Pro Ala Pro Ser Pro Thr Val Thr Trp Thr Pro Ala 20 25 Glu Pro Gly Pro Ala Leu Asn Tyr Pro Gin Glu Glu Ala Thr Leu Asn 40 Glu Met Phe Arg Glu Val Glu Glu Leu Met Glu Asp Thr Gin His Lys 55 Leu Arg Ser Ala Val Glu Glu Met Glu Ala Glu Glu Ala Ala Ala Lys 70 75 Thr Ser Ser Glu Val Asn Leu Ala Ser Leu Pro Pro Asn Tyr His Asn 90 Glu Thr Ser Thr Glu Thr Arg Val Gly Asn Asn Thr Val His Val His 100 105 110 Gin Glu Val His Lys Ile Thr Asn Asn Gin Ser Gly Gin Val Val Phe 115 120 125 Ser Glu Thr Val Ile Thr Ser Val Gly Asp Glu.Glu Gly Lys Arg Ser 130 135 140 His Glu Cys Ile Ile Asp Glu Asp Cys Gly Pro Thr Arg Tyr Cys Gin 145 150 155 160 Phe Ser Ser Phe Lys Tyr Thr Cys Gin Pro Cys Arg Asp Gin Gin Met 165 170 175 Leu Cys Thr Arg Asp Ser Glu Cys Cys Gly Asp Gin Leu Cys Ala Trp 180 185 190 -115- Gly His Cys Thr Gin Lys Ala Thr Lys Gly Gly Asn Gly Thr Ile Cys 195 200 205 Asp Asn Gin Arg Asp Cys Gin Pro Gly Leu Cys Cys Ala Phe Gin Arg 210 215 220 Gly Leu Leu Phe Pro Val Cys Thr Pro Leu Pro Val Glu Gly Glu Leu 225 230 235 240 Cys His Asp Pro Thr Ser Gin Leu Leu Asp Leu Ile Thr Trp Glu Leu 245 250 255 Glu Pro Glu Gly Ala Leu Asp Arg Cys Pro Cys Ala Ser Gly Leu Leu 260 265 270 Cys Gin Pro His Ser His Ser Leu Val Tyr Met Cys Lys Pro Ala Phe 275 280 285 Val Gly Ser His Asp His Ser Glu Glu Ser Gin Leu Pro Arg Glu Ala 290 295 300 Pro Asp Glu Tyr Glu Asp Val Gly Phe Ile Gly Glu Val Arg Gin Glu 305 310 315 320 Leu Glu Asp Leu Glu Arg Ser Leu Ala Gin Glu Met Ala Phe Glu Gly 325 330 335 Pro Ala Pro Val Glu Ser Leu Gly Gly Glu Glu Glu Ile 340 345 INFORMATION FOR SEQ ID NO:18: SEQUENCE CHARACTERISTICS: LENGTH: 1047 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: NAME/KEY: CDS LOCATION: 1..1047 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: ATG CAG CGG CTC GGG GGT ATT TTG CTG TGT ACA CTG CTG GCG GCG GCG 48 Met Gin Arg Leu Gly Gly Ile Leu Leu Cys Thr Leu Leu Ala Ala Ala 1 5 10 GTC CCC ACT GCT CCT GCT CCT TCC CCG ACG GTC ACT TGG ACT CCG GCG 96 Val Pro Thr Ala Pro Ala Pro Ser Pro Thr Val Thr Trp Thr Pro Ala 25 116 GAG CCG GGC CCA GCT CTC AAC TAC CCT CAG GAG GAA GCT ACG CTC AAT Glu Pro Gly Pro Ala Leu Asn Tyr Pro Gin Giu Glu Ala Thr Leu Asn GAG ATG TTT CGA GAG GTG GAG

GAG

Glu Glu Met Phe Arg Giu Val Glu 55 CTG ATG GAA GAC ACT CAG CAC AAA Leu Met Giu Asp Thr Gin His Lys 192

CTG

Leu CGC AGT Arg Ser GCC GTG GAG Ala Val Glu 70 GAG ATG GAG GCG Giu Met Giu Ala

GAA

Giu 75 GAA GCA GCT GCT Giu Ala Ala Ala

AAA

Lys so ACG TCC TCT GAG Thr Ser Ser Glu

GTG

Val AAC CTG GCA AGC Asn Leu Ala Ser

TTA

Leu 90 CCT CCC AAC Pro Pro Asn GAG ACC AGC Glu Thr Ser CAG GAA GTT Gin Glu Val 115

ACG

Thr 100 GAG ACC AGG GTG Giu Thr Arg Val

GGA

Gly 105 AAT AAC ACA GTC Asn Asn Thr Val TAT CAC AAT Tyr His Asn CAT GTG CAC His Val His 110 GTG GTC TTT Val Val Phe 288 336 384 CAC AAq ATA ACC His Lys Ile Thr

AAC

Asn 120 AAC CAG AGT GGA Asn Gin Ser Gly

CAG

Gin 125 TCT GAG Ser Giu 130 ACA GTC ATT ACA Thr Val Ile Thr

TCT

Ser 135 GTA GGG GAT GAA Val Gly Asp Giu

GAA

Glu 140 GGC AAG AGG AGC Giy Lys Arg Ser

CAT

His 145 GAA TGT ATC ATT Glu Cys Ile Ile

GAT

Asp

ISO

GAA GAC TGT GG Glu Asp Cys Gly ACC AGG TAC TGC Thr Arg Tyr Cys

CAG

Gin 160 432 480 528 TTC TCC AGC TTC Phe Ser Ser Phe

AAG

Lys 165 TAC ACC TGC CAG Tyr Thr Cys Gin

CCA

Pro 170 TGC CGO GAC CAG Cys Arg Asp Gin GAG ATG Gin Met 175 CTA TGC ACC Leu Cl's Thr GOT CAC TGC Gly His Cys 195

CGA

Arg 180 GAC AGT GAG TGC Asp Ser Glu Cys

TGT

Cys 185 GGA GAC CAG CTG Gly Asp Gin Leu TGT GCC TGG Cys Ala Trp 190 ACC ATC TGT Thr Ile Cys 576 624 ACC CAA AAG GCC Thr Gin Lys Ala

ACC

Thr 200 AAA GGT GGC AAT Lys Gly Gly Asn

GG

Gly 205 GAC AAC Asp Asn 210 CAG AGO GAT TGC Gin Arg Asp Cys

CAG

Gin 215 CCT GGC CTG TGT Pro Gly Leu Cys

TGT

Cys 220 GCC TTC CAA AGA Ala Phe Gin Arg

GCC

Gly 225 CTG CTG TTC CCC Leu Leu Phe Pro

GTG

Val1 230 TGC ACA CCC CTG Cys Thr Pro Leu

CCC

Pro 235 GTG GAG GGA GAG Val Glu Gly Giu

CTC

Leu 240 672 720 768 TGC CAT GAC CCC Cys His Asp Pro

ACC

Thr 245 AGC CAG CTG CTG Ser Gin Leu Leu

GAT

Asp 250 CTC ATC ACC TGG Leu Ile Thr Trp GAA CTG Giu Leu 255 117- GAG CCT GAA Glu Pro Glu TGC CAG CCA Cys Gin Pro 275

GGA

Gly 260 GCT TTG GAC CGA Ala Leu Asp Arg CCC TOC GCC AGT Pro Cys Ala Ser GGC CTC CTA Gly Leu Leu 270 CCA GCC Trc Pro Ala Phe 816 864 CAC AGC CAC AGT His Ser His Ser

CTG

Leu 280 GTG TAC ATG TGC Val Tyr Met Cys

AAG

Lys 285 GTG GGC Val Gly 290 AGC CAT GAC CAC Ser His Asp His

AGT

Ser 295 GAG GAG AGC CAG Glu Glu Ser Gin

CTG

Leu 300 CCC AGG GAG GCC Pro Arg Glu Ala 912

CCG

Pro 305 GAT GAG TAC GAA Asp Glu Tyr Glu

GAT

Asp 310 GTT GGC TTC ATA Val Gly Phe Ile

GGG

Gly 315 GAA GTG CGC CAG Glu Val Arg Gin

GAG

Glu 320 960 1008 CTG GAA GAC CTG Leu Glu Asp Leu

GAG

Glu 325 CGG AGC CTA GCC Arg Ser Leu Ala

CAG

Gin 330 GAG ATG GCA TTT Glu Met Ala Phe GAG GGG Glu Gly 335 CCT GCC CCT GTG GAG TCA CTA GGC GGA GAG GAG GAG ATT Pro Ala Pro Val Glu Ser Leu Gly Gly Glu Glu Glu Ile 1047

Claims

118- THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS: 1. An isolated nucleic acid molecule selected from the group consisting of: a) a nucleic acid comprising SEQ ID NO:3; b) a nucleic acid comprising a nucleotide sequence that has at least nucleotide sequence identity with SEQ ID NO:9 over the whole length of SEQ ID NO:9; c) a nucleic acid comprising a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence that has at least 80% amino acid sequence identity with amino acid residues 21-266 of SEQ ID NO:8 over S. the whole length of amino acid residues 21-266 of SEQ ID NO:8; a nucleic acid which encodes a polypeptide comprising the amino acid sequence of amino acid residues 24-350 of SEQ ID NO:2; e) a nucleic acid which encodes a polypeptide that comprises a naturally occurring allelic variant of the amino acid sequence of SEQ ID NO:11 or SEQ ID NO:14, wherein said naturally occurring allelic variant modulates cellular signal transduction or cellular proliferation, and wherein said ^nucleic acid which encodes a naturally occurring allelic variant of the amino acid sequence of SEQ ID NO:11 hybridizes to the complement of SEQ ID NO:12 under stringent wash conditions, and (ii) said nucleic acid which encodes a naturally occurring allelic variant of the amino acid sequence of SEQ ID NO:14 hybridizes to the complement of SEQ ID NO:15 under stringent wash conditions, wherein stringent wash conditions are 0.2X SSC, 0.1% SDS at 50-65 0 C; f) a nucleic acid comprising a nucleotide sequence that is the complement of d) or and g) a recombinant eukaryotic cell expression vector comprising the nucleic acid of f) or a nucleic acid which comprises at least 500 nucleotides of a nucleotide sequence that has at least 80% nucleotide sequence identity with SEQ ID NO:12 or SEQ ID NO:15, over the whole length of SEQ ID NO:12 or SEQ ID NO:15, respectively, and encodes a P 'OPER.LHRrs CInP2(~PAJunc'V2i II CIrmdoc. I RilAn

119- polypeptide that modulates cellular signal transduction or cellular proliferation. 2. The isolated nucleic acid molecule of Claim 1, wherein said isolated nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:1, and SEQ ID NO:3. 3. The isolated nucleic acid molecule of Claim 1, wherein said isolated nucleic acid molecule comprises a nucleotide sequence that has at least 85% nucleotide sequence identity with SEQ ID NO:9 over the whole length of SEQ ID NO:9. 4. The isolated nucleic acid molecule of Claim 3, wherein said isolated nucleic acid .molecule comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:9 and the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633. The isolated nucleic acid molecule of Claim 1, wherein said isolated nucleic acid molecule encodes a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, amino acid residues 20-350 of SEQ ID NO:2, amino acid residues 22-350 of SEQ ID NO:2 and amino acid residues 24- 350 of SEQ ID NO:2. 6. The isolated nucleic acid molecule of Claim 1, wherein said isolated nucleic acid molecule comprises a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence that has at least 80% amino acid sequence identity with amino acid residues 21-266 of SEQ ID NO:8 over the whole length of amino acid residues 21-266 of SEQ ID NO:8. 7. The isolated nucleic acid molecule of Claim 6, wherein said isolated nucleic acid molecule encodes a polypeptide comprising an amino acid sequence selected from P IOPFRIIERQERc CImSlk(MIUX1U2 52%) I CI -dcl 'A,0cc,

120- the group consisting of SEQ ID NO:8 and amino acid residues 21-266 of SEQ ID NO:8. 8. The isolated nucleic acid molecule of Claim la), Ib), Ic), Id) or le), wherein said isolated nucleic acid molecule further comprises: i) a vector nucleic acid sequence; and/or ii) a nucleic acid sequence encoding a heterologous polypeptide. 9. The isolated nucleic acid molecule of Claim Ig), wherein said isolated nucleic acid molecule further comprises a nucleic acid sequence encoding a heterologous S polypeptide. 10. A host cell comprising the recombinant eukaryotic cell expression vector of Claim lg). ee 11. A host cell comprising a vector comprising the nucleic acid of any one of Claims la), Ib), Ic), Id), 2, 3, 4, 5, 6 or 7 wherein said nucleic acid is a recombinant .nucleic acid. 12. An isolated polypeptide selected from the group consisting of: a) a polypeptide comprising at least 15 contiguous amino acids of SEQ ID NO:8, SEQ ID NO: 1 or SEQ ID NO:14; b) a polypeptide comprising a naturally occurring allelic variant of the amino acid sequence of amino acid residues 21-266 of SEQ ID NO:8, SEQ ID NO:11, or SEQ ID NO:14, wherein said naturally occurring allelic variant modulates cellular signal transduction or cellular proliferation and wherein said naturally occurring allelic variant of the amino acid sequence of SEQ ID NO:8 is encoded by a nucleic acid molecule which hybridizes to the complement of SEQ ID NO:9 under stringent wash conditions, (ii) said naturally occurring allelic variant of the amino acid sequence of SEQ ID NO:11 is encoded by a nucleic acid molecule which hybridizes to the P 'OPEVUEH\Rcs CMIQ \2 WJ .Ik252 I CIrIS dc I3"' 121 complement of SEQ ID NO:12 under stringent wash conditions, and (iii) said naturally occurring allelic variant of the amino acid sequence of SEQ ID NO:14 is encoded by a nucleic acid molecule which hybridizes to the complement of SEQ ID NO:15 under stringent wash conditions, and wherein stringent wash conditions are 0.2X SSC, 0.1% SDS at 50-65'C; c) a polypeptide comprising amino acid residues 24-350 of SEQ ID NO:2; and d) a polypeptide comprising an amino acid sequence which has at least amino acid sequence identity with the amino acid sequence of amino acid residues 21-266 of SEQ ID NO:8, SEQ ID NO:11 or SEQ ID NO:14 over the whole length of amino acid residues 21-266 of SEQ ID NO:8, SEQ ID NO:11, or SEQ ID NO:14, respectively, and modulates cellular signal transduction or cellular proliferation. 13. The isolated polypeptide of Claim 12, wherein said polypeptide comprises at least 15 contiguous amino acids of SEQ ID NO:8. 14. The isolated polypeptide of Claim 12, wherein said polypeptide comprises at least contiguous amino acids of SEQ ID NO: 11 or SEQ ID NO:14. The isolated polypeptide of Claim 12, wherein said polypeptide comprises at least contiguous amino acids of SEQ ID NO:11 or SEQ ID NO:14. 16. The isolated polypeptide of Claim 12, wherein said polypeptide comprises at least contiguous amino acids of SEQ ID NO:11 or SEQ ID NO:14. 17. The isolated polypeptide of Claim 12, wherein said polypeptide comprises at least 100 contiguous amino acids of SEQ ID NO:11 or SEQ ID NO:14. 18. The isolated polypeptide of Claim 12, wherein said polypeptide comprises at least contiguous.amino acids of SEQ ID NO:8. P kOPFRUEAIRs C(I msC"(XUntC)5>fl I cIr ndZ !'AI"g-

122- 19. The isolated polypeptide of Claim 12, wherein said polypeptide comprises at least contiguous amino acids of SEQ ID NO:8. The isolated polypeptide of Claim 12, wherein said polypeptide comprises at least contiguous amino acids of SEQ ID NO:8. 21. The isolated polypeptide of Claim 12, wherein said polypeptide comprises at least 100 contiguous amino acids of SEQ ID NO:8. 22. The isolated polypeptide of Claim 12, wherein said isolated polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:8 and amino acid residues 21-266 of SEQ ID NO:8. 23. The isolated polypeptide of Claim 12, wherein said isolated polypeptide comprises acid residues 20-350 of SEQ ID NO:2, amino acid residues 22-350 of SEQ ID NO:2, and amino acid residues 24-350 of SEQ ID NO:2. :oo 24. The isolated polypeptide of Claim 12, wherein said isolated polypeptide comprises a polypeptide selected from the group consisting of: a) a polypeptide consisting of 15 contiguous amino acids of SEQ ID NO:8, SEQ ID NO:11 or SEQ ID NO:14; and b) a polypeptide consisting of a naturally occurring allelic variant of amino acid residues 21-266 of SEQ ID NO:8, SEQ ID NO:11 or SEQ ID NO:14, wherein said naturally occurring allelic variant modulates cellular signal P 'OPE.RUEHRc CIn j cU ,o259~li CIsdm In IA

123- transduction or cellular proliferation and wherein said naturally occurring allelic variant of the amino acid sequence of amino acid residues 21-266 of SEQ ID NO:8 is encoded by a nucleic acid molecule which hybridizes to the complement of SEQ ID NO:9 under stringent wash conditions, (ii) said naturally occurring allelic variant of the amino acid sequence of SEQ ID NO:11 is encoded by a nucleic acid molecule which hybridizes to the complement of SEQ ID NO:12 under stringent wash conditions, and (iii) said naturally occurring allelic variant of the amino acid sequence of SEQ ID NO:14 is encoded by a nucleic acid molecule which hybridizes to the complement of SEQ ID NO:15 under stringent was conditions, and wherein stringent wash conditions are 0.2X SSC, 0.1% SDS at 50-65 0 C. 27. The antibody or immunologically active portion thereof of Claim 26, wherein said antibody or immunologically active portion thereof specifically binds to a polypeptide consisting of 15 contiguous amino acids of SEQ ID NO:8, SEQ ID NO:11 or SEQ ID NO:14. S 28. The antibody or immunologically active portion antibody or immunologically active portion polypeptide consisting of 20 contiguous amino NO:11 or SEQ ID NO:14. 29. The antibody or immunologically active portion antibody or immunologically active portion polypeptide consisting of 30 contiguous amino NO:11 or SEQ ID NO:14. thereof of Claim 26, wherein said thereof specifically binds to a acids of SEQ ID NO:8, SEQ ID thereof of Claim 26, wherein said thereof specifically binds to a acids of SEQ ID NO:8, SEQ ID The antibody or immunologically active portion thereof of Claim 26, wherein said antibody or immunologically active portion thereof specifically binds a polypeptide P kOPERJEH\Rcs CI-C(AMIJ-u.252911 CIMS doc) IAW

124- that consists of an amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:11 or SEQ ID NO:14. 31. The antibody or immunologically active portion thereof of Claim 30, wherein said antibody or immunologically active portion thereof specifically binds a polypeptide that consists of the amino acid sequence of amino acid residues 85-138 of SEQ ID NO:8. 32. The antibody or immunologically active portion thereof of Claim 30, wherein said antibody or immunologically active portion thereof specifically binds a polypeptide that consists of the amino acid sequence of amino acid residues 21-266 of SEQ ID NO:8. 33. The antibody or immunologically active portion thereof of any one of Claims 26- 32, wherein said antibody or immunologically active portion thereof is selected from the group consisting of a human antibody, a humanized monoclonal antibody, a chimeric monoclonal antibody and an immunologically active portion of any one of the foregoing. 34. The antibody or immunologically active portion thereof of any one of Claims 26- 32, wherein said antibody or immunologically active portion thereof is a monoclonal antibody or an immunologically acitive portion of a monoclonal antibody. The antibody or immunologically active portion thereof of any one of Claims 26- 33, wherein said antibody or immunologically active portion thereof is an immunologically active portion selected from the group consisting of an Fab fragment and an F(ab') 2 fragment. P NOPERVEH\Rci C1n W n6V 252Y I CO1 doM- I 3r 125 36. The antibody or immunologically active portion thereof of any one of Claims 26- wherein said antibody or immunologically active portion thereof comprises a detectable label. 37. The antibody or immunologically active portion thereof of Claim 36, wherein said detectable label is an enzyme, a prosthetic group, a fluorescent material, a luminescent material, a bioluminescent material or a radioactive material. 38. A method for producing a polypeptide of Claim 12 comprising culturing the host cell of Claim 10 under conditions in which the recombinant expression vector is expressed, and said polypeptide is produced. 39. A method for producing a polypeptide of Claim 22 or Claim 23 comprising culturing the host cell of Claim 11 under conditions in which the recombinant nucleic acid is expressed, and said polypeptide is produced. A method for detecting the presence of a polypeptide of any one of Claims 12-25 in a sample comprising: a) contacting the sample with an antibody or immunologically active portion thereof of any one of Claims 26-37; and *too b) determining whether said antibody binds to a polypeptide in the sample to thereby detect the presence of said polypeptide of any one of Claims 12-25 in the sample. 41. A kit comprising an antibody or immunologically active portion thereof of any one of Claims 26-37 and instructions for use. 42. Use of a kit for detecting a polypeptide of any one of Claims 12-25 in a sample, said kit comprising an antibody or immunologically active portion thereof of any one of Claims 26-37 and instructions for use. P OPER\)EH\Res CI IsQN W( 5."M I cIm, i 'I(X

126- 43. A method for detecting the presence of a nucleic acid molecule of any one of Claims 1-7 in a sample comprising: a) contacting the sample with a nucleic acid probe or primer which specifically hybridizes to a nucleic acid molecule of any one of Claims 1-7; and b) determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample to thereby detect the presence of a nucleic acid molecule of any one of Claims 1-7 in the sample. 44. The method of Claim 43, wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe. 45. Use of a kit for detecting a nucleic acid molecule of any one of Claims 1-7 in a sample, said kit comprising a nucleic acid probe or primer which specifically hybridizes to a nucleic acid molecule of any one of Claims 1-7 and instructions for use. 46. A method for identifying a compound which binds to a polypeptide of any one of SClaims 12-25 comprising: a) contacting a polypeptide of any one of Claims 12-25, or a cell expressing said polypeptide with a test compound; and b) determining whether the polypeptide binds to the test compound. 47. The method of Claim 46, wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of: a) detection of binding by direct detection of test compound/polypeptide binding; b) detection of binding using a competition binding assay; and c) detection of binding using an assay for detecting cellular signal transduction or cellular proliferation. P \UPERJ.EHXRes CIm k2X(Kwun6225 M3' I I A XOW

127- 48. A method of modulating the cellular signal transduction or cellular proliferation activity of a polypeptide of any one of Claims 12-25 comprising contacting a polypeptide of any one of Claims 12-25 or a cell expressing said polypeptide with an antibody or immunologically active portion thereof of any one of Claims 26-37 in a sufficient concentration to modulate the cellular signal transduction or cellular proliferation activity of said polypeptide. 49. A method for identifying a compound which modulates the cellular signal transduction or cellular proliferation activity of a polypeptide of any one of Claims 12-25 comprising: a) contacting a polypeptide of any one of Claims 12-25 with a test compound; and b) determining the effect of the test compound on the cellular signal transduction or cellular proliferation activity of said polypeptide to thereby identify a compound which modulates the cellular signal transduction or cellular proliferation activity of said polypeptide. 50. An antibody or immunologically active portion thereof of any one of Claims 26-37 for use in therapy or diagnosis. 51. Use of an antibody or immunologically active portion thereof of any one of Claims 26-37 for the manufacture of a medicament for treatment of a developmental, differentiative, or proliferative disorder. 52. A polypeptide of any one of Claims 12-25 for use in therapy or diagnosis. 53. Use of a polypeptide according to any one of Claims 12-25 for the manufacture of a medicament for treatment of a developmental, differentiative, or proliferative disorder. 54. A nucleic acid molecule of any one of Claims 1-9 for use in therapy or diagnosis. p 'OPERJE I Mcs C m I* Iunc I2n I iMS dec I Id A ,A

128- Use of a nucleic acid molecule of any one of Claims 1-9 for the manufacture of a medicament for treatment of a developmental, differentiative, or proliferative disorder. 56. A nonhuman host cell comprising a transgene that comprises the nucleic acid molecule of any one of Claims la), Ib), Ic), Id), 2, 3, 4, 5, 6 or 7. 57. A pharmaceutical composition comprising a nucleic acid molecule of any one of claims 1-9 and a pharmaceutically acceptable carrier. 58. A pharmaceutical composition comprising a polypeptide of any one of claims 12- -25 and a pharmaceutically acceptable carrier. o 59. A pharmaceutical composition comprising an antibody or immunologically active portion thereof of any one of claims 26-37 and a pharmaceutically acceptable carrier. A method for treatment, prophylaxis or diagnosis of a developmental, differentiative, or proliferative disorder, comprising administering to a subject a CRSP expression or activity modulating amount of a nucleic acid molecule of any one of claims 1-9. 61. A method for treatment, prophylaxis or diagnosis of a developmental, differentiative, or proliferative disorder, comprising administering to a subject a CRSP expression or activity modulating amount of a polypeptide of any one of claims 12-25. 62. A method for treatment, prophylaxis or diagnosis of a developmental, differentiative, or proliferative disorder, comprising administering to a subject a P OPERUEHkHc, Csi, I c(ni do 'I-AX,

129- CRSP expression or activity modulating amount of an antibody or immunologically active portion thereof of any one of claims 26-37. 63. An isolated nucleic acid molecule according to any one of claims 1 to 9 or 54, a host cell according to any one of claims 10 to 11 or 56, an isolated polypeptide according to any one of claims 12 to 25 or 52, an antibody or immunologically active portion according to any one of claims 26 to 37 or 50, a method according to any one of claims 38 to 40, 43 to 44, 46 49 or 60 to 62, a kit according to claim 41, a use according to claim 42, 45, 51, 53 or 55 or a pharmaceutical composition according to any one of claims 57 to 59 substantially as hereinbefore described with S reference to the Figures and/or Examples DATED this 13th day of June, 2006 MILLENNIUM PHARMACEUTICALS, INC. by DAVIES COLLISON CAVE Patent Attorneys for the Applicant(s) 00**